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ABSTRACT
Parkinson’s disease (PD) is the most common neurodegenerative movement
disorder. Pathologically, loss of nigrostriatal neurons and dopamine released by these
neurons are responsible for PD motor symptoms. During PD, activation of resident
microglia and infiltrating lymphocytes leads to progressive neuroinflammation and
reduction in the number and function of regulatory immune cells. Neuroinflammation
contributes to progressive neurodegeneration and declining motor function. Reducing
neuroinflammation is the target for novel PD therapeutics. Our goal is to increase the
number and function of regulatory T cells (Tregs) in PD patients to decrease
neuroinflammation and reduce PD symptoms. One potential therapy is granulocytemacrophage colony stimulating factor (GM-CSF) which induces Tregs, decreases
neuroinflammation, and protects dopaminergic neurons in the 1-methyl-4-phenyl-1,2,3,6tetrahydropyridine (MPTP) model of PD.
In a Phase 1 trial, recombinant human GM-CSF (sargramostim) was welltolerated in PD patients, increased Treg frequency and function, and improved motor
function. Expression of helper T cell-related genes in CD4+CD25- cells in blood was
determined by PCR array. Sargramostim increased expression of both pro- and antiinflammatory cytokine genes supporting the notion that sargramostim alters the immune
response by increasing the expression of immune mediators, including anti-inflammatory
genes.
As T cells do not express GM-CSF receptors and to explore myeloid-mediated
Treg induction, GM-CSF-induced bone marrow-derived dendritic cells were further
cultured with GM-CSF and/or stimulated with nitrated α-synuclein. Continued culture with
GM-CSF yielded little change in dendritic cells as determined by surface co-stimulatory
molecule expression, and proinflammatory cytokine expression and release; however,
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their ability to induce Tregs was diminished. In contrast, stimulation with nitrated αsynuclein, regardless of continued culture in GM-CSF, increases proinflammatory gene
expression by dendritic cells, but showed variable effects on Treg induction. In the
MPTP model, adoptive transfer of GM-CSF-induced tolerogenic dendritic cells protect
dopaminergic neurons in the substantia nigra, decrease neuroinflammation, and
increase splenic Tregs in a fashion similar to direct administration of GM-CSF.
In conclusion, GM-CSF induces Tregs in part by acting on dendritic cells to
change their response to stimulation. The data suggest that GM-CSF may not suppress
neuroinflammation directly, but rather alters the immune response with increased
expression of anti-inflammatory mediators and induction of Tregs. Moreover, the
introduction of nitrated α-synuclein and possibly other misfolded proteins diminishes
homeostasis and Treg induction.
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CHAPTER 1
INTRODUCTION
PARKSINSON’S DISEASE
Pathology
Parkinson’s disease (PD) is the second most common neurodegenerative
disease after Alzheimer’s disease (de Lau and Breteler, 2006; Olanow et al., 2009). PD
has several pathological hallmarks. One, is degeneration of the nigrostriatal pathway,
the dopaminergic neurons which project rostrally from the substantia nigra pars
compacta to the dorsal striatum where they synapse on GABAergic neurons (Jenner,
2008). The loss of nigrostriatal dopaminergic neurons and released dopamine ultimately
decrease glutamatergic signaling from the thalamus to the motor cortex resulting in
decreased motor function. Dopaminergic neurons in the substantia nigra pars compacta
are particularly susceptible to PD degeneration, even compared to other dopaminergic
neuron populations in adjacent brain regions.

The reasons for increased neuronal

susceptibility to damage and loss are not clear. Ideas include, decreased ability of these
neurons to scavenge reactive oxygen species (Hornykiewicz and Kish, 1987), decreased
expression of neuromelanin (Hirsch et al., 1988), decreased ability to degrade misfolded
proteins (Dauer and Przedborski, 2003), increased generation of reactive oxygen
species (ROS), decreased mitochondria mass, and decreased myelination which results
in these dopaminergic neurons being more sensitive to energy stressors (Surmeier et
al., 2011; Haddad and Nakamura, 2015).
Accumulation of Lewy bodies and Lewy neurites, proteinaceous aggregates
predominately made up of misfolded, post-translationally modified α-synuclein (α-Syn) is
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another PD hallmark (Spillantini et al., 1997; Duda et al., 2000; Giasson, 2000; Luk et
al., 2009).

Lewy bodies were initially identified as eosinophilic inclusions found

throughout the basal ganglia and thalamus (Spillantini et al., 1997; Fornai et al., 2003;
Shults, 2006). They are primarily composed of α-Syn, ubiquitin, parkin, microtubule
associated protein 1B, phosphorylated IκBα, synphilin-1, amongst other proteins (Jensen
et al., 2000; Fornai et al., 2003; Noda et al., 2005). Due to α-Syn abundance at the
synaptic terminal, it is putatively involved in vesicular transport and neurotransmitter
release (Shults, 2006; Bendor et al., 2013). In the cell, α-Syn is normally found as an
unstructured monomer (Uversky et al., 2001) or tetramer (Bartels et al., 2011). When
bound to lipid membranes, α-Syn can adopt a more α-helical-rich structure (Davidson et
al., 1998; Perrin et al., 2000).

In Lewy bodies, α-Syn takes on a fibril structure

(Spillantini et al., 1998) with cross β-sheet conformation (Heise et al., 2005; Vilar et al.,
2008).

α-Syn in Lewy bodies also is post-translationally modified, including

ubiquitination (Hasegawa et al., 2002; Nonaka et al., 2005), phosphorylation (Fujiwara et
al., 2002; Wang et al., 2012), nitration (Duda et al., 2000; Giasson, 2000), and truncation
(Li et al., 2005; Anderson et al., 2006). While post-translational modifications such as
nitration increase the propensity of α-Syn to fold into oligomers (Yamin et al., 2003;
Hodara et al., 2004; Uversky et al., 2005), it is unclear in PD if α-Syn becomes modified
prior to or after misfolding and forming Lewy bodies. It is also unclear if Lewy body
formation results in or causes PD pathology. The Braak hypothesis posits that α-Syn
aggregation starts in the enteric nervous system (Braak et al., 2003; Braak et al., 2004).
According to the hypothesis, misfolded α-Syn accumulates and spreads neuron to
neuron into and throughout the central nervous system. The resuting Lewy bodies may
cause neurodegeneration.

Evidence for the Braak hypothesis includes α-Syn

expression being highest in regions with the highest accumulation of Lewy bodies, the
detection of Lewy body pathology in neuronal transplants, the transfer of α-Syn between
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neurons and between neurons and astrocytes ex vivo, and pathology induced by
transfer of exogenous α-Syn into rodents (McCann et al., 2016; Karampetsou et al.,
2017; Loria et al., 2017; Rietdijk et al., 2017). Despite the above evidence, there is
evidence that the Braak hypothesis is not completely correct, such as α-Syn from PD
patients being unable to cause pathology in rodents, the severity of PD symptoms not
always correlating with the degree of Lewy body pathology, and detection of Lewy body
pathology in non-PD patients (Prusiner et al., 2015; McCann et al., 2016).

Future

studies will rectify the different lines of evidence.
A final hallmark of PD is neuroinflammation which will be discussed in detail in a
later section.
Symptoms
PD is generally diagnosed by the symptoms presented. The four cardinal motor
symptoms of PD are resting tremor, rigidity, bradykinesia, and postural instability with
gait disturbance (Olanow et al., 2009). All four cardinal symptoms may not be present in
all PD patients, but the presence of these symptoms forms the basis of a PD diagnosis.
At the time of PD cardinal symptom presentation, 50-60% of nigral dopaminergic
neurons are already lost (Agid, 1991). Many non-motor symptoms are associated with
the enteric nervous system which present in PD patients prior to the presentation of the
cardinal motor symptoms. For example, PD patients may develop olfactory disruptions,
drooling, urinary disturbances, sexual dysfunction, orthostatic hypotension, fatigue, rapid
eye movement (REM) sleep dysfunction, and insomnia (Olanow et al., 2009; Ou et al.,
2016).

These symptoms are all non-descript and may be associated with other

disorders, and as a result, these symptoms are not used as PD diagnostic criteria.
These non-motor symptoms may be due to the loss of neurons caused by the
accumulation of α-Syn aggregates and act as evidence for the Braak hypothesis.
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Another major set of non-motor symptoms is neurocognitive symptoms such as
depression, delirium, hallucinations, anxiety and dementia (Olanow et al., 2009; Ou et
al., 2016). Approximately 50% of PD patients suffer from these cognitive symptoms and
about 30% of PD patients are diagnosed with dementia (Aarsland et al., 2005) making
treatment of cognitive symptoms an important aspect PD patient care (Hely et al., 2005;
Olanow et al., 2009). The development of these non-motor symptoms may suggest a
link between PD and Alzheimer’s disease. In line with this idea, PD patients may display
amyloid beta plaques, similar to Alzheimer’s disease patients (Mastaglia et al., 2003;
Lashley et al., 2008), and Alzheimer’s disease patients plaques contain α-Syn (Uéda et
al., 1993).
Risk factors
Age is the number one risk factor for PD (de Lau and Breteler, 2006).

PD

prevalence increases from less than 0.5% at age 60 to around 4% by age 80 (de Lau
and Breteler, 2006).

There are several occupational and environmental risk factors

which increase the risk of developing PD, including, exposure to pesticides and
herbicides (de Lau and Breteler, 2006; Noyce et al., 2012; Bellou et al., 2016), heavy
metal exposure and welding (de Lau and Breteler, 2006), residing in rural areas, drinking
well water (de Lau and Breteler, 2006; Noyce et al., 2012; Bellou et al., 2016), ever
having an influenza infection (Harris et al., 2012), or head trauma (de Lau and Breteler,
2006; Noyce et al., 2012). Factors which diminish the risk of developing PD include
drinking coffee and caffeine (de Lau and Breteler, 2006; Noyce et al., 2012; Bellou et al.,
2016), smoking cigarettes (de Lau and Breteler, 2006; Noyce et al., 2012; Bellou et al.,
2016), using non-steroidal anti-inflammatory drugs (NSAIDS), especially ibuprofen (Gao
et al., 2011; Noyce et al., 2012; Bellou et al., 2016), and red measles infection (Harris et
al., 2012).
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While most cases of PD are classified as sporadic and the underlying cause is
not known, a minority of patients have underlying genetic risk factors can increase the
risk of PD. For example, having a first degree relative with PD or tremor increases the
risk of developing PD (Noyce et al., 2012). The first identified gene associated with PD
is SNCA, the gene for α-Syn (Hardy et al., 2003). Duplication, triplication, or mutation of
SNCA are all associated with development of PD (Hardy et al., 2003; Singleton et al.,
2003; Ahn et al., 2008). Other genes involved in familial PD are PARK2 (the gene for
parkin, an ubiquitin ligase), UCHL1 (the gene for UCHL-1, an ubiquitin hydrolase),
PINK1 (the gene for Pink1, a PTEN-induced kinase which protects mitochondria),
PARK7 (the gene for DJ-1, an oxidative stress sensor), PARK8 (the gene for LRRK2),
as well as others (Hardy et al., 2003; de Lau and Breteler, 2006). Mutations in these
genes are causative for PD. Genome-wide associated studies identified several other
genes that are associated with PD patients such as CPLX1 (complexin 1 protein
involved in synaptic vesicle exocytosis), KAT8 (the gene from lysine acetyltransferase
8), CD38 (a cyclic ADP ribose hydrolase), PYGO2 (a signal transduction protein), HLADR (MHC class II), TOX3 (a gene associated with neuron survival), SATB1 (a gene
associated with T cell and Treg development), as well as others (Ahmed et al., 2012;
Wissemann et al., 2013; Dumitriu et al., 2016; Chang et al., 2017).

Despite being

identified as being associated with PD, it is unclear if these genes are playing a
pathogenic role in PD or if these genes are changed because of PD.
Models
Rodents do not develop PD naturally. To mimic PD in rodents, several different
intoxicants that mimic the neurodegeneration, neuroinflammation, Lewy body formation,
and motor dysfunction to differing degrees. The first of these models is 1-methyl-4phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced PD, which was first identified in
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humans who self-administered improperly synthesized desmethylprodine (Gupta, 2011).
These patients presented with rapid on-set PD symptoms. MPTP is a pro-neurotoxin
which rapidly diffuses across the blood-brain barrier (Heikkila et al., 1984; Markey et al.,
1984). In the brain, MPTP is metabolized by monoamine oxidase B (MAO-B) to 1methyl-4-phenylpyridinium (MPP+), the active neurotoxin (Chiba et al., 1984; Heikkila et
al., 1984; Markey et al., 1984; Scotcher et al., 1990). MPP+ is structurally similar to
dopamine (Klein et al., 1985), as a result, MPP+ is taken up through dopamine
transporters into dopaminergic neurons. Within neurons, MPP+ may be sequestered
into vesicles (Staal and Sonsalla, 2000) which protects the neurons. MPP+ may enter
the mitochondria and block electron transport chain complex I (Singer et al., 1988).
Blocking the electron transport chain results in energy depletion, neurodegeneration,
and neuroinflammation (Mizuno et al., 1987; Scotcher et al., 1990; Przedborski et al.,
1996; Niranjan et al., 2010).

While MPP+ kills neurons itself, genetic knockout of

proinflammatory cytokines such as interleukin (IL)-18 (Sugama et al., 2004) and tumor
necrosis factor (TNF)-α (Ferger et al., 2004) leads to decreased dopaminergic neuron
loss after MPTP intoxication compared to wild type.

This suggests a significant

percentage of neuron loss is due to subsequent neuroinflammation and not MPP+ itself.
CD4+ helper T cells are important for neuroinflammation because the absence of this
cell type protects most dopaminergic neurons from degeneration (Benner et al., 2008;
Brochard et al., 2009). After neuroinflammation resolution, no additional dopaminergic
neurons are lost (Jackson-Lewis et al., 1995). While the MPTP model recapitulates the
specific neurodegeneration and neuroinflammation found in PD, few if any Lewy bodies
are detected, unless MPTP is administered through an osmotic pump (Fornai et al.,
2005; Shimoji et al., 2005). Also, due to the rapid onset of neurodegeneration, there
may (Sundström et al., 1990; Tillerson and Miller, 2003; Fornai et al., 2005) or may not
(Hirst and Ferger, 2008; Hutter-Saunders et al., 2012) be motor impairment. The lesion
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in the MPTP model is more variable in female mice (Przedborski et al., 2001), meaning
that commonly only male mice are used. After MPTP intoxication, female mice express
higher GFAP (suggesting greater astrocyte activation), decreased expression of the
dopamine transporter in the striatum, and administration of 17β-estradiol in both male
and female mice is neuroprotective, all of which may contribute to the increased
variability of MPTP lesion in female mice (Ookubo et al., 2008; Ookubo et al., 2009).
This is potentially a problem since female mice are not included in experiments testing
efficacy of potential therapies.
Another toxin-based PD model is 6-hydroxydopamine (6-OHDA), an oxidized
form of dopamine. Unlike MPTP, which is peripherally administered, 6-OHDA cannot
cross the blood brain barrier (Garver et al., 1975). Therefore, 6-OHDA must be injected
into the substantia nigra, median forebrain bundle, or striatum (Ungerstedt, 1968; Jeon
et al., 1995; Rodrigues et al., 2003; Ma et al., 2014) to induce nigrostriatal degeneration.
6-OHDA is usually injected unilaterally to minimize toxicity, leading to unilateral
neuroinflammation and neurodegeneration (Cicchetti et al., 2002; Rodrigues et al., 2003;
Walsh et al., 2011), unlike MPTP where neurodegeneration and neuroinflammation are
bilateral. After injection, 6-OHDA is taken up into catecholaminergic neurons through
catecholamine transporters (Kostrzewa and Jacobowitz, 1974; Luthman et al., 1989).
Once in neurons, 6-OHDA has two fates, oxidization which forms hydrogen peroxide,
which subsequently forms ROS or impairment of complex I and IV of the electron
transport chain (Heikkila and Cohen, 1971, 1972; Glinka and Youdim, 1995; Glinka et
al., 1996). Both the generation of ROS and inhibition of the electron chain leads to
neurodegeneration of catecholaminergic neurons and neuroinflammation. Unlike MPTP,
which causes neurodegeneration and neuroinflammation specific for dopaminergic
neurons, 6-OHDA affects both dopaminergic and noradrenergic neurons.

As with
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MPTP, 6-OHDA does not induce Lewy body formation (Duty and Jenner, 2011; Bove
and Perier, 2012). While MPTP intoxication may or may not lead to motor symptoms, 6OHDA intoxication generates noticeable motor deficits. After unilateral administration of
6-OHDA lesion, administration of amphetamine is injected causing ipsilateral rotation in
a dose-dependent fashion (Carey, 1992; Robinson et al., 1994).
Because pesticide and herbicide exposure has been linked to increased risk of
PD,

pesticides

and

herbicides

were

neurodegeneration in rodent models.

used

to

model

PD

symptoms

and

Both paraquat (a herbicide) and rotenone (a

herbicide and insecticide) can be administered peripherally and taken up into the brain.
Rotenone is lipophilic and rapidly crosses the blood brain barrier and paraquat is actively
transported through neutral amino acid transporter (Shimizu et al., 2001). Administration
of either toxin causes nigrostriatal pathway degeneration (Betarbet et al., 2000;
McCormack et al., 2002). Rotenone is neurotoxic by inhibiting electro transport chain
complex I (Betarbet et al., 2000).

Paraquat is neurotoxic by redox cycling and

generating reactive oxygen and nitrogen species (Bus et al., 1976; Day et al., 1999).
Unlike the 6-OHDA and MPTP models, injection of rotenone or paraquat increases
expression of α-Syn and induces formation of inclusions that are similar to Lewy bodies
found in PD patients (Brooks et al., 1999; Betarbet et al., 2000; Manning-Bog et al.,
2002).

In addition, administration of both rotenone and paraquat lead to motor

symptoms of decreased rearing and spontaneous movement also mimicking PD (Alam
and Schmidt, 2004; Cannon et al., 2009). Rotenone and paraquat failed to achieve
more acceptance because of variable degrees of degeneration following administration
(Duty and Jenner, 2011; Bove and Perier, 2012).
Familial PD can also be modeled in rodents. As indicated above, several genes
have been implicated in the development of familial PD. The gene most associated with
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PD is SNCA. Mice that overexpress mouse or human α-Syn, or express A30P or A53T
mutants of α-Syn develop Lewy body-like inclusions in the nigrostriatal pathway (Kahle
et al., 2000; van der Putten et al., 2000; Giasson et al., 2002; Lee et al., 2002; Rieker et
al., 2011). However, the degree of neurodegeneration in the nigrostriatal pathway is
inconsistent (Masliah et al., 2000; Matsuoka et al., 2001). This lack of dopaminergic
neuron degeneration, even in older rodents, is a major reason these models have not
gained more prominence. The knockout of other genes associated with PD such as
parkin (PARK2), PINK1 (PINK1), and DJ-1 (PARK7) are used as models of PD,
however, these models also lack neurodegeneration (Goldberg et al., 2003; Goldberg et
al., 2005; Kitada et al., 2007).
Lastly, it should be noted that genetic and toxin models of PD exist in non-rodent
organisms such as non-human primates, C. elegans and Drosophila.

Non-human

primates do not develop PD spontaneously, but can develop PD symptoms after toxin
administration (Emborg, 2007).

However, due to the cost and specialized facilities

needed, the non-human primate models of PD have not been widely used. PD models
in C. elegans and Drosophila are beneficial because these organisms contain limited
numbers of neurons and other cells in the CNS allowing for easy nerve tracing, quick
generation time, and testing on large numbers needed for high throughput screening
(Duty and Jenner, 2011).

However, these model organisms are more genetically

divergent from PD patients than rodent models, meaning that results generated from
these models may not translate into the human population.
Treatments
Since PD symptoms are caused by the loss of dopamine in the striatum, the
most clinically useful therapies for PD are replacing lost dopamine. The most common
therapy for PD is levodopa given alone or with carbidopa, an inhibitor of aromatic-L-
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amino acid decarboxylase, the enzyme which decarboxylates levodopa to dopamine
(Calne, 1993; Samii et al., 2004; Dhall and Kreitzman, 2016; Oertel and Schulz, 2016).
While this therapy is beneficial in the short-term, long-term treatment with levodopa often
leads to dyskinesia (Calne, 1993; Rascol et al., 2000; Samii et al., 2004; Stocchi et al.,
2010).

Other

approved

PD

therapies

include

inhibition

of

cathechol-O-

methyltransferase, the enzyme that metabolizes dopamine (Muller, 2015; Oertel and
Schulz, 2016), and dopamine agonists (Calne, 1993; Oertel and Schulz, 2016).
Combination therapy of rasagiline, an inhibitor of the dopamine-metabolizing enzyme
MAO-B, and pramipexole, a dopamine receptor 2 agonist, is successful at reducing PD
symptoms in a recent clinical trial (Olanow et al., 2017).

In addition, selegiline

monotherapy, another MAO-B inhibitor, decreased the combined Unified Parkinson’s
Disease Rating Scale (UPDRS) score, showing improvement compared to placebo
(Mizuno et al., 2017).
While these therapies are effective at replacing lost dopamine, these therapies
do not address the underlying the cause of disease, the loss of dopaminergic neurons.
One therapeutic strategy is the generation of the antibodies against α-Syn. In practice,
passive transfer of anti-α-Syn antibodies increases clearance of α-Syn fibrils (Games et
al., 2014; Lindstrom et al., 2014).

Passive transfer of antibodies and increased

autoantibodies against α-Syn, reduce α-Syn fibrils, and inclusions protect neurons from
further degeneration (Masliah et al., 2005; Games et al., 2014; Lindstrom et al., 2014).
While clinical trials using monoclonal antibodies to α-Syn (PRX002) were performed in
humans, and these antibodies are safe to administer (Schenk et al., 2017), to date,
these antibodies have yet to successfully reduce PD symptoms. Other novel therapeutic
approaches

that

slow

or

stop

dopaminergic

neurons

loss

by

decreasing

neuroinflammation could be used. Such therapies such as minocycline and pioglitazone
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were protective in rodent models of PD (Peng et al., 2006; Laloux et al., 2012), but these
therapies were not been effective in PD patients (Investigators., 2006; Investigators.,
2015; Simon et al., 2015). Despite advances in therapies for PD, a novel therapy which
diminishes neuroinflammation is needed because the progression of neurodegeneration
could be slowed.

NEUROINFLAMATION AND PARKINSON’S DISEASE
Inflammatory immune cells in PD
One byproduct of nigrostriatal degeneration and Lewy body formation is
inflammation. During PD, several types of immune cells are activated. The first of these
immune cell types is microglia, which reside in the brain.

Microglia arise from two

sources (Chan et al., 2007; Kettenmann et al., 2011). In the postnatal brain, a limited
number of blood monocytes migrate into the brain and differentiate into microglia. The
second and major source of microglia are myeloid progenitors that arise from the bone
marrow then migrate into the brain during embryonic development.

These two

populations can be differentiated by the expression of CX3CR1 (found on resident
microglia) and CCR2 (found on microglia infiltrating in postnatal mice) (Mizutani et al.,
2012). Microglia have several described functions including pruning synapses (Paolicelli
et al., 2011; Tremblay et al., 2011), repairing and promoting neuronal survival after
damage (Cherry et al., 2014; Michell-Robinson et al., 2015), as well as clearing
pathogens in the brain (Michell-Robinson et al., 2015; Orihuela et al., 2016). Microglia
primed for repair and neuronal survival are designated M2 microglia. These microglia
release anti-inflammatory cytokines IL-4, IL-13, IL-10 and transforming growth factor
beta (TGF-β), and release neurotrophic factors such as prostanoids, and arginase
(Minghetti and Levi, 1998; Orihuela et al., 2016). Conversely, M1 microglia are primed
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to release proinflammatory cytokines such as interferon gamma (IFNγ), TNF-α, IL-12, IL1β, and IL-6 as well as the release of reactive oxygen and reactive nitrogen species
(Michell-Robinson et al., 2015; Orihuela et al., 2016). The combination of these M1 and
M2 microglia are responsible for resolution of inflammation and repair of damaged
neurons in the central nervous system.
During PD and other neurodegenerative disease, the debris from dead and dying
neurons and the accumulation and release of amyloid aggregates, such as Lewy bodies,
activate microglia (Meda et al., 1995; Beyer et al., 2000; Zhang et al., 2005; Kempuraj et
al., 2016). Aggregated α-Syn binds to pattern recognition molecules such as CD36 and
Toll-like receptors 1, 2 and 4, to stimulate the release of proinflammatory mediators from
microglia (Su et al., 2008; Stefanova et al., 2011; Fellner et al., 2013; Daniele et al.,
2015). In PD, activated microglia accumulate in the striatum, globus pallidus, thalamus,
and pons compared to age-matched controls as determined in vivo by positron emission
tomography (PET) scanning for activated microglia marker PK11195 (Gerhard et al.,
2006). In the postmortem brain, HLA-DR positive cells increase in the substantia nigra
of PD patients compared to non-PD controls (McGeer et al., 1988). Microglia in the post
mortem PD patients show increased expression of the adhesion molecules ICAM-1 and
LFA-1 which are important for the migration of microglia and lymphocytes to regions of
neuronal loss (Miklossy et al., 2006). PD patients also exhibit increased MHC II-positive
cells in several different brain regions including the substantia nigra and putamen
(Imamura et al., 2003). Taken together, M1-activated microglia in PD patients and are in
proximity of the degenerating neurons, suggesting that they play a role in degeneration.
Outside the central nervous system, dendritic cells (DCs), macrophages, and
monocytes are the most important non-granulocyte myeloid cells.

These cells are

derived from common myeloid progenitors in the bone marrow (Geissmann et al., 2010).
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These cells are all part of the innate immune system which play an important role in the
activation of the adaptive immune response (Medzhitov and Janeway, 1997; Liu, 2001).
DCs are found in lymphoid tissue such as Peyer’s patches and non-lymphoid tissue
such as the skin, lungs, and nasopharynx. DCs arise from two origins, myeloid origin
dendritic cells which originate from myeloid progenitor cells, or plasmacytoid dendritic
cells which originate from the common dendritic cell progenitor or the lymphoid
progenitor (Rutella et al., 2006). After activation, DCs migrate from the peripheral tissue
to the T cell zone of the draining lymph nodes to activate T cells (Martín-Fontecha et al.,
2009; Merad et al., 2013).

The primary role of DCs is uptake, processing, and

presentation of antigens that activate T cells (Merad et al., 2013). DCs can release
cytokines and other proinflammatory mediators that influence the immune environment
biasing the activation of T cells, leading to activation of the adoptive immune response.
Macrophages are found within the tissues and monocytes are found in the blood
(Gordon and Taylor, 2005).

Both cell types play a role in antigen processing and

adaptive immune cell activation, but to a lesser extent than DCs (Steinman, 1991;
Banchereau and Steinman, 1998). Primarily, macrophages and monocytes are involved
in clearance of pathogens and debris (Gordon and Taylor, 2005).

As with DCs,

macrophages and monocytes release cytokines and proinflammatory mediators such as
ROS that facilitate clearance of pathogens and wound healing.
In PD, the percentages of B and T cells are increased (see below), suggesting an
important role for antigen-presenting cells (APCs) in the progression of disease. Few
studies tested the percentage of DCs in PD. One study published a decrease in the
percentage of both plasmacytoid and myeloid DCs (Ciaramella et al., 2013). However,
another study showed these populations are not changed (Goldeck et al., 2016). In
addition, PD patients show increased classical monocytes (CD14+ CD16-), the major
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circulating monocyte population, and decreased non-classical monocytes (CD14+
CD16+), the major phagocytic macrophages (Grozdanov et al., 2014). Monocytes from
PD patients also exhibit a decreased phagocytic index compared to controls. Classical
monocytes in the PD patients display increased expression of CCR2, a chemokine
receptor needed for monocyte recruitment to sites of inflammation (Funk et al., 2013).
There is conflicting data concerning the release of IL-1β, TNF-α, and IL-6 from LPSstimulated monocytes derived from PD patients.

One publication indicated these

cytokines were increased (Grozdanov et al., 2014), while another publication showed
these cytokines were decreased (Hasegawa et al., 2000).
Lymphocytes are immune cells which are derived from a common lymphoid
progenitor in the bone marrow (Galy et al., 1995; Kondo et al., 1997). There are three
lymphocyte subpopulations: natural killer (NK) cells, B cells and T cells. NK cells can be
differentiated by the expression of CD16, CD56, CD27, and CD11b on their surface and
release perforin and granzyme-containing granules which kill cancer cells and virusinfected cells (Goh and Huntington, 2017).

B cells display immunoglobulins on the

surface (Pike and Ratcliffe, 2002). When activated, B cells undergo somatic
hypermutation of the immunoglobulin V region, class-switching of the immunoglobulin
constant region, and (for some B cells) differentiation into immunoglobulin-secreting
plasma cells (Hwang et al., 2015). There are 2 major T cell lineages: CD4+ helper T
cells and CD8+ cytotoxic T cells. CD4+ helper T cells are further subdivided into helper
T subtypes (Th1, Th2, Th17), regulatory T cells (Tregs) and several other subsets
depending on the cytokines released (Luckheeram et al., 2012; Tripathi and Lahesmaa,
2014).

These helper T cells bias the immune response to clear antigens that are

activating the immune system (Luckheeram et al., 2012). Helper T cells can also be
divided into naïve helper cells (CD4+ CD45RA+), which have yet to be activated in
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response to antigens, and memory helper T cells (CD4+ CD45RO+) which have
previously been activated and are maintained to more rapidly respond to that antigen in
the future (Berard and Tough, 2002). CD8+ T cells are cytotoxic, able to bind to and kill
tumor or infected cells by release of perforin and granzyme-containing granules or
through Fas ligand-Fas interactions (Harty et al., 2000). Unlike B cells which can bind
antigens without presentation, both CD8+ and CD4+ T cells need antigens to be
presented in the cleft of major histocompatibility complex (MHC) I or MHC II, respectively
(Teh et al., 1988; Bour et al., 1995). T cells can also be divided into αβ or γδ T cells
based on which T cell receptor gene segments are utilized by the T cell receptor. In the
periphery, most T cells are αβ T cells, but approximately 5% of the T cell population are
γδ T cells (Carding and Egan, 2002). In conclusion, the three lymphocyte subtypes
control infection, with B and T cells being the primary components of the cellular
adoptive immune response.
In PD patients, the percentage and function of lymphocytes is altered.
Circulating NK cells are increased (Niwa et al., 2012) and circulating B cells are
decreased in PD patients compared to healthy controls (Bas et al., 2001; Niwa et al.,
2012; Stevens et al., 2012; Horvath and Ritz, 2015). Interestingly, PD patients have
increased autoantibodies (Benkler et al., 2012), possibly including antibodies against αSyn (Papachroni et al., 2007). This suggests that even with decreased B cell numbers,
B cell-derived antibody production may be increased. To date, no study has discerned
significant changes in the percentages of plasma cells in PD patients. Within the T cell
population, PD patients exhibit increased circulating CD8+ (Bas et al., 2001; Baba et al.,
2005) and γδ T cells (Fiszer et al., 1994), but a decreased the percentage of circulating
CD4+ T cells (Bas et al., 2001; Baba et al., 2005; Hutter-Saunders et al., 2012; Niwa et
al., 2012; Stevens et al., 2012; Horvath and Ritz, 2015). In PD, the percentage of
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memory helper T cells (CD4+ CD45RO+) is increased and the percentage of naïve
helper T cells (CD4+ CD45RA+) is decreased (Bas et al., 2001; Hutter-Saunders et al.,
2012; Stevens et al., 2012; Horvath and Ritz, 2015). The percentage of proinflammatory
helper T cell subsets Th1 and Th17 is increased and anti-inflammatory Th2 and Treg
CD4+ cells are decreased (Chen et al., 2015). The ratio of IFNγ- to IL-4-producing
CD4+ cells is significantly increased in PD patients, also suggesting a shift toward Th1
and away from Th2 (Baba et al., 2005).

The ability of Tregs from PD patients to

suppress proliferation of CD4+ CD25- cells in culture is diminished compared to Tregs
from age-matched controls (Hutter-Saunders et al., 2012). Furthermore, PBMCs from
PD patients show increased basal expression of IFNγ, IL-1β, TNF-α, IL-8, MCP-1 and
MIP-1α, further highlighting that PD patients display increased expression of
proinflammatory cytokines and chemokines (Reale et al., 2009).

Combined, these

results indicate that lymphocyte percentages and functions are dysregulated leading to
increased proinflammatory environments with diminished regulatory immune functions.
A final population of immune cells are granulocytes, which are comprised of
neutrophils, eosinophils, and basophiles, and differentiated from the common
granulocyte progenitor (Akashi et al., 2000). Unlike monocytes, macrophages, DCs, and
lymphocytes which are all mononuclear cells, granulocytes possess multiple-lobed
nuclei and are called polymorphonuclear cells. As the name in implies, granulocytes
also contain large numbers of granules, which contain proteases, cytotoxins, and
antimicrobial peptides, and are released to eliminate extracellular pathogens as part of
their function in the innate immune system (Geering et al., 2013). Neutrophils are the
most abundant immune cell population and are the first cells to respond after infection
(Mestas and Hughes, 2004; Jones et al., 2016). When neutrophils respond to infection,
they phagocytize extracellular pathogens that are eliminated by the production of ROS
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and antimicrobial peptides and enzymes (Mayer-Scholl et al., 2004; Kolaczkowska and
Kubes, 2013).

For tumors, helminths, and pathogens too large to phagocytize,

neutrophils release proinflammatory mediators such as IL-12, cationic defensins,
extracellular enzymes such as elastase, collagenase, and matrix metalloproteinase
(Olsson and Venge, 1974; Olofsson et al., 1976; Cadman and Lawrence, 2010;
Kolaczkowska and Kubes, 2013). Basophils and eosinophils represent less than 5% of
the white blood cells in circulation and play roles in helminth infection, asthma, and
allergies (Cadman and Lawrence, 2010; Stone et al., 2010; Siracusa et al., 2013).
Basophils and eosinophils function by IgE bound to Fc receptors, which induce release
of Th2 cytokines such as IL-4, IL-5, IL-9 and IL-13, leukotrienes, and histamines (Stone
et al., 2010; Siracusa et al., 2013).
Even though granulocytes, especially neutrophils, play an important role in
inflammation, little research has been performed to evaluate changes in number and
function during PD. One study indicated no increase in peripheral neutrophil number
(Atac Ucar et al., 2016). However, the total number of granulocytes are increased in the
blood (Horvath and Ritz, 2015), but this study did not differentiate subsets of
granulocytes.

Release of nitrogen oxygen species from PD patient neutrophils was

increased compared to controls, suggesting increased proinflammatory function (Gatto
et al., 1996). Combined, these data suggest that the increase in granulocyte number
and the increased release of reactive nitrogen species contribute to the inflammation in
PD.
Released mediators in PD
In addition to immune cells, the immune system requires the release of mediators
to carry out its function.

These mediators may be cytokines, chemokines, reactive

oxygen and nitrogen species, prostaglandins, histamines, leukotrienes, anti-microbial
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peptides and extracellular enzymes which bias the immune system, regulate
inflammation,

control

regulatory

functions

of

the

immune

system,

act

as

chemoattractants for immune cells, have intrinsic capacity to remove pathogens, and
regulate the functions of non-immune cells (Bogdan et al., 2000; Vaday and Lider, 2000;
Borish and Steinke, 2003; Peters-Golden et al., 2005; Zhang and An, 2007; Azad et al.,
2008; O'Mahony et al., 2011; Ricciotti and FitzGerald, 2011; Mangoni et al., 2016).

In

PD, the concentration of proinflammatory mediators are increased compared to healthy
controls. This includes increased concentration of proinflammatory cytokines such as IL6, IL-1β and nitrate (a reactive nitrogen species) in the cerebrospinal fluid (CSF) (Mogi et
al., 1994; Blum-Degen et al., 1995; Qureshi et al., 1995; Scalzo et al., 2010). Counter to
the expectation, an increase of IL-6 concentration in CSF correlated with diminished
motor symptoms of PD (Müller et al., 1998).

The concentration of serum

proinflammatory mediators appears to be more variable in some studies showing
increased IL6, IL-1β, or RANTES (Rentzos et al., 2007; Lindqvist et al., 2012; Dursun et
al., 2015) or decreased IL-6, IL-1α, IL-8, TNF-α and nitrite concentrations (Dursun et al.,
2015; Cubukcu et al., 2016; Gupta et al., 2016). PD patients also exhibit increased
serum IL-10, an anti-inflammatory cytokine (Rentzos et al., 2009), perhaps indicating a
general increase in cytokine production or a compensatory response to the
proinflammatory environment.

In the postmortem brain, PD patients also exhibit

increased reactivity for proteins modified with 4-hydroxy-2-nonenal, an oxidized lipid
(HNE) (Yoritaka et al., 1996), protein containing carbonyls (Alam et al., 1997a), and 8hydroxyguanine (an oxidized nucleotide DNA base) (Alam et al., 1997b), all are markers
of an oxidatively stressed environment. In the CSF, PD patients show increased 8hydroxyguanine compared to controls, suggesting increased oxidative damage (Abe et
al., 2003). PD lymphocytes also show increased micronuclei and more single strand
breaks in the chromosomal DNA, suggesting that the oxidative damage detected in the
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brain is also in peripheral immune cells (Migliore et al., 2001; Petrozzi et al., 2001;
Migliore et al., 2002).
In summary, there is a sustained proinflammatory environment in affected brain
tissue. This is demonstrated by increased activation of microglia (McGeer et al., 1988;
Imamura et al., 2003), dysregulation of peripheral immune cells (Bas et al., 2001; Niwa
et al., 2012), and increased concentrations of proinflammatory mediators in serum and
CSF (Mogi et al., 1994; Blum-Degen et al., 1995; Qureshi et al., 1995; Rentzos et al.,
2007; Scalzo et al., 2010; Lindqvist et al., 2012; Dursun et al., 2015). The presence of
pro-inflammatory mediators in regions of neurodegeneration suggests a role for
neuroinflammation in PD pathogenesis.

Mitigating neuroinflammation could diminish

disease severity or slow degeneration in PD and may create an environment where
repair can be initiated.

GRANUCLOCYTE-MACROPHAGE COLONY STIMULATING FACTOR (GMCSF)
Structure, function and signaling of GM-CSF to its receptor
One of the therapeutics that may be used to mitigate neuroinflammation and
immune system dysfunction in PD is the cytokine GM-CSF (colony stimulating factor-2,
CSF2). In the body, GM-CSF is a monomer with four helical domains (Shearer, 2003).
GM-CSF binds to its receptor (CSF2R), which is composed of two subunits. The α
subunit that contains the site of GM-CSF binding and the β subunit is a common chain
shared by GM-CSF, IL-3 and IL-5 receptors, and is important for intracellular signaling
(Hercus et al., 2009). The crystal structure of the GM-CSF receptor bound to GM-CSF
portrays a hexamer complex of 2 α subunits, 2 β subunits of the GM-CSF receptor
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binding 2 GM-CSF monomers (Hansen et al., 2008). After GM-CSF binding, the kinase
JAK2 phosphorylates tyrosine amino acids in the cytoplasmic tail of both subunits of the
GM-CSF receptor (Shearer, 2003; Hansen et al., 2008; Hercus et al., 2009).
Phosphorylated tyrosines recruit the signal transducing STAT family members such as
STAT1 and STAT5, MAPK pathway members such as ERK1/2, and PI3-K pathway
members for downstream signaling (Shearer, 2003; Hercus et al., 2009). As expected
from activating of several pathways in several different cell types, GM-CSF displays
several functions, the most important of which is that GM-CSF acts on CD34+ immune
stem cells to suppress lymphocyte progenitor differentiation and promote differentiation
into macrophages, IL-12-producing DCs, and granulocytes (Shearer, 2003).
Therapeutic application of GM-CSF in rodent models and humans
GM-CSF has been used in two opposing ways to therapeutically modulate the
immune system. First, GM-CSF can be used as an adjuvant to improve the immune
response to an antigen. Recombinant GM-CSF, when combined with the hepatitis B
vaccine, increased anti-hepatitis B antibody titer suggesting a more protective response
(Cruciani et al., 2007). GM-CSF has also been and is continuing to be used as an
adjuvant for vaccines in melanoma, prostate cancer, pancreatic cancer, colon cancer,
breast cancer, and renal cancer (Jones et al., 1996; Ryan et al., 2000; Parmiani et al.,
2007; Spitler et al., 2009; Garcia et al., 2014) (NCT00064129, NCT00669734,
NCT01134614, NCT02466906, NCT01479244, NCT00458536).
reduce myelosuppression in these cancers.

GM-CSF is used to

However, GM-CSF does not reliably

increase T cell or antibody responses to antigens of these tumors, potentially due to
differences in the dose of GM-CSF used.
In contrast to its role as an adjuvant, GM-CSF can also act to suppress immune
responses in models of autoimmunity. In the experimental myasthenia gravis mouse

21
model, there is progressive muscle weakness due to an immune response to muscle
acetylcholine receptor (Sheng et al., 2011).

Administration of GM-CSF decreases

severity of muscle weakness and production of antibodies reactive to acetylcholine
receptor, decreases CD4+ T cell expression of proinflammatory cytokines, and increases
Treg percentage. The experimental model of thyroiditis is induced by immunization with
thyroglobulin, leading to destruction of thyroid follicles (Vasu et al., 2003).
Administration of GM-CSF diminishes thyroid damage, decreases expression of
disease-exacerbating IL-12, and increases the percentage of Tregs (Vasu et al., 2003;
Ganesh et al., 2009). Additional research determined that GM-CSF acts on DCs that
can induce Tregs and the suppression of autoimmunity (Ganesh et al., 2009;
Bhattacharya et al., 2011). NOD mice are a model of type 1 diabetes that develop
insulitis and is mitigated by GM-CSF treatment (Cheatem et al., 2009).

GM-CSF

administration increases the percentages of Tregs, Treg expression of IL-10 and TGF-β,
and percentages of dendritic cells.

In addition to the aforementioned autoimmunity

models, GM-CSF can also diminishes the colitis in the dextran sulfate sodium model
(Sainathan et al., 2008). In this model, GM-CSF treatment diminished expression of
proinflammatory cytokines IL-1α, IL-1-β, and TNFα, and increased indolamine 2,3
dioxygenase (IDO) expression in plasmacytoid DCs in the gut. In a model of traumatic
brain injury, GM-CSF administration diminished the number Iba-1+ microglia, decreased
lesion size, and spared more damage to the cortex (Kelso et al., 2015). Lastly, GM-CSF
was protective in the MPTP PD model.

Administration of GM-CSF protects

dopaminergic neurons and diminishes the number of activated microglia following MPTP
(Kosloski et al., 2013). This neuroprotective effect is mediated by an increase in Tregs,
as the transfer of the induced Tregs was sufficient for neuroprotection and diminished
neuroinflammation.

In conclusion, GM-CSF can act to diminish the inflammatory

response in autoimmunity by acting on DCs to induce Tregs.
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One of the benefits of using GM-CSF as a therapy is that it is an FDA approved
drug called sargramostim (Leukine), which is recombinant human GM-CSF produced in
yeast with a leucine to proline substitution at position 23 (Dorr, 1993; Waller, 2007).
Sargramostim decreased neutrophil recovery time and increased survival times in acute
myelogenous leukemia (Rowe et al., 1995) and lymphoid neoplasia (Nemunaitis et al.,
1991). Administration of sargramostim also diminishes the recovery time of immune
cells following bone marrow replacement (Nemunaitis et al., 1991; Hussein et al., 1995).
Sargramostim and filgrastim (recombinant GM-CSF produced in E. coli) display similar
therapeutic effects (Beveridge et al., 2009), but sargramostim-treated patients reported
fewer adverse events (Dorr, 1993).
Because of the benefit of GM-CSF in models of autoimmunity, ongoing research
is determining whether sargramostim can act as an adjuvant or as an anti-inflammatory
mediator in human patients. As indicated above, ongoing research is testing the efficacy
of sargramostim as an adjuvant for the hepatitis B vaccine and to increase immune
responses to various tumors. In addition, sargramostim is also being investigated for its
ability to diminish clinical symptoms of Crohn’s disease, a chronic inflammatory disease
of the gastrointestinal tract. In several trials (Korzenik et al., 2005; Takazoe et al., 2009;
Valentine et al., 2009), but not all (Roth et al., 2012), sargramostim diminishes clinical
severity compared to placebo control. Additional clinical trials have been completed to
better investigate the clinical efficacy of sargramostim, but results have not been
published (NCT00206674, NCT00206596). To date, none of these trials addressed if
the changes in clinical score were related to changes in immune cell, especially Treg,
number or function. The ability of sargramostim to mitigate the cognitive decline in
Alzheimer’s disease is also being tested in ongoing clinical trials (NCT01409915 and
NCT02667496).

In PD, sargramostim decreased the Unified Parkinson’s Disease
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Rating Scale (UPDRS) part III clinical score in patients, mitigated the loss of beta ERD in
the precentral gyrus, and increased Treg percentage and function (Gendelman et al.,
2017). These data suggest that sargramostim mitigates PD symptoms which may be
related to Treg number and/or function.

In total, GM-CSF and sargramostim have

immune modulatory function related to increases in immune cell number. Depending on
which cells are increased, GM-CSF may display an immune-stimulating or immunediminishing function.

MECHANISMS OF TREG INDUCTION
Tregs are derived from two sources. The first is thymic-derived or natural Tregs,
the second is induced or peripheral Tregs. Natural Tregs are derived from the thymus
and are part of the mechanism of central tolerance (Bluestone and Abbas, 2003;
Povoleri et al., 2013). These CD4+ T cells recognize self-antigens presented in the
thymus with intermediate strength as part of CD4+ T cell differentiation. Natural Tregs
express high CD25, Foxp3, GITR, CTLA-4, and Helios. Induced Tregs are derived from
mature, naïve CD4+ T cells that interact with APCs in the periphery. The absence of
sufficient antigen stimulation, the presence of co-stimulatory molecules and cytokines
such as IL-10 and TGF-β bias the activation of CD4+ T cells to induced Tregs. Induced
Tregs express variable amounts of CD25, Foxp3, GITR, and CTLA-4, but not Helios.
Despite different origins, natural Tregs and induced Tregs possess similar suppressive
functions such as release of immunosuppressive cytokines including IL-10 and TGF-β,
cell to cell suppression with co-stimulatory molecules like CTLA-4, competition for
growth factors such as IL-2 and tryptophan, and modulation of the functions of APCs.
Dendritic cells are the primary immune cells that induce Tregs in the periphery.
As described above, two populations of dendritic cells, plasmacytoid and myeloid, arise
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from different progenitors (Rutella et al., 2006). Both dendritic cell populations display
two maturation states, immature cells which actively take up antigens, but exhibit low
antigen presentation capability, and mature dendritic cells which exhibit less antigen
uptake and increased antigen presentation capabilities (Maldonado and von Andrian,
2010; Raker et al., 2015). Dendritic cells are functionally characterized as immunogenic
or tolerogenic dendritic cells, which induce naive helper T cells to differentiate effector or
regulatory helper T cells, respectively (Maldonado and von Andrian, 2010). Tolerogenic
dendritic cells induce Tregs by multiple mechanisms including release of antiinflammatory cytokines IL-10 and TGF-β, increased expression of IDO and its by-product
kynurenine, and altered surface co-stimulatory molecule expression (Steinman et al.,
2003; Maldonado and von Andrian, 2010; Li and Shi, 2015; Raker et al., 2015). The
percentage of tolerogenic dendritic cells can be increased naturally by increased
expression of anti-inflammatory cytokines, increased concentration of glucocorticoids,
other anti-inflammatory modulators such as VIP and vitamin D3, and pharmacological
inducers such as GM-CSF (Maldonado and von Andrian, 2010). As indicated above,
GM-CSF induces tolerogenic dendritic cells which can be productive in models of
autoimmunity.

GM-CSF-induced tolerogenic dendritic cells induce Treg formation

through the co-stimulatory molecules OX40L and Jagged-1 (Gopisetty et al., 2013;
Haddad et al., 2016; Kumar et al., 2017). Because of the neuroprotective effects of GMCSF in PD patients and in the MPTP model, research is warranted to determine whether
the induction of tolerogenic dendritic cells is a mechanism of neuroprotection.

SUMMARY AND CONCLUSIONS
PD is a neurodegenerative disease characterized by the loss of dopaminergic
neurons in the pars compacta substantia nigra and accumulation of α-Syn-containing
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Lewy bodies.

During PD disease, microglia become activated and the peripheral

immune system becomes dysregulated.

Included in this peripheral dysfunction is a

decrease in Treg percentage and function and increased expression of proinflammatory
mediators, suggesting a bias toward inflammation. Correcting this imbalance would be a
novel therapeutic for PD.

GM-CSF is a cytokine which, among other functions,

increases the number and function of Tregs. Administration of GM-CSF increases the
percentage of Tregs, diminishes neuroinflammation and protectes dopaminergic neurons
in the MPTP model. Sargramostim diminishes UPDRS part III scores and increases
Treg percentage and function in PD patients. In models of autoimmunity, GM-CSF
diminishes autoimmunity by inducing tolerogenic dendritic cells which induce Tregs and
suppress inflammation. This project investigates whether tolerogenic dendritic cells are
protective in the MPTP model of PD.

26

CHAPTER TWO
GENE EXPRESSION IN T RESPONDER CELLS IN PD PATIENTS
TREATED WITH SARGRAMOSTIM
ABSTRACT
In Parkinson’s disease (PD) the percentage of peripheral immune cells and
mediators is altered.

The increase in proinflammatory cytokines and helper T cell

subsets and the decrease in anti-inflammatory cytokines and helper T cell subsets may
contribute to the pathology and progression of PD. A novel therapeutic agent that could
restore balance between proinflammatory and anti-inflammatory cells and cytokines may
decrease the symptoms of disease, slow the progression of disease, and create an
environment to recover lost neurons. Sargramostim is recombinant human GM-CSF
which is an FDA approved drug. From a phase I clinical trial, we isolated CD4+ CD25- T
cells from healthy controls, PD placebo controls, or sargramostim-treated PD patients
and isolated RNA for PCR arrays to test expression of genes for helper T cell
differentiation. We hypothesized that sargramostim-treated PD patients would show
increased expression of anti-inflammatory genes and decreased expression of
proinflammatory genes. We found that sargramostim increased the expression of both
pro- and anti-inflammatory genes as well as genes involved in helper T cell
differentiation and proliferation. These data demonstrate that sargramostim increases
the expression of genes associated with all helper T cell subsets, and in general
expands the immune response.

This suggests that GM-CSF alters the immune

response in PD patients, including increasing Tregs and anti-inflammatory immune cells
and cytokines.
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INTRODUCTION
Part of PD pathology of PD is inflammation in the substantia nigra and striatum.
This neuroinflammation is mediated by activated resident microglia as well as infiltrating
immune cells, including lymphocytes (Qian et al., 2010; Gonzalez and Pacheco, 2014).
These activated cells release reactive oxygen and nitrogen species as well as
proinflammatory cytokines and chemokines (Whitton, 2007). This oxidizing environment
leads to the post-translational modification of proteins such as nitration of α-synuclein
(Duda et al., 2000; Giasson, 2000).

The resulting inflammatory and oxidizing

environment promotes the loss of more dopaminergic neurons which, in turn, leads to
more neuroinflammation and increased neurodegeneration (Mosley et al., 2012).
Not only is there inflammation in the brains of PD patients, the peripheral immune
system shows signs of dysregulation.

Peripheral blood of PD patients contain

decreased numbers of plasmacytoid and myeloid dendritic cells in the blood (Ciaramella
et al., 2013), and increased numbers of total granulocytes (Horvath and Ritz, 2015), but
neutrophil number is not increased (Atac Ucar et al., 2016).

Total numbers of

monocytes are not changed in PD patients’ blood; however, classical monocytes
(CD14+ CD16-) are increased in PD patients while non-classical monocytes (CD14CD16+) are decreased in PD patients (Grozdanov et al., 2014). In addition to changes
in the myeloid cells, changes within the lymphocyte population have also been
described. PD patients display increased γδ T cells (Fiszer et al., 1994) and CD8+ T
cells (Baba et al., 2005), but decreased B cells (Niwa et al., 2012; Stevens et al., 2012;
Horvath and Ritz, 2015) and CD4+ T cells (Baba et al., 2005; Hutter-Saunders et al.,
2012; Niwa et al., 2012; Stevens et al., 2012; Horvath and Ritz, 2015). More specifically,
PD patients exhibit decreased naïve CD4+ T cells (CD4+ CD45RA+) and increased

28
memory CD4+ T cells (CD4+ CD45RO+) (Hutter-Saunders et al., 2012; Stevens et al.,
2012; Horvath and Ritz, 2015). In addition, the percentage of different helper T cell
subsets is also changed within PD patients. Percentages of proinflammatory Th1 and
Th17 helper T cells are increased, but the percentage of the anti-inflammatory Th2
helper T cells and Tregs are decreased (Chen et al., 2015).

Tregs also possess

decreased ability to suppress the proliferation of CD4+ CD25- responder T cells in
culture (Hutter-Saunders et al., 2012), suggesting that Tregs from PD patients are less
functional. In addition to these alterations in immune cell number and function, serum
proinflammatory cytokines including IL-6, MCP-1, MIP-1α, IL-1β, IFNγ, and TNF-α are
increased in serum (Reale et al., 2009; Scalzo et al., 2010; Lindqvist et al., 2012).
Reestablishing immune homeostasis is a novel target for PD treatment.
increasing the percentages

and concentration

of

By

anti-inflammatory cells and

concentrations of cytokines, thus decreasing the percentage of proinflammatory cells
and concentration of cytokines, neuroinflammation and neuroprotection can be
mitigated. Several potential therapies target diminution of neuroinflammation and are
neuroprotective in models of PD; some increase Treg percentage and function. One
potential therapeutic is vasoactive intestinal peptide (VIP).

This short peptide is

neuroprotective in the MPTP model (Delgado and Ganea, 2003; Reynolds et al., 2010;
Olson et al., 2015) and induces Tregs (Gonzalez-Rey and Delgado, 2007). Adoptive
transfer of splenocytes from VIP-treated mice is neuroprotective (Olson et al., 2015).
VIP decreases reactive microglia numbers in the substantia nigra following MPTP
intoxication (Delgado and Ganea, 2003; Reynolds et al., 2010; Olson et al., 2015). This
effect of VIP is mediated by binding to VIP receptor 2, since a specific agonist to this
receptor, but not VIP receptor 1, has the same neuroprotective effect as VIP (Olson et
al., 2015).

Bee venom, and its active component phospholipase A, protects
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dopaminergic neurons and decreases neuroinflammation in the MPTP of PD (Doo et al.,
2010; Chung et al., 2012; Chung et al., 2015; Kim et al., 2016). This neuroprotection
was mitigated by Treg depletion, suggesting that bee venom acts through Tregs (Chung
et al., 2012; Chung et al., 2015). However, in a clinical trial, bee venom was unable to
decrease Unified Parkinson’s Disease Rating Scale (UPDRS) scores of PD patients
(Hartmann et al., 2016). Minocycline is another anti-inflammatory drug that is protective
in the MPTP model of PD (Du et al., 2001; Wu et al., 2002). However, like bee venom,
minocycline was unable to diminish PD symptoms in a clinical trial (Investigators, 2006).
Lastly, pioglitazone, a ligand for peroxisome proliferator-activated receptor gamma
(PPAR-γ), treatment results in protected neurons and reduced neuroinflammation in
MPTP-intoxicated mice (Laloux et al., 2012).

However, pioglitazone was unable to

improve outcomes in PD patents (Investigators., 2015; Simon et al., 2015). Despite
neuroprotection and decreased neuroinflammation from the use of these and other
therapeutics in PD models, no therapy to date has proven effective in PD patients.
GM-CSF represents a new potential therapy for PD. Pre-treatment with GM-CSF
protects dopaminergic neurons and decreases neuroinflammation in the model of MPTP
(Kosloski et al., 2013). GM-CSF also increases the percentage of splenic Tregs in a
dose-dependent manner. Adoptive transfer of Tregs from GM-CSF-treated mice are into
MPTP-intoxicated mice decrease neuroinflammation and neurodegeneration, suggesting
that the neuroprotective benefits of GM-CSF are mediated, at least in part, by the
induced Tregs. GM-CSF is a readily translatable drug since it is already FDA approved
for humans. Sargramostim (Leukine) is a yeast-produced recombinant human protein
which is FDA approved for reconstitution of the immune system post-chemotherapy
(Waller, 2007).

Sargramostim decreased the symptoms of Crohn’s disease, an

inflammatory gastrointestinal disorder (Korzenik et al., 2005; Takazoe et al., 2009;
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Valentine et al., 2009), but no research has been done to determine if gut inflammation
is decreased or Treg numbers are increased in these patients. The Nebraska Medical
Center initiated a phase I clinical trial to test the benefit of sargramostim in PD patients.
This trial tested Treg percentage and function as well as neurological changes, motor
functions and metabolomic changes.

If Tregs are having an in vivo effect, we

hypothesized that anti-inflammatory cytokines would be increased with decreased
proinflammatory cytokines expression by CD4+ CD25- T cells, which are suppressed by
Tregs. To test this, we isolated CD4+ CD25- T cells and used PCR arrays to test the
expression of genes related to CD4+ T cells expression and differentiation. Here, we
present the expression of these genes in healthy controls, and PD patients treated with
either placebo or sargramostim.

METHODS
Study Design
A single-center, randomized, double-blind phase 1 clinical trial was performed at
the University of Nebraska Medical Center (UNMC) and was approved by the UNMC
Institutional Review Board (Gendelman et al., 2017). Briefly, PD patients were recruited
according to the following inclusion criteria: age 35-85, onset and persistence of
symptoms ≥3 years and a Hoehn and Yahr disease scale ≤ stage 4. Exclusion criteria
include diagnosis of multiple system atrophy, corticobasal degeneration, prior head
injury, stroke, brain surgery, mental illness, cognitive impairment, autoimmune disease,
systemic inflammatory disorder, hematologic disorders, PD symptoms lasting less than 3
years, and more than one blood relative diagnosed with PD. This trial also excluded
individuals who had taken lithium, neuroleptics, or immunomodulatory treatment within

31
90 days of starting the study. Allergies to benzyl alcohol, colony-stimulating factors or
yeast-derived products and ferrous metal implants were also grounds for exclusion.
Age-matched, non-PD controls were also recruited. After referral to the clinical research
center (CRC), written informed consent was obtained in accordance with Good Clinical
Practice guidelines.
Healthy, non-PD controls, and PD patients had 3 pretreatment appointments to
establish neurological and immunological baselines (visits 1-3). The 3rd appoint was the
final appointment for the healthy controls and the PD patients were randomized in equal
numbers to receive sargramostim or placebo.

PD patients self-administered a

subcutaneous injection of saline (placebo) or 6 µg/kg/day sargramostim every day for 56
days. Every two weeks during this treatment phase, patients continued doctor visits for
blood draws and to monitor health and motor function (visits 4-7). Patients returned for a
post-treatment visit one month after ceasing treatment (visit 8). During each visit, blood
was drawn, the patient was examined by a physician, and the UPDRS part III clinical
assessment was performed. Patients remained on anti-PD medications and UPDRS III
evaluation was performed while patients were in the "ON" state. Table 2.1 is a summary
of the study design and the number of patients from each treatment group included for
the gene expression analysis.
A subset of healthy controls, placebo-treated PD patients, and sargramostimtreated PD patients were used for the following studies. Multiple methods were used to
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Table 2.1 Study design
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Table 2.1 Study design
The table describes of the study design for this clinical trial. The treatment phase, visit,
and weeks indicate when each visit occurs relative to starting treatment with placebo or
sargramostim and which visit belongs to each treatment phase. For the treatment
groups, the number of patients from which RNA was isolated out of the total number of
patients is indicated.
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isolate CD4+ CD25- cells, which were isolated from blood and combined with CD4+
CD127low CD25- cells remaining after Treg isolation. The combination was used for
flow cytometric analysis and RNA isolation.
Isolation of CD4+ cells
CD4+ cells were isolated by isolating lymphocytes using lymphocyte separation
media (LSM, MP Biomedicals LLC Santa Ana, CA) prior to positive CD4+ isolation.
Briefly, the whole volume of a single tube of blood was diluted by the addition of an
equal volume of 1x HBSS (Gibco, Carlsbad, CA). The lymphocytes and monocytes
were separated by layering diluted blood on top of LSM before centrifugation at 400 xg
for 20 min without breaking. The buffy coat was transferred to a new tube and was
washed in 3 volumes of 1x HBSS. Cells were concentrated by centrifugation at 200 xg
for 10 min. To the cell pellet, 80 μl of Miltenyi CD4+ buffer (0.5% bovine serum albumin
(BSA), 2 mM EDTA in 1x DPBS (Gibco)) and 20 μl anti-CD4 magnetic beads (Miltenyi
Biotec Auburn, CA) were added for every 1x107 cells. After incubation at 4°C for 15 min,
cells were washed in 2 ml Miltenyi CD4+ buffer for every 1x107 cells and cells were
concentrated by centrifugation at 300 xg for 10 min. The cell pellet was resuspended in
500 μl Miltenyi CD4+ buffer and the whole volume was pipetted into a Miltenyi LS
column which was placed in a magnet. The column was washed three times with 2 ml
Miltenyi CD4+ buffer. Five milliliters of Miltenyi CD4+ buffer was added to the column,
the column was removed from the magnet, and the buffer was forced through the
column into a 15 ml conical tube using a plunger. This procedure was used to isolate
cells for XIL visits 1 and 2, YEA visits 1 and 2, ZNB visits 1 and 2, BED visit 1, CAE visit
1, DBF visit 1, and ECG visit 1.
Isolation of Responder T cells
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Responder T cells were isolated according to the protocol for the R&D CD4+
enrichment kit as follows.

Briefly, lymphocytes were isolated by LSM as described

above. The resulting lymphocytes were resuspended in 1 ml 1x R&D CD4+ enrichment
kit column buffer (R&D systems, Minneapolis, MN). In addition to antibodies for the
selection of CD4+ CD25- cells, 2 μg/1x106 cells of anti-CD16 (clone 3G8 BD, Franklin
Lakes, NJ), anti-CD8 (clone HIT8a BD), and anti-CD25 (clone M-A251 BD) and 1
μg/1x106 cells anti-CD16 (clone 245536 R&D Systems) was added to enhance purity.
Cells were incubated with antibodies at RT for 15 min mixing the tube every 2 min,
washed 2 times in 1x column buffer, and resuspended in 2 ml R&D column buffer before
adding to the column. After incubating the cells on the column for 10 min, the cells were
washed through the column with R&D column buffer and cells were concentrated by
centrifugation at 400 xg for 5 min. These cells were combined with the cells isolated
following the cell rosetting protocol as described below.

This method was used for

isolating cells from the following patient visits: XIL visits 3, 4 and 5, YEA visit 3, ACC visit
3, ZNB visits 3, 4 and 5, BED visit 2, CAE visit 2, DBF visit 2, ECG visit 2, FDH visits 1
and 2, HFJ visits 1 and 2, and IGK visits 1 and 2.
Isolation of CD4+ CD25- cells
As with the responder T cells, lymphocytes and monocytes were isolated by LSM
and these buffy coat cells were washed in 1x HBSS. To the cell pellet, 80 μl of Miltenyi
CD4+ buffer (0.5% BSA, 2 mM EDTA in 1x DPBS) and 20 μl anti-CD25 magnetic beads
(Miltenyi Biotec) were added for every 1x107 cells. After incubation at 4°C for 15 min,
cells were washed in 2 ml Miltenyi CD4+ buffer for every 1x107 cells, concentrated by
centrifugation at 300 xg for 10 min, resuspended in 500 μl Miltenyi CD4+ buffer, and the
whole volume was added into a Miltenyi LD column. The column was washed 3 times
with 2 ml Miltenyi CD4+ buffer.

The CD25-depleted cells were concentrated by
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centrifugation at 300 xg for 10 min, and 40 μl Miltenyi CD4+ buffer and 10 μl CD4+
antibody cocktail was added for every 1x107 cells. After incubation at 4°C for 5 min, 30
μl Miltenyi CD4+ buffer and 20 μl of Miltenyi microbeads were added for every 1x107
cells. After incubation at 4°C for 10 min, 500 μl Miltenyi CD4+ buffer was added and the
whole volume was added into a Miltenyi LS column. Cell effluents through the column
were collected as CD4+ CD25- T cells. Cells were counted and combined with T cells
isolated from the rosetted procedure for flow cytometry and RNA isolation. This method
was used for T cell isolation for the following patient visits: XIL visits 7 and 8, ZNB visits
6, 7 and 8, BED visits 3-8, CAE visits 3, DBF visits 3-8, ECG visits 3, HFJ visits 3-8, IGK
visit 3, JHL visits 1-8, KIM visits 1-3, LJN visits 1-8, MKO visits 1-8, and NLP visits 1-8.
Isolation of CD4+ CD127low CD25- cells
Tregs (CD4+ CD127low CD25+) were isolated from 6 tubes of blood using the
RosetteSep human CD4+ CD127low CD25+ isolation kit (Stemcell Technologies,
Vancouver, BC) as follows. Briefly, 50 μL/mL RosetteSep human CD4+ CD127low preenrichment cocktail was added to whole blood and the mixture was incubated for 20 min
at RT. Whole blood (25 ml) was layered onto 15 ml density media in a Sep-Mate-50
tube and cells were separated by centrifugation at 1,200 xg for 10 min. The top layer,
which contains mononuclear cells, was decanted and washed two times in Treg buffer
(1x DPBS with 2% fetal bovine serum (FBS, Sigma, St. Louis, MO)). To isolate CD25+
cells, EasySep positive selection cocktail was added at 50 µl/ml, incubated at RT for 15
min, 50 µl nanoparticles/ml was added, and incubated at RT for 10 min. The tube was
placed in a magnet field and incubated for 5 min. While remaining in the magnetic field,
cells were washed 9 times by decanting supernatant and 2.5 ml of Treg buffer was
added.

The negatively selected CD25- T cells decanted in the washes were

concentrated by centrifugation at 400 xg for 5 min. Red blood cells in the pellet were
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osmolysed by incubating in 9 ml autoclaved ultrapure water for 30 sec and 1 ml 10x PBS
was added to restore osmolarity and cells were concentrated by centrifugation at 400 xg
for 5 min. The cells were counted and combined with the CD4+, responder T cells or
CD4+ C25- cells isolated above for flow cytometry and RNA isolation. This method was
performed for all patient visits and these cells combined with cells isolated using the
above methods.
Flow cytometry
Flow cytometric analysis was performed at the UNMC flow cytometry research
facility. A volume corresponding to 250,000 cells was brought to 100 μl by the addition
of flow cytometry stain buffer (FSB, 0.5% BSA and 0.1% sodium azide in 1x DPBS) and
the cells were stained by the addition of anti-CD4-FITC (clone RPA-T4 BD), anti-CD25PE (clone M-A251 BD), anti-CD127-PERCPCy5.5 (clone HIL-7R-M21BD), antiCD45RA-AF700 (clone HI100, BD), anti-CD45RO-APC (clone UCHL1, BD) and antiCCR7-PECy7 (clone 3D12 BD) at 4°C for 20 min. Cells were washed twice by the
addition of 2 ml FSB per wash, concentrated by centrifugation at 400 xg for 5 min,
resuspended in 500 μl flow cytometry fix (1% formaldehyde in 1x DPBS), and cells were
incubated at RT for 10 min. Fixed cells were concentrated by centrifugation at 400 xg
for 5 min. The cell pellet was resuspended in 300 μl FSB prior to analysis with a BD
LSR II flow cytometer interfaced with FACSDiva analytical software (version 8.0) (BD
Biosciences, San Jose, CA).
RNA isolation, cDNA conversion and PCR arrays
With fewer than 3x106 total cells, then all cells were pelleted at 400 xg for 10 min
and frozen at -80°C for RNA isolation when remaining samples were collected. With
more than 3x106 cells, half of the cells were pelleted and frozen as above. The other
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half of the cells were brought to ~1x106 cells/ml with the addition of complete media
(RPMI 1640 supplemented with L-glutamine (Gibco), 10% FBS (Sigma), 1 mM sodium
pyruvate (Gibco), 1x MEM non-essential amino acids (Hyclone, Logan, Utah), 1x
Penicillin-Streptomycin (Gibco), 10 mM HEPES (Sigma), 2 mM L-glutamine (Gibco) and
55 nM 2-mercaptoethanol (Gibco)) and 100 μl was added to each well of a U-bottom 96well plate. An additional 100 μl media containing ~5x105 anti-CD3/CD28 magnetic, costimulatory dynabeads was added to each well (Gibco). After 6 hours of stimulation, the
cells were removed from the 96-well plate, combined and concentrated at 400 xg for 10
min, and cell pellets were frozen at -80°C.
RNA was isolated according to the directions in the RNeasy mini kit (Qiagen,
Valencia, CA).

Briefly, cell pellets were resuspended in Buffer RLT (350 µl RLT

buffer/~5x106 cells) supplemented with 10 μl β-mercaptoethaol/ml RLT and cells were
lysed by passing through a 20 Ga needle 10 times. The cell lysate was clarified by
centrifugation at 20,800 xg for 3 min, supernatant added to an equal volume of 70%
ethanol, added to a spin column, and passed through at 10,800 xg for 1 min. The flow
through was discarded and the filter was washed in RW1 buffer. DNA was digested
using the RNase-free DNase kit (Qiagen) by adding 10 μl DNase I and 70 μl RDD buffer
per column, and the digestions were incubated at RT for 15 min. The column was
washed in RW1 a second time and then in RDD buffer two times. RNA was eluted by
the addition of water. The eluted RNA was passed through the column a second time to
maximize RNA yield and RNA concentration was determined by UV spectrometry at
260, 280, and 230 nm (NanoDrop spectrophotometer, ThermoScientific, Waltham, MA).
Single-stranded cDNA was made as directed using the RevertAID single strand
cDNA synthesis kit (ThermoScientific). Briefly, depending on the RNA concentration,
100, 125 or 250 ng RNA was brought to 11 μl with water provided in the kit and 1 μl
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poly(T) primers and the secondary structure of RNA was disrupted by heating at 65°C
for 5 min. A master mix of 4 μl reaction buffer, 2 μl dNTPs, 1 μl ribolock RNase inhibitor
and 1 μl reverse transcriptase/sample was added and synthesis was performed at 42°C
for 1 hr. The reaction was terminated by heating at 70°C for 5 min. The multiple
reactions of each sample were combined and frozen at -20°C until the PCR arrays were
performed.
The expression of genes related to helper T cell differentiation was determined
using a Helper T cell differentiation array which was performed according to the
manufacturer’s protocol SABiosciences (Frederick, MD). Briefly, water, 2x RT2 ROX
master mix, and the cDNA was combined and 25 μl was added to each well of the array.
PCR was performed using an Realplex S2 thermocycler (Eppendorf, Hamburg,
Germany) with a 10 min hot start at 95°C, then 40 cycles of a two-steps of 95°C for 15
sec and 60°C for 1 min followed by a melting curve.

GAPDH was used as the

housekeeping gene. Data analysis was performed using the Qiagen software and fold
changes were determined using the ΔΔCt method.
Statistical analysis
For flow cytometry samples, the Mann-Whitney U test was used to determine
significant differences between the healthy controls, placebo-treated PD patients and
sargramostim-treated PD patients at each visit. Statistics for flow cytometry data were
performed by GraphPad (La Jolla, CA) Prism version 6. For the PCR arrays, the RT2
Profiler PCR array data analysis software version 3.5 was used to calculate the fold
change between samples. For downregulated genes, fold changes are the negative
inverse of fold change.
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RESULTS
Flow cytometry characterization of CD4+ CD25Flow cytometric analysis was performed on CD4+ CD25- T cells isolated from
participants to identify various subpopulations of T cells over the trial in the treatment
groups. In Figure 2.1A, the percentage of CD4+ T cells in the total population for each
visit was graphed. Consistently, around 40% of the total population was CD4+ T cells
for the healthy controls, the placebo-treated PD patients and the sargramostim-treated
PD patients.

The identity of the non-CD4 cells was not determined, though they

appeared to be the same size and granularity as the CD4+ cells suggesting they were
lymphocytes and/or monocytes.

In Figure 2.1B, no significant differences in the

percentage of naïve CD4+ T cells (CD4+ CD45RA+ CCR7+) were discerned between
placebo-treated and sargramostim-treated PD patients, with the exception at visit 7
where sargramostim-treated patients have a significant decrease in these T cells.
Healthy controls were not different from either PD patient group at visits 1-3.

No

differences were detected between the percentage of central memory (CD4+ CD45RO+
CCR7+) or effector memory (CD4+ CD45RO+ CCR7-) helper T cells between healthy
controls, placebo-treated, and sargramostim-treated PD patients at any visit (Figure
2.1C and 2.1D respectively). Interestingly, sargramostim-treated PD patients tend to
possess increased effector memory helper T cells compared to the placebo-control
patients at visits 6 and 7 (Figure 2.1D). In Figure 2.1E, the percentages of Tregs (CD4+
CD127- CD25+) were not different between the healthy controls, placebo-treated PD
patients, and sargramostim-treated PD patients at any visit. At visit 6, activated effector
T cells (CD4+ CD127+ CD25+) in sargramostim-treated PD patients were elevated
compared to placebo-treated PD patients, but this was the only visit with a significant
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Figure 2.1 Flow cytometric analysis of CD4+ CD25- cells
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Figure 2.1 Flow cytometric analysis of CD4+ CD25- cells
CD4+ CD25- cells were isolated from the blood of healthy controls (black lines), placebotreated (blue lines) and sargramostim-treated (red lines) PD patients at each visit. Flow
cytometric analysis was used to determine the surface expression of CD4, CD127,
CD25, CD45RO, CD45RA and CCR7. Within the whole blood, we determined the
percentage of total CD4+ T cells (A). The percentage of naïve helper T cells (CD4+
CD45RA+ CCR7+) (B), central memory helper T cells (CD4+ CD45RO+ CCR7+) (C),
effector memory helper T cells (CD4+ CD45RO+ CCR7-) (D), regulatory T cells (CD4+
CD127- CD25+) (E) activated effector helper T cells (CD4+ CD127+ CD25+) (F) within
the total CD4+ T cell population was determined. Significance was determined by the
Mann-Whitney U test at each visit. a-p < 0.05.
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difference and there were no differences compared to the healthy controls (Figure 2.1F).
These data demonstrate that the isolated T cells population showed roughly equal
percentages of these T cell subpopulations over time.

As such, changes in gene

expression were not due to differences in cell type being analyzed.
Gene expression comparing to PD patients to controls
After isolating RNA from each sample, we determined the A260/A80 and
A260/A230 by UV spectrometry.
contamination control.

Each PCR array contains a genomic DNA

The result is included in Table 2.2 to give an indication of

RNA/cDNA quality. The first gene expression analysis we performed was to compare all
PD patients to healthy controls pre-treatment (visits 1-3). In unstimulated CD4+ CD25cells (Figure 2.2A), PD patients upregulated more than 2-fold several genes associated
with proinflammatory cell types. For instance, STAT4 is a transcription factor induced by
IL-12 (Watford et al., 2004), EOMES, a transcription factor upregulated in activated Th1
helper T cells (Lupar et al., 2015), RORC is the master transcription factor for Th17
helper T cells (Martinez et al., 2008; Jetten, 2009), and IL18RAP is the beta chain for the
IL-18 receptor (Fiszer et al., 2007). PD patients also downregulated by more than 2-fold
anti-inflammatory genes such as CCR4, a chemokine receptor selectively expressed on
Th2 helper T cells (Yoshie and Matsushima, 2015), and ICOS, a co-stimulatory molecule
the favors development of Th2 helper T cells and proliferation and survival of Tregs
(Simpson et al., 2010).
We also analyzed the gene expression of CD4+ CD25- cells stimulated with
CD3/CD28 beads for 6 hours from healthy control and all PD patients prior to treatment
(Figure 2.2B). PD patients increase the expression of IRF4, a gene involved in the
differentiation and function of Th2 and Tregs (Zheng et al., 2009), by more than 2-fold
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Table 2.2 RNA quality analysis
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Table 2.2 RNA quality analysis
A table listing the ratio of the RNA absorbance at 260 and 280 nm (A260/A280) and the
ratio of RNA absorbance at 260 and 230 nm (A260/A230). Lastly, we tested each
sample for genomic contamination of the cDNA. There was no genomic contamination
when the ct value for the included control well on each PCR array was >35. When the ct
value was in the cycle 30-35 range, genomic contamination is possible. Genomic DNA
was confirmed when the ct value was less than cycle 30. The PCR array for patient
DBF at visit 2 unstimulated could not be determined because an improper PCR cycle
program was used and there was insufficient sample to repeat the analysis. This
sample was excluded from all analyses.
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Figure 2.2 Gene expression comparing PD patients to healthy controls pre-treatment
with and without CD3/CD28 stimulation
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Figure 2.2 Gene expression comparing PD patients to healthy controls pretreatment with and without CD3/CD28 stimulation
RNA was extracted from the isolated CD4+ CD25-, and cDNA copies were made from it
prior to PCR using an array for human CD4+ T cell differentiation. The fold change in
expression from each gene was compared for the PD patients compared to healthy
controls using the ΔΔCt method. Heat maps were generated for all genes more than 2fold up- or downregulated for (A) unstimulated and (B) CD3/CD28 bead-stimulated CD4+
CD25- cells. The numbers are the fold change. Red shaded cells are upregulated
genes and green shaded cells are downregulated genes. The shade of color denotes
the degree of upregulation.
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compared to healthy controls.

However, PD patients exhibited 2-fold decreased

expression of anti-inflammatory genes such as IL5, TNFSF11, CCR4, CCL7, IL9,
PTGDR2 and ICOS. Expression of proinflammatory genes such as SOCS5, IL17RE
and IL17A were decreased in PD patients. Combined, these data suggest PD patients
express more proinflammatory genes at rest compared to healthy controls. However,
after stimulating CD4+ CD25- cells with CD3/CD28 beads, PD patients display lower
gene expression compared to healthy controls.
Gene expression compared to baseline for placebo or sargramostim PD patients
We next tested the expression of genes in the placebo-treated and
sargramostim-treated PD patients at visits 4, 5, 6, 7 and 8 compared to the baseline
(visits 1-3) in unstimulated CD4+ CD25-. Figure 2.3A is a heatmap of all 2-fold gene
expression changes in placebo-treated PD patients for each visit compared to the
baseline. The gene changes in the placebo-treated PD patients were smaller compared
to sargramostim-treated patients and no discernible peak in the expression was evident
over time.
Figure 2.3B is a heat map of all 2-fold gene changes at each visit for the
sargramostim-treated patients compared to baseline. Some increased genes were nonassociated genes; those involved in T cell differentiation and proliferation and included
GATA4, TNFRSF9, IL2, KIF2C, and HOXA3.

Expression of proinflammatory genes

were increased including IL21, IL12B, IL17A, IL1R1, IL17RE, SOCS5, and HAVCR2.
Increased anti-inflammatory gene expression included IL4, CCL7, IL1RL1, IL9, PPARG,
LRRC32, TNFSF11, IL13, IL5, PTGDR2, CCR4, and ICOS.

Expression of non-

associated genes such as STAT1, MAF, and RUNX3 were also decreased. Several
proinflammatory genes displayed decreased expression including STAT4, RORA, IRF1,
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Figure 2.3 Gene expression comparing unstimulated CD4+ CD25- on-treatment and
post-treatment visits to baseline for placebo- or sargramostim-treated PD patients
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Figure 2.3 Gene expression comparing unstimulated CD4+ CD25- on-treatment
and post-treatment visits to baseline for placebo- or sargramostim-treated PD
patients
RNA was extracted from the isolated CD4+ CD25-, and cDNA copies were made from it
prior to PCR using an array for human CD4+ T cell differentiation. The fold change of
expression from each gene was compared for the placebo and sargramostim-treated PD
patients on-treatment (visits 4-7) and post-treatment (visits 4-8) relative to baseline
(visits 1-3) using the ΔΔCt method. Heat maps were generated for all genes more than
2-fold up- or downregulated for the unstimulated CD4+ CD25- from (A) placebo-treated
PD patients and (B) sargramostim-treated PD patients. The numbers are the fold
change. Red cells are upregulated genes and green cells are downregulated genes.
The color shade denotes the degree of upregulation. Pro-inflammatory genes are those
related to Th1 and Th17 cells. Anti-inflammatory genes are related to Th2 and Tregs.
The non-associated genes are found in all T cells, regardless of subset.
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and IL18RAP. Anti-inflammatory genes including CCL5, ID2, Jak1, STAT6, and GATA3
were also decreased. In general, the peak in gene expression was at visit 5. At visits 6
and 7, expression remained elevated in sargramostim-treated PD patients compared to
baseline, but the expression was decreased compared to visit 5. In general, there is no
peak in decreased expression of genes. Interestingly, there was a trend to decreasing
expression of CCL5 (the gene for the chemokine RANTES) over treatment, with
expression lowest at visit 7.

Post-treatment (visit 8), most genes returned to near

baseline, though some genes remained increased or decreased.
Counter to our hypothesis, sargramostim increased the expression of both proand anti-inflammatory genes compared to baseline in CD4+ CD25- T cells. It is not
surprising that sargramostim increased the expression of genes associated with
proliferation, since sargramostim increases the number and percentage of CD4+ T cells
compared to placebo control (unpublished data).

The increase in anti-inflammatory

genes is in line with increased Treg number and function from peripheral blood
(Gendelman et al., 2017). From the data presented here, proinflammatory genes were
also increased. Interestingly, sargramostim does not change in the number of Teffs
(CD4+ CD127+ CD25+) in whole blood and the T cells isolates for these analyses
compared to placebo controls. These data demonstrate that sargramostim can stimulate
the expression of proinflammatory and anti-inflammatory genes in helper T cells.
However, to what degree these changes in gene expression promote the differentiation
of helper T cells to different subsets was not determined.
Because the identity of helper T cells is often revealed after activation, we
stimulated cells with CD3/CD28 beads. Figure 2.4A is a heat map of the 2-fold gene
changes in CD3/CD28 bead-stimulated CD4+ CD25- cells from placebo on- or post-
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Figure 2.4 Gene expression comparing CD3/CD28-stimulated CD4+ CD25- at baseline
to on- and post-treatment visits for placebo-or sargramostim-treated PD patients
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Figure 2.4 Gene expression comparing CD3/CD28-stimulated CD4+ CD25- at
baseline to on- and post-treatment visits for placebo- or sargramostim-treated PD
patients
RNA was isolated from the isolated CD4+ CD25-, and copied to generate cDNA prior to
PCR using an array for human CD4+ T cell differentiation. The fold change of
expression from each gene by PD patients was compared to healthy controls using the
ΔΔCt method. Heat maps were generated for all genes that were more than 2-fold upor downregulated for the stimulated CD4+ CD25- from (A) placebo-treated PD patients
and (B) sargramostim-treated PD patients. The numbers are fold change. Red shaded
cells are upregulated genes and green shaded cells are downregulated genes. The
shade of color denotes the degree of upregulation. Pro-inflammatory genes are those
related to Th1 and Th17 cells. Anti-inflammatory genes are related to Th2 and Tregs.
The non-associated genes are found in all T cells and are not related to only subset.
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treatment compared to baseline.

We were unable to isolate sufficient cells for

stimulation at each visit for each patient. Due to lack of samples, data were grouped by
treatment phase as opposed to grouping by visit. As in Figure 2.3, gene changes are
smaller in the placebo-treated PD patients compared to sargramostim-treated PD
patients. In addition, there were no apparent changes were discerned in the pattern of
gene expression on treatment or post treatment compared to baseline.
Figure 2.4B is a heat map of all 2-fold gene changes in CD3/CD28 beadstimulated CD4+ CD25- T cells from sargramostim-treated PD patients on- or posttreatment compared to baseline. CD3/CD28 bead-stimulated CD4+ CD25- T cells from
the sargramostim-treated patients on treatment showed upregulated several nonassociated genes such as GATA4, HOXA10, PERP, HOXA3, and KIF2C and a
downregulated IL2, STAT1, MAF, and IL2RA.

Several proinflammatory genes were

upregulated such as IL17A, IL17RE, IL18, IL12B, and RORC, while several were
downregulated such as IFNG, TNF, STAT4, and IL18RAP. Anti-inflammatory genes that
were upregulated included PTGDR2, ASB2, UTS2, PPARG, IL4, ICOS, and LRRC32
were increased. But the expression CCL5, FOXP3, IRF4, STAT6, REL, and JAK1 were
downregulated.

Many of the genes changed in the CD3/CD28-stimulated cells are

similar to the genes changed in unstimulated cells (Figure 2.3). For example, nonassociated genes like GATA4 and PERP, pro-inflammatory genes like IL17A and
IL17RE, and anti-inflammatory genes like IL4 and PTGDR2 are upregulated in both
unstimulated- and CD3/CD28-stimulated CD4+ CD25- cells.

Interestingly, the fold

change is smaller after CD3/CD28-stimulation compared to unstimulated cells.

In

general, the fold change on-treatment is higher and returns to near baseline at the posttreatment visit, however only one sample in the sargramostim-treated post-treatment
group.
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Combined, Figures 2.3 and 2.4 demonstrate sargramostim increases the
expression of many genes, both pro- and anti-inflammatory, in unstimulated CD4+
CD25- T cells compared to pre-treatment baseline.

However, stimulating this cell

population with CD3/CD28 beads also increased the expression of these genes in all
treatment phases, but decreases the effect of sargramostim treatment on gene
expression.
Gene expression comparing the placebo to sargramostim PD patients
Figures 2.3 and 2.4 demonstrated changes in gene expression relative to
baseline for the placebo controls and sargramostim-treated group.

Another way of

analyzing these data is to test sargramostim-treated gene expression relative to the
placebo control at each visit. In Figure 2.5, the gene expression in unstimulated CD4+
CD25- cells in the sargramostim-treated PD patients was compared to the placebotreated PD patients at each visit. At baseline (visits 1-3), some genes that were more
than 2-fold up- or downregulated. These changes were relatively small, indicating little
differences in gene expression between T cells isolated from PD patients at baseline.
Starting by 2 weeks (visit 4) after treatment initiation and increasing to visit 5 noticeable
increases were evident in expression of non-associated genes such as GATA4,
TNFRSF9, PERP, and KIF2C. Expression of several non-associated genes such as
HOXA3, RUNX1, STAT4, and STAT1 also was decreased. As in Figure 2.3, expression
of proinflammatory genes such as IL21, IL12B, IL1R1, and IL17A was increased.
Downregulated expression of proinflammatory genes included RORA and IL18RAP. As
hypothesized, sargramostim treatment increased the expression of anti-inflammatory
genes such as CCL7, TNFRSF11, IL13, IL1RL1, IL4, LRRC32, PPARG, and PTGDR2,
but downregulated some genes such as STAT6, CCL5, and ID2.
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Figure 2.5 Gene expression comparing unstimulated CD4+ CD25- cells from placebotreated compared to sargramostim-treated PD patients
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Figure 2.5 Gene expression comparing unstimulated CD4+ CD25- cells from
placebo-treated compared to sargramostim-treated PD patients
RNA was extracted from the isolated CD4+ CD25-, and copied to cDNA prior to PCR
using an array for human CD4+ T cell differentiation. Fold changes of expression from
each gene was compared for the PD patients compared to healthy controls using the
ΔΔCt method. Heat maps were generated for all genes more than 2-fold up- or
downregulated for the unstimulated CD4+ CD25 cells. Red shaded cells are
upregulated genes and green shaded cells are downregulated genes. The color shade
denotes the degree of upregulation. Pro-inflammatory genes are those related to Th1
and Th17 cells. Anti-inflammatory genes are related to Th2 and Tregs. The nonassociated genes are found in all T cell subsets.
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These data are in line with Figure 2.3 demonstrating that sargramostim increases
the expression of CD4+ T cell proliferation/differentiation, proinflammatory and antiinflammatory genes.

The peak expression appears to be at visit 5 (4 weeks after

initiation of treatment), although the timing is different for different genes. Gene
expression appears to remain elevated at visits 6 and 7, but by visit 8 (the posttreatment visit), gene expression returned to near baseline. This demonstrates that
sargramostim treatment increased the expression of genes relative to placebo patients
as well as relative to baseline.
We also tested the expression of genes in the CD3/CD28 bead-stimulated CD4+
CD25- T cells from sargramostim-treated PD patients relative to placebo-treated PD
patients (Figure 2.6). As in Figure 2.4, there were insufficient samples to compare visit
by visit, so we tested by treatment phase.

There was only one sample for the

sargramostim treatment group post treatment. As in Figure 2.5, at baseline, there were
some genes that were more than 2-fold increased or decreased in expression after
sargramostim treatment. These were relatively small changes and indicative that PD
patients display similar responses to CD3/CD28 stimulation at baseline. During the ontreatment phase, sargramostim treatment increased the expression of several nonassociated genes, such as GATA4, PERP, and KIF2C. Sargramostim also
downregulated several non-associated genes such as IL2, STAT4, IL2RA, STAT4, and
STAT1.

Even after ceasing sargramostim treatment, KIF2C and GATA4 expression

remained elevated.
Sargramostim treatment also increased the expression of proinflammatory genes
such as IL17RE, IL17A, TLR6, and IL1R1, and significantly downregulated the
expression of several proinflammatory genes including IFNG, TNF, IL18RAP, RORA,
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Figure 2.6 Gene expression comparing unstimulated CD4+ CD25- T cells from placebotreated PD patients compared to sargramostim-treated PD patients
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Figure 2.6 Gene expression comparing unstimulated CD4+ CD25- T cells from
placebo-treated compared to sargramostim-treated PD patients
RNA was extracted from the isolated CD4+ CD25- T cells and copied to cDNA, prior to
PCR using an array for human CD4+ T cell differentiation. The fold change of
expression from each gene was compared for the PD patients compared to healthy
controls using the ΔΔCt method. Heat maps were generated for all genes more than 2fold up- or downregulated for the stimulated CD4+ CD25 cells. Red colored cells are
upregulated genes and green colored cells are downregulated genes. The color shade
denotes the degree of upregulation. Pro-inflammatory genes are those related to Th1
and Th17 cells. Anti-inflammatory genes are related to Th2 and Tregs. The nonassociated genes are found in all T cells subsets.
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and IRF1. Post-treatment, gene expression appears to return to near baseline for both
the upregulated and downregulated genes.

Sargramostim also increased the

expression of several anti-inflammatory genes such as IL1R1, HOXA10, TNFSF11 and
PTGDR2, and downregulated several anti-inflammatory genes such as IRF4, IL4R,
CCL5, NR4A1, and ID2. Post-treatment gene expression returned to near baseline for
all genes, although CEBPB was upregulated on-treatment and is decreased posttreatment.
These data demonstrate that sargramostim alters expression of many genes in
CD3/CD28-stimulated CD4+ CD25- T cells. As in Figure 2.4, the increases in gene
expression are smaller in the CD3/CD28 bead-stimulated compared to the unstimulated
cells.

This is probably due to the CD3/CD28 beads activating, and leading to

upregulation of gene expression in the placebo control cells, thereby diminishing the
relative increase in gene expression due to sargramostim. Combined, Figures 2.3, 2.4,
2.5, and 2.6 demonstrate that sargramostim does increased the expression of genes
relative to both the pre-treatment baseline as well as placebo treatment. This increase
in expression is in genes associated with T cell proliferation and differentiation, and in
proinflammatory and anti-inflammatory genes, demonstrating broad effects across T cell
subsets.
Gene expression of individual placebo and sargramostim PD patients
From the above data, values were combined for all patients as another way to
analyze these data by changes in gene expression for each patient. Seven patients (4
placebo controls (BED, HFJ, JHL, and MKO) and 3 sargramostim-treated patients (DBF,
LJN, and NLP)) who had data for all 8 trial visits were utilized. Gene expression of
unstimulated cells at visits 4, 5, 6, 7 and 8 was determined relative to the baseline (visits
1-3) for each patient. In addition to determining gene expression for each individual, we
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also tested if the degree of gene change was related to changes in the percentages of
peripheral Tregs, which were increased in the sargramostim-treated patients
(Gendelman et al., 2017). Figure 2.7 shows the extent of gene expression as a function
of CD4+ CD25+ Foxp3+ Treg percentages in peripheral blood for the 2 genesthat were
most increased by sargramostim treatment (Figure 2.5) for each category including nonassociated genes (Figure 2.7A and B), proinflammatory genes (Figure 2.7C and D), and
anti-inflammatory genes (Figure 2.7E and F). The degree of gene change in response
to sargramostim treatment varies between patients, but consistently patients LJN and
NLP showed the greatest gene change. These patients also had the highest percentage
of Tregs within the CD4+ population. Increase in Tregs percentages was associated
with increased expression of all genes reported. The sargramostim-treated patient DBF
displayed gene expression and Treg percentage closer to the placebo controls,
suggesting that this patient’s response was less compared to patients LJN and NLP.
This figure shows that while each patient responded to different degrees, the trend within
the group is replicated with each patient. Notably, patients with the highest increase in
gene expression also showed the highest increase in the percentage of Tregs, which
provides evidence that these patients responded to sargramostim treatment.

We

hypothesized that the increase in Tregs would reduce the expression of proinflammatory
genes; however, patients with the highest percentage of Tregs also display elevated
expression of proinflammatory genes. This suggests that Tregs are not suppressing the
expression of inflammatory cytokines in this cell population.
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Figure 2.7 Gene expression related to Treg frequency in placebo- and sargramostimtreated PD patients
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Figure 2.7 Gene expression related to Treg frequency in placebo- and
sargramostim-treated PD patients
For each patient, the gene expression was compared to the baseline. The frequency of
Tregs (CD4+ CD25+ Foxp3+) within the CD4+ population was determined from the
whole blood. GATA4 (A) and TNFSF9 (B) are the non-associated genes with the
highest expression in sargramostim-treated patients relative to placebo control PD
patients. IL21 (C) and IL12B (D) are the pro-inflammatory genes with the highest
expression in sargramostim-treated patients compared to placebo controls. CCL7 (E)
and TNFSF11 (F) are the two anti-inflammatory genes with the highest expression in
sargramostim-treated patients relative to placebo controls. Each patient is a separate
color. Placebo controls are filled circles and the sargramostim-treated patients are open
circles.
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Ingenuity Pathway Analysis of placebo compared to sargramostim PD patients
To determine how the genes whose expression was altered by sargramostim
related to helper T cell subsets, Ingenuity Pathway Analysis (IPA) was used. In the
unstimulated T cells, comparing sargramostim-treated patients relative to placebo
control showed genes altered by sargramostim associated with all helper T cell subsets
(Figure 2.8A). In addition, increases in GM-CSF (which in the figure is indicated by the
gene name CSF2) is associated directly or indirectly to the expression of several genes
which were increased, including IL-2R, TNF-α, IL-4, IFNγ, IL-15, IL-13 and Foxp3.
Mapping the same pathways using stimulated T cell expression data to compare
sargramostim-treated patients to placebo-treated patients, showed downregulation of
many genes, including genes were increased in the unstimulated cells (IL2R, TNFα,
IFNγ, and IL13) (Figure 2.8B). \We also identified that GM-CSF (CSF2) was directly or
indirectly associated with the expression of several altered genes including STAT1, TNFα, IFNγ, IL-13, Foxp3 and IL-2R.

DISCUSSION
In this chapter, gene changes in the CD4+ CD25- T cells in PD patients treated
with sargramostim were described. First, the percentages of different populations of T
cells over time were determined to ensure that the distribution of analyzed T cells did not
change over time. While some significant differences were evident at individual visits in
cells isolated between placebo-treated and sargramostim-treated T cells, overall the
distribution of analyzed cells did not change over time or between treatment groups.
Interestingly, that sargramostim increased the percentage of effector memory helper T
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Figure 2.8 Ingenuity pathway analysis of genes altered by sargramostim in unstimulated
and stimulated CD4+ T cells
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Figure 2.8 Ingenuity Pathway Analysis of genes altered by sargramostim in
unstimulated and stimulated helper T cells
Ingenuity Pathway Analysis was used to map the gene changes from sargramostimtreated patients relative to placebo controls for the (A) unstimulated cells and (B)
stimulated cells. The T cell differentiation pathways are showed. Genes that are
upregulated are red, downregulated genes are green. In this analysis, the genes which
are directly or indirectly associated with GM-CSF (CSF2) are indicated by purple lines.
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cells and fewer naïve helper T cells, possibly indicating an activation of helper T cells,
though this may be an artifact of isolation.

Sargramostim increases many genes

associated with proliferation and differentiation of CD4+ T cells, which is consistent with
the increase in total CD4+ T cells in the whole blood of sargramostim-treated patients
compared to placebo controls (unpublished data). It should be noted that CD25+ T cells
were positively selected against for these analyses. Given that ~2% of the analyzed
cells are Teffs (CD4+ CD127+ CD25+) and ~2% are Tregs (CD4+ CD127- CD25+),
most cells are CD25-. However, by excluding CD25+ T cells, this analysis may be
missing relevant gene changes in the effector T cell population, which may be the cells
expressing genes that effect PD. However, since CD4+ CD25- cells are the responder T
cells suppressed by Tregs in the in vitro proliferation suppression assay (Gendelman et
al., 2017), these are one population cells that Tregs target to suppress in vivo.
Additional studies would be needed to determine which helper T cell populations and
functions are most important for PD pathogenesis and to what degree Tregs suppress
these cells and functions.
As expected, there was an increase in the expression of anti-inflammatory
genes. Some of these are genes for cytokines released from Th2 cells, such as IL4,
IL13, and IL5 (Zhu and Paul, 2008). Treg-related genes were also increased such as
LRRC32, the gene for GARP, a transcription factor which is important for Treg
development (Tran et al., 2009).

IKZF2 is a gene within the IKAROS family of

transcription factors, including Helios, which is expressed in Tregs (Bhairavabhotla et al.,
2016).

Thymic-induced (or natural) Tregs contain increased IKZF2 expression

compared to induced Tregs (Thornton et al., 2010).

Since Helios is preferentially

expressed in natural Tregs, this suggests that the increase in the percentage of Tregs
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after sargramostim treatment may be due to the expansion of natural Tregs and not
inducing Tregs in the periphery.
In addition to genes associated with Th2 and Tregs, sargramostim also increases
expression of anti-inflammatory genes such as PPARG, the gene for the nuclear
receptor PPARγ. Agonists to PPARγ such as pioglitazone were successful at protcting
neurons in preclinical studies (Laloux et al., 2012), but unsuccessful at reducing PD
symptoms (Investigators., 2015).

Sargramostim increases ICOS expression, a co-

stimulatory molecule on T cells which promotes the release of Th2-related cytokines
(Simpson et al., 2010). The expression of the chemokine CCL7 is responsible for the
recruitment of a variety of immune cells, especially monocytes (Cheng et al., 2014).
However, CCL7 expression appears to promote a Th2 immune response (Katzman and
Fowell, 2008). Expression of TNFSF11 (the gene for RANKL) promotes the survival of
DCs and Tregs (Wong et al., 1997; Loser et al., 2006).

As such, the increase in

TNFSF11 may be promoting the increase by sargramostim-treated PD patients.
Interestingly, even though Tregs represent about 1% of the population of cells in this
analysis, genes associated with Tregs and immunosuppression are noticeably
increased. This suggests that the expression of these genes is very high in the Treg
population, or these genes are expressed in cells that are beginning to upregulate CD25
which are not phenotypically Tregs. FOXP3 expression was tested in this analysis and
was generally not increased noticeably, further supporting the interpretation that few
cells in this analysis are Tregs or expressed genes associated with terminal Treg
differentiation. Combined, these data show that sargramostim increases the expression
of anti-inflammatory genes that may be playing a role in the increased Treg numbers
and/or functions.
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Several genes were upregulated in sargramostim-treated patients relative to
baseline and relative to the placebo control involved in helper T cell proliferation.
Notable genes associated with proliferation include IL2 and IL2RA, which are the major
cytokine and receptor for T cell proliferation (Olejniczak and Kasprzak, 2008). One of
the genes with the highest gene expression is GATA4, which is not highly transcribed in
T cells (Caramori et al., 2001).

GATA4 does regulate the transcription of IL-5

(Yamagata et al., 1995; Yamagata et al., 1997), which was also upregulated by
sargramostim, suggesting that the increase in GATA4 expression promotes increased
IL5 expression. TNFRSF9 (the gene for CD137 (4-1BB), a cell surface protein which is
upregulated upon T cell activation) is also upregulated by sargramostim treatment (Vinay
and Kwon, 1998; Myers and Vella, 2005). Both HOXA3 and HOXA10 are genes for
transcription factors involved in the proper development of lymphocytes and other
immune cells (Thorsteinsdottir et al., 1997; Su and Manley, 2000; Su and Manley, 2002).
Interestingly, PERP, a gene involved in p53-mediated apoptosis (Ihrie et al., 2003) is
also increased by sargramostim treatment. This suggests that T cell activation and
possibly apoptosis are increased.
To our surprise, sargramostim treatment increased the expression of
proinflammatory genes. We found that there were genes involved in both Th1 and Th17
phenotypes that were upregulated. Th1-related genes which were increased include
IL12B, IL18 and receptors all of which promote and are released from Th1 CD4+ T cells
(Zhu and Paul, 2008). However, sargramostim also decreased expression of several
factors also involved in Th1 differentiation such as TBX21 (gene for t-bet, the master
Th1 transcription factor) and EOMES (another Th1 transcription factor) (Zhu and Paul,
2008). Sargramostim also increased several genes associated with Th17 cells including
IL21, IL17A, IL17RE, and RORC (Zhu and Paul, 2008). Genes for Toll-like receptors
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(TLR) 4 and 6 were upregulated. Notably, α-synuclein binds to TLR4 and activates
astrocytes and microglia (Rannikko et al., 2015) and TLR4 may promote α-synuclein
clearance (Stefanova et al., 2011).

Clearly this increase in proinflammatory gene

expression is not indicative of Treg-mediated suppression or other anti-inflammatory
mediators. Alternatively, it suggests that sargramostim not only increases Tregs and
anti-inflammatory genes; but rather induces the expression of many genes expressed by
several different T cell subsets.
From the above data, the gene changes reported were obtained by combining all
data from all patients within a treatment group. Additionally, we tested if these combined
gene changes are indicative of gene changes in each patient.

While there were

differences among patients, trends from the combined data are present within each
patient.

From this analysis, in the patients for which a complete data set exists,

sargramostim treatment increased percentage of Tregs in whole blood, but Teffs were
not changed (Gendelman et al., 2017).

This trial did not specifically assess gene

expression by Th1, Th2, and Th17 cells, so it is unclear to what extent the percentages
of these helper T cell subsets are affected by sargramostim is unclear. To test the
relationship between gene expression in the CD4+ CD25- T cells and increased
percentages of Tregs in whole blood, we graphed the expression of genes with the
highest upregulation compared to Treg percentage. Patients LJN and NLP displayed
the highest level of gene expression and the highest percentage of Tregs. In both
patients, lower Treg percentage and lower gene expression at visit 8 followed treatment
cessation. Placebo-treated patients BED and MKO tended to display the lowest Treg
response and lower gene expression.

The differences in gene expression and

percentage of Tregs suggest that the responses are different between patients. These
data suggest that the effects of Tregs are consistent with the increase in gene
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expression, including the proinflammatory cytokines. Because the binding of GM-CSF to
its receptor can activate several signal cascades (Shearer, 2003; Hercus et al., 2009), it
appears that this activation increases the expression of many genes of different
functions.

Further work will be needed to determine which of these pathways are

important for increasing the expression of these genes and increase Treg levels.
One of the surprising results is that the CD3/CD28-stimulated T cells from
sargramostim-treated patients display decreased expression of many genes from all 3
groups compared to baseline or placebo control patients. It is unclear why this is the
case, but several possibilities exist. It could be that sargramostim treatment is activating
gene expression in T cells, and CD3/CD28 stimulation cannot increase expression
further.

As a result, the difference in gene expression is decreased compared to

unstimulated cells. It may also be the case that sargramostim treatment may be altering
the kinetics of CD3/CD28 stimulation. Since we tested gene expression at a single time
point, it is possible that gene expression peaked earlier or later, so the relative change in
expression here may not be indicative of altered kinetics.

A final possibility is that

sargramostim or the existing Tregs population dampens the ability of the T cells to be
activated. The result was that after sargramostim treatment, T cells did not increase the
expression of all genes compared to T cells from placebo-treated PD patients. The
isolated CD4+ T cells from both the placebo and sargramostim-treated PD patients
display similar Treg numbers that are relatively small, so it would not be thought that
these Tregs are influencing the ability of the other helper T cells to activate after
stimulation with CD3/CD28 beads. However, since sargramostim-treated PD patients
display more functional Tregs compared to placebo control (Gendelman et al., 2017),
there may be more Treg suppression when stimulated with CD3/CD28 beads. It is also
possible that sargramostim has some suppressive effect apart from activated Tregs, but
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this has not been described. The bottom line is that more work is needed to test how
sargramostim is affecting T cells and T cell activation both in culture and in vivo.
In

conclusion,

sargramostim

treatment

increased

the

expression

of

proinflammatory, anti-inflammatory and non-associated genes in unstimulated CD4+
CD25- T cells. Interestingly, sargramostim treatment decreases the expression of these
genes after CD3/CD28 stimulation. Increases in gene expression were associated with
an increased percentage of Tregs, suggesting that the patient-to-patient differences are
due to different responses to sargramostim treatment.

These results suggest that

sargramostim treatment does not suppress proinflammatory gene expression in CD4+
CD25- T cells, which would be expected from the increase in anti-inflammatory genes
and the percentages of Tregs.
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CHAPTER THREE
GM-CSF-GENERATED BONE MARROW DERIVED DCs INDUCE
REGULATORY T CELLS AND ARE NEUROPROTECTIVE IN MPTP
INTOXICATED NICE
ABSTRACT
As shown in Chapter 2, GM-CSF increases the percentage and the function of
Tregs in Parkinson’s disease and the MPTP model. However, the mechanism by which
GM-CSF increases the percentage and function of Tregs is unclear. Models of
autoimmunity demonstrated that GM-CSF induces a tolerogenic state in DCs which
promotes Tregs leading to suppression of autoimmunity and inflammation. Herein, I
tested if GM-CSF promotes and maintains a tolerogenic state in bone marrow-derived
dendritic cells (BMDCs) stimulated with nitrated α-synuclein (N-α-Syn) as determined by
flow cytometry, gene expression, cytokine release, and ability to induce Tregs. In
addition, the ability of tolerogenic DCs to protect dopaminergic neurons, decrease
neuroinflammation, and increase the percentage of Tregs in the spleen, was tested. I
found that GM-CSF was unable to maintain a tolerogenic state in DCs after stimulation,
but there was an alteration of how the BMDCs respond to stimulation. The adoptive
transfer of BMDCs did protect tyrosine hydroxylase-positive neurons, decreased
neuroinflammation, and increased the percentage of Tregs in the 1-methyl-4-phenyl1,2,3,6-tetrahydropyridine (MPTP) model. These results suggest that tolerogenic DCs
can be protective, in part by increasing the percentage of Tregs. BMDC supernatants
were unable to directly protect MES23.5 cells, but did decrease the expression of
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proinflammatory mediators from cultured microglia, suggesting tolerogenic DCs may
possess functions in vivo in addition to inducing Tregs.

INTRODUCTION
As stated previously, Parkinson’s disease (PD) patients exhibit a decreased
percentage of Tregs in peripheral blood (Chen et al., 2015) and function (HutterSaunders et al., 2012). Administering GM-CSF increased the percentage of Tregs in the
MPTP model which is associated with neuroprotection and decreased
neuroinflammation (Kosloski et al., 2013) and sargramostim (human recombinant GMCSF) increased the percentage of Tregs in PD patients and improved Treg function
while improving motor symptoms (Gendelman et al., 2017). Interestingly, T cells are not
thought to express the receptor for GM-CSF, CSF2R, based on 2 lines of evidence.
Treating T cells with GM-CSF induces proliferation to a decreased extent compared to
IL-2 and could not support the survival of T cells (Santoli et al., 1988). Also, by flow
cytometry, CD3+ T cells lack surface expression of the alpha chain of the CSF2R
(Rosas et al., 2007). However, in a single report, the GM-CSF receptor is expressed on
the surface of CD4+ CD25+ T cells and GM-CSF promotes the proliferation of Tregs
(CD4+ CD25+ Foxp3+) (Kared et al., 2008). These data suggest that GM-CSF is unable
to induce the formation of Tregs from the non-Treg T cell population, but may promote
the proliferation of existing Tregs.
The ability of GM-CSF to induce Tregs and suppress inflammation is curious
given that the main role of GM-CSF is to mobilize myeloid cells, including
macrophages/monocytes, neutrophils and other granulocytes from the bone marrow to
the periphery (Ushach and Zlotnik, 2016). As a result, GM-CSF has been thought of as
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a proinflammatory cytokine. GM-CSF and sargramostim have been used in clinical trials
as an adjuvant for the hepatitis B vaccine (Overton et al., 2010) and several cancers
including renal cancer, melanoma, prostate cancer, lung cancer, and pancreatic cancer
(Parmiani et al., 2007; Waller, 2007). In addition, in the experimental autoimmune
encephalomyelitis (EAE) model of multiple sclerosis, GM-CSF may (King and Thomas,
2007) or may not (Pierson and Goverman, 2017) be required for the development of
paralysis in the model and the GM-CSF-secreting CD4+ T cells induce EAE (Codarri et
al., 2011). Because GM-CSF is not thought to exert its effects directly on CD4+ cells
and because GM-CSF has proinflammatory effects by expanding granulocytes and
monocytes, it is unclear how the percentage of Tregs is being increased.
Despite the known functions of GM-CSF in myeloid cells, a growing body of
research has demonstrated GM-CSF can exert beneficial effects in models of
autoimmunity and inflammation. For example, administering GM-CSF suppresses the
immune response to thyroglobulin in the model of autoimmune thyroiditis (Gangi et al.,
2005), skeletal muscle nicotinic acetylcholine receptor in the mouse model of
myasthenia gravis (Sheng et al., 2008), and lymphocyte infiltration into the pancreas in
the NOD model of type 1 diabetes (Cheatem et al., 2009). In addition, in models of
inflammatory disease such as colitis (Sainathan et al., 2008) or traumatic brain injury
(Kelso et al., 2015), treatment with GM-CSF also decreases inflammation to reduce the
symptoms of disease. As with the MPTP model (Kosloski et al., 2013), in many of these
models GM-CSF increases the percentage of Tregs (Sheng et al., 2008; Cheatem et al.,
2009; Ganesh et al., 2009). From these data, the prevailing thought is that GM-CSF
increases Tregs by acting on DCs inducing a tolerogenic state (Gaudreau et al., 2007;
Bhattacharya et al., 2011). The tolerogenic DCs express OX40L and Jagged-1 (Jag-1)
which bind to OX40 and Notch-3 respectively on T cells and are important for the
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increase in the percentage of Tregs in culture (Gopisetty et al., 2013; Haddad et al.,
2016). Tolerogenic DCs promote the proliferation of Tregs and induce naïve CD4+ T
cells to become Tregs (Bhattacharya et al., 2011). The resulting Tregs induced by
tolerogenic DCs may be antigen specific or antigen independent. In either case,
increases in Tregs reduces the inflammatory immune response and reduces the
symptoms of disease.
Like immature DCs, tolerogenic DCs display low expression of co-stimulatory
molecules like MHC II, CD40, CD80, CD86, among others, and low expression of
cytokines (Lutz and Schuler, 2002; Steinman et al., 2003; Rutella et al., 2006; Liu and
Cao, 2015). What cytokines are expressed are commonly anti-inflammatory, such as IL10. Tolerogenic DCs also display increased expression IDO, an enzyme which
metabolizes with tryptophan to kynurenine, and the expression of IDO and increased
release of kynurenine are associated with induction of Tregs (Rutella et al., 2006).
Unlike immature DCs, tolerogenic dendritic cells should maintain this low expression
even in the presence of a maturation stimulation (Mahnke et al., 2002). Maintenance of
a tolerogenic state will make DCs less able to activate naïve CD4+ cells to effector
helper T cells by reducing all 3 T cell maturation signals, but maintains the ability to
induce Tregs (Lutz and Schuler, 2002; Mahnke et al., 2002).
In the study described in this chapter, I hypothesized that GM-CSF promotes and
maintains a tolerogenic state in DCs which is the mechanism by which GM-CSF is
neuroprotective. We tested this in 2 DC lines (DC2.4 and DC3.2) and in BMDCs. We
also sought to determine if adoptive transfer of tolerogenic DCs are able to protect
dopaminergic neurons, reduce neuroinflammation, and increase the percentage of Tregs
in the spleen after MPTP, similar to GM-CSF administration. I also tested if BMDC
supernatant protects the MES23.5 dopaminergic neuron cell line and decreases the
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expression of proinflammatory mediators from activated BV2 microglia cell lines. Lastly,
I tested if GM-CSF increases the number or tolerogenic state of splenic DCs, the DCs
likely to be inducing Tregs in the spleen.

METHODS
Animals
Male 6-18-week-old C57BL6/J mice (Jackson labs, Bar Harbor, ME) were used
in all experiments described below. All procedures were performed in accordance with
the National Institutes of Health guidelines and all procedures were approved by the
Institutional Animal Care and Use Committee of the University of Nebraska Medical
Center.
DC2.4 and DC3.2 cell culture
DC2.4 and DC3.2 cells were generously provided by the laboratory of Dr.
Kenneth Rock (University of Massachusetts Medical Center, Worcester, MA). Both cell
lines were cultured in HCM-10% media (RPMI 1640 + L-glutamine (Gibco), 10% FBS
(Atlanta Biologicals, Flowery Branch, GA), 1x MEM nonessential amino acids (Hyclone),
100 U penicillin, 100 g/ml Streptomycin (Gibco), 10 mM HEPES (Gibco), 2 mM Lglutamine (Gibco), and 55 nM 2-mercaptoethanol (Gibco)). Both cell lines were passed
by drawing off the whole volume of old media into a 15 ml conical tube (BD Falcon,
Corning, NY) and pipetting 3 ml of 0.25% trypsin containing EDTA (Hyclone) per T-75
flask. Flasks were incubated at 37°C for 2 min to remove adhered cells from the bottom.
The flask was tapped to dislodge cells and the whole volume was pipetted into the 15 ml
conical tube to dilute the trypsin and cells were concentrated by centrifugation at 400 xg
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for 5 min. The supernatant was discarded and the cell pellet was resuspended in 1 ml
HCM-10% media, and an aliquot was diluted 1:10 in trypan blue (Sigma) for cell
counting. A volume of cell suspension corresponding to ~2x106 cells was pipetted into a
T-75 flask (BD Falcon) in 10 ml HCM-10% media.
incubator at 37°C, 5% CO2 incubator.

The flasks were placed in an

Cells were passed whenever they reached

confluence, which was about every 3 days.
BMDC differentiation
BMDCs were differentiated from bone marrow according to standard protocols
(Lutz et al., 2000; Bhattacharya et al., 2011).

The methods for differentiating and

stimulating BMDCs are outlined in Figure 3.1. Briefly, male 6-18-week-old C57BL6/J
mice (Jackson Labs) were sacrificed by CO2 asphyxiation and cervical dislocation and
both femurs were removed and washed twice in ice cold 10 ml 1x Hanks Buffered Salt
Solution (HBSS, Gibco). Each femur was flushed with 5 ml 1x HBSS and the cells were
collected into a petri dish. The cell suspension was drawn up through a 20 Ga. needle
into a 50 ml conical tube (BD Falcon) and cells were concentrated by centrifugation at
200 xg for 10 min. The supernatant was discarded and the pellet was resuspended in 1
ml ACK lysis buffer (Gibco) per mouse. The red blood cells were lysed by incubation at
37°C for 2 min. Lysis was stopped by adding 1x HBSS and the cells were passed
through a 70 μM cell strainer and the flow through was collected in a 50 ml conical tube.
Cells were concentrated by centrifugation at 200 xg for 10 min. The supernatant was
discarded and the cell pellet was resuspended in R10 media (RPMI 1640 + L-glutamine
(Gibco), 10% heat-inactivated FBS (Atlanta Biologicals), 100 U penicillin, 100 g/ml
streptomycin (Gibco), 10 mM HEPES (Gibco), 2 mM L-glutamine (Gibco), and 55 nM 2-
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Figure 3.1 Method for BMDC generation
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mercaptoethanol (Gibco)).

A cell suspension was diluted 1:10 in trypan blue for

counting. Cells were brought to a concentration so that each well of a 6-well plate (BD
Falcon) contained 4x106 cells and 20 ng/ml mouse recombinant GM-CSF (Peprotech,
Rocky Hill, NJ) in 4 ml of R10 media. For the experiment testing optimal conditions for
BMDC maturation, wells contained 10 ng/ml GM-CSF and some wells contained 10
ng/ml IL-4 (Peprotech, Rocky Hill, NJ). BMDCs were incubated for 4 days in the 37°C,
5% CO2 incubator.
Four and 6 days after isolating BMDCs the media was changed as follows. The
6-well plate was removed from the incubator and the volume of media was removed and
pipetted into 50 ml conical tubes and cells were concentrated by centrifugation at 200 xg
for 10 min. Two ml R10 media was added to each well. The supernatant was discarded
and the cell pellet was resuspended in R10 media supplemented with 40 ng/ml mouse
recombinant GM-CSF so the total volume was brought to 4 ml, and the plate was placed
back in the 37°C, 5% CO2 incubator.
On the eighth day after isolating bone marrow, the BMDCs had differentiated and
could be treated as follows. The 6-well plates were removed from the incubator and the
whole volume was pipetted from each well into a 50 ml conical tube and 1 ml of R10
media was added to each well. Cells were concentrated by centrifugation at 200 xg for
10 min. The supernatant was discarded and the cell pellet was resuspended in R10
media supplemented with 40 ng/ml mouse recombinant GM-CSF or R10 media alone
depending on experiment. One ml of the cell suspension was added to each well and
the 6-well plate was placed back in the 37°C, 5% CO2 incubator for 2 days.
On day 10 after starting BMDC culture, stimulation was done as follows. BMDCs
were stimulated with 10, 30 or 100 μg/ml of nitrated recombinant mouse α-Syn (N-αSyn), which was made as described previously (Benner et al., 2008). BMDCs were also
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stimulated with 0.1, 10, 30 and 100 μg/ml E. coli O55:B5 LPS (Sigma). To test gene
expression, BMDCs were stimulated for 6 hr, a time frame in which there should be
maximal expression of proinflammatory cytokine genes (Crabtree and Durand, 1986;
Crabtree, 1989). For all other experiments, BMDCs for stimulated for 24 hr. At that
time, BMDCs were removed for flow cytometry or to produce lysate for Western blot or
the conditioned media was removed for cytokine detection, nitrite release detection, and
kynurenine detection.
Griess assay
The Griess assay was performed 2 different ways according to the
manufacturer’s protocol (Promega Fisher Waltham, MA). The assays for DC2.4 and
DC3.2 cells in Figure 3.2 were performed using the Promega kit as follows. Standards
were diluted in HCM-10% media and were serially diluted to create a standard curve.
Wells of a flat-bottom 96-well plate (BD Falcon) contained 50 μl of supernatant added.
All wells contained 50 μl sulfanilamide added and the plate was incubated wrapped in
foil at RT for 5 min. All wells contain 50 μl NED solution added and the plate was
incubated at RT for 5 min wrapped in foil. The plate was read at 540 nm.
The Griess assays in Figure 3.5, 3.8, and 3.23 were performed using the
ThermoFisher (Waltham, MA) kit as follows. Nitrite standard was diluted in R10 or BV2
media and serially diluted in R10 or BV2 media to generate a standard curve.

In

addition, the 96-well plate contained 150 μl of BMDCs or BV2 cells supernatant added.
To detect nitrite, 130μl MQ water, and 20 μl of the mixed Griess assay reagents added
to all wells. The 96-well plate was incubated at RT for 30 min wrapped in foil before the
absorbance was read at 540 nm.
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For both assays, the absorbance was background corrected by subtracting the
average reading from wells containing fresh media, not that from cells, from all other
wells. Based on the standard curve the concentration of nitrite was calculated from the
absorbance.
AlamarBlue cell viability assay
For DC2.4 and DC3.2 cells, the alamarBlue cell viability was performed by
plating cells at 1x105 cells per well into a U-bottom 96-well plate with 20 ng/ml mouse
recombinant GM-CSF added to the appropriate wells for 2 days. To the appropriate
wells, 10 μg/ml E. coli O55:B5 LPS (Sigma) was added 24 hr before reading to stimulate
cells. After 24 hr of treatment, 15 μl alamarBlue solution (ThermoFisher) was added to
all wells and after 4 hours of incubation the absorbance was read at 570 and 600 nm.
For BMDCs, cells were treated in 6-well plates with R10 media alone or with R10
media supplemented with 20 ng/ml mouse recombinant GM-CSF for 2 days prior to
stimulation with 10 μg/ml E. coli O55:B5 LPS (Sigma) or 30 μg/ml recombinant N-α-Syn
for 24 hr as described above. At this time, BMDCs were removed from the 6-well plate
using a cell scraper and 1x105 BMDCs was plated into each well of a U-bottom 96-well
plate and 15 μl alamarBlue was added to each well. After 4 hrs, the absorbance was
read at 570 and 600 nm.
For both methods, the percentage of alamarBlue dye which was reduced (which
can only happen in viable cells with functioning mitochondria) was calculated according
to the manufacturer’s directions.
Flow cytometry
DC2.4, DC3.2 and BMDCs were stained for flow cytometric analysis as follows.
After removing cells from the dish by either trypsin-EDTA or cell scraper for DC2.4 and
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DC3.2 cells or BMDCs respectively, cells were counted and ~5x105 cells were added to
each 5 ml flow stain tube (BD Falcon) for staining. The Fc receptors were blocked in a
solution of 10 μg/ml rat gamma globulin FSB (1x DPBS, (Gibco) supplemented with
0.5% BSA and 0.1% sodium azide). After blocking for 30-60 min on ice, anti-CD11calexaFluor 488, anti-CD11b-PECy7, anti-Jagged-1-PE, anti-OX40L-APC, anti-MHC IIalexaFluor 700, anti-CD86-eFluor450, anti-CD39-PerCP-eFluor 710 (eBioscience, Santa
Clara, CA) and anti-CD73-APC-vio 770 (Miltenyi Biotec) antibodies stained cells for 30
min at 4°C. Cells were washed 2 times in 2 ml FSB and cells were concentrated by
centrifugation at 400 xg for 5 min. Cells were fixed in a solution of 1% formaldehyde in
1x DPBS for 15 min at RT. Cells were concentrated by centrifugation at 400 xg for 5 min
and the pellet was resuspended in FSB for analysis using a BD LSR II flow cytometer
(Franklin Lakes, NJ) at the University of Nebraska Medical Center Flow Cytometry
Research Facility.

Single cells were gated from the total event population and the

percentage of total cells or CD11c+ cells expressing each marker was determined. The
mean fluorescent intensity (MFI) of each marker in the CD11c+ cells was also
determined.
For testing the percentage of Tregs in total splenocytes, non-adhered cells from
CD4+/BMDC co-culture, or cells enriched after Miltenyi CD4+ CD25+ kit, ~5x105 cells
were blocked in a solution of 10 μg/ml rat gamma globulin in FSB for 30-60 min. Cells
were stained with anti-CD4-PECy7 and anti-CD25-PE for 30 min at 4°C. Cells were
washed twice in 2 ml FSB and concentrated by centrifugation at 400 xg for 5 min. Cells
were then fixed and permeablized for 1 hr at 4°C using the buffer from the
Foxp3/transcription factor staining buffer set (eBioscience). Cells were washed in 2 ml
1x permeablization buffer and concentrated by centrifugation at 400 xg for 5 min. Cells
were stained with anti-Foxp3-APC for 30 min at 4°C. Cells were washed twice by the
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addition of 2 ml of 1x permeabization buffer followed by concentration by centrifugation
at 400 xg for 5 min. Cells were resuspended in FSB prior to analysis using the BD LSR
II at the University of Nebraska Medical Center Flow Cytometry Research Facility.
Within the single cell population, the percentages of CD4+ T cells was determined. The
percentage of CD4+ T cells double positive for CD25+ Foxp3+ was reported as the
percentage of Tregs within the CD4+ T cell population.
Luminex array
The release of cytokines and chemokines was determined from BMDCs cultured
for 2 days in R10 media alone or R10 media supplemented with 20 ng/ml GM-CSF prior
to no stimulation or 1 day stimulation with 30 μg/ml N-α-Syn.

The cell culture

supernatant was clarified at 10,000 xg for 5 min and the resulting supernatant was
transferred to a 1.5 ml snap-cap tube and stored at -80°C until analysis could be
performed. Concentration of cytokines and chemokines was determined with Luminex
xMAP mouse cytokine and chemokines magnetic bead panel (Milipore, Billerica, MA)
according to the manufacturer’s protocol. Briefly, 25 μl of supernatant was added to the
provided 96-well plate. Standards and controls were prepared and diluted according to
the protocol and 25 μl was added to the appropriate well. Assay buffer was added to
supernatant samples and R10 media was added to all controls and standards. A master
mix containing antibody-coated magnetic beads against IFNγ, IL-1α, IL-1β, IL-2, IL-4, IL5, IL-6, IL-7, IL-9, IL-10, IL-12p40, IL-12p70, IL-13, Lix, IL-15, IL-17, IP-10, MIP-2, MIG,
RANTES, and TNF-α was added to all wells and the 96-well plate was incubated at 4°C
overnight. Magnetic beads were concentrated and washed on a magnet. Detection
antibodies were added to each well and the samples were incubated at RT for 60 min.
Strepavidin-PE was added to all wells and the 96-well plate was incubated at RT for 30
min. The beads were concentrated and washed in a magnet as above and resupended
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in sheath solution.

All wells were analyzed using the Milipore Magpix system and

Luminex Xponent 4.2 software.

A standard curve was generated for each of the

cytokines and chemokines and based on this standard curve the concentration of each
cytokine and chemokine was calculated. For this experiment, for each of the 4 treatment
groups, supernatants from 7 different wells containing BMDCs were used. Supernatant
from each of the 7 wells of supernatant were run in duplicate or triplicate.
RNA isolation, cDNA conversion and PCR array
To test the expression of proinflammatory genes, BMDCs were cultured in R10
media alone or R10 media supplemented with 20 ng/ml GM-CSF for 2 days prior to
stimulation of cells with 30 μg/ml N-α-Syn, or BMDCs were left unstimulated with for 6
hr. BMDCs were removed from the 6-well dish by a cell scraper and cells were washed
two times in 1x DPBS (Gibco). There were 6 separate wells for BMDCs for each of four
treatment groups. Cells were transferred to a 1.5 ml snap-cap tube and cells were
frozen at -80°C until RNA isolation. The RNeasy mini kit (Qiagen) was used to isolate
total RNA from all samples as follows. The cell pellet was resuspended in RLT buffer
supplemented with 2-mercaptoethanol and homogenized by trituration through a 27 Ga.
needle 10 times. The lysate was clarified by concentration at 20,800 xg for 3 min.
To test the expression of proinflammatory genes in the midbrain, BMDCs were
transferred into mice via i.v. injection at 14 and 7 days prior to MPTP intoxication. As
controls, mice were injected with DPBS and intoxicated with MPTP. Two days after
MPTP intoxication, mice were sacrificed by CO2 asphyxiation and cervical dislocation.
Brains were removed, hemisected and the midbrain was placed in a 1.5 ml tube
containing 1 ml RNAlater (ThermoFisher).

Brains were incubated at 4°C overnight

before being weighed and frozen at -80°C. To isolate RNA, the midbrains were thawed,
homogenized in 350 µl β-mercaptoethanol-supplemented RLT buffer (Qiagen, Valencia,
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CA) for every 30 mg tissue.

Tissues were sequentially homogenized by trituration

through 18, 20 and 27 Ga needles.

The tissue homogenate was clarified by

concentration at 20,800 xg for 3 min.
The clarified supernatants from both cell pellets and from tissue were transferred
to a new 1.5 ml tube containing 70% ethanol in water. This mixture was pipetted into a
filter and the nucleic acids were concentrated on the filter by centrifugation at 10,000 xg
for 20 sec. The flow through was discarded. The filter was washed in RW1 at 10,000 xg
for 20 sec. DNase I from the RNase-free DNase kit (Qiagen) was diluted in RDD buffer,
pipetted on the membrane, and incubated at RT for 15 min. The filter was washed in
RW1 then 2 times in RPE buffer by centrifugation at 10,000 xg for 20 sec. The filter was
eluted by the addition of 50 μl RNase-free water and centrifugation at 10,000 xg for 1
min. The flow through was added back to the filter and was eluted a second time at
10,000 xg for 1min to increase RNA yield. The concentration of RNA, as well as the
260/280 and 260/230 ratios were determined by UV spectrophotometry using a Thermo
ND-100 Nanodrop spectrophotometer.
Copying of mRNA to cDNA was achieved using the RevertAID first strand cDNA
synthesis kit (ThermoFisher) according to the manufacturer’s protocol. Briefly, 500 ng of
RNA was brought to 11 μl by the addition of nuclease-free water and 1 μl oligo dT
primers was added to each sample and heated at 65°C for 5 min. After breaking the
secondary structure of RNA, a master mix containing 5x reaction buffer, Ribolock Rnase
inhibitor, 10 mM dNTPs, and RevertAID M-MuLV reverse transcriptase was added to all
samples and incubated at 42°C for 1 hr. After the production of cDNA from the mRNA
template, the reaction was terminated by 5 min incubation at 70°C. All samples were
brought to 100 μl by the addition of nuclease-free water and samples were frozen at 20°C until PCR could be performed.
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Each cDNA sample was added to RNase-free and DNase-free water (Invitrogen),
2x RT2 SYBR green master mix (Qiagen), and 25 μl of this solution was added to each
well of a mouse inflammatory response and autoimmunity array (Qiagen), and PCR was
performed using an Eppendorf Realplex 2S Master Cycler (Eppendorf, Hamburg,
Germany). The PCR program used for this array which was as follows: hot start at 95°C
for 10 min, followed by 40 cycles of 95°C for 15 sec and 60°C for 1 min. After 40 cycles,
a melting curve was performed, Ct values were determined, and fold changes
determinedusinng the ΔΔCt method using RT2 Profiler PCR array data analysis version
3.5. Changes were normalized relative to media-cultured, unstimulated BMDCs or from
the PBS control midbrains.
IDO expression by Western blot
To determine the relative expression of IDO relative to β-actin, Western blots
were run as follows. BMDCs were pretreated for 2 days in R10 media alone or R10
media supplemented with 20 ng/ml GM-CSF and either unstimulated or 30 μg/ml N-αSyn for 1 day. These BMDCs were removed from the dish by cell scraper, washed in 1x
DPBS and concentrated into a 1.5ml snap-cap tube which was frozen at -80°C until
analysis could be performed. The cell pellets were thawed and lysed in 250 μl RIPA
buffer (ThermoFisher) for 5 min on ice. After mixing by vortexing, the lysate was clarified
by centrifugation at 14,000 xg for 15 min at 4°C. The supernatant was transferred to a
new 1.5ml tube.
Protein concentration of the clarified lysate was determined by BCA assay
(Pierce) as described by the manufacturer. Briefly, BSA standards (ThermoFisher) were
pipetted to a flat-bottom 96-well plate to make a standard curve and 25 μl of each
sample was added to the same 96-well plate. The BCA working solution was prepared
and 200 μl added to each well and the 96-well plate was incubated at 37°C for 30 min.
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The plate was allowed to equilibrate to RT for 10 min and read at 562 nm.

The

absorbance reading was background corrected by subtracting the absorbance of the
control not containing protein from all other wells. Based on the standard curve, the
protein concentration for each sample was calculated.
To perform Western blots, a volume of lysate corresponding to 10 μg of total
protein was brought to 30 μl MQ water and 30 μl 2x sample buffer (Bio-Rad, Hercules,
CA) supplemented with 2-mercaptoethanol. Proteins were denatured by heating at 95°C
for 5 min. The whole volume was loaded into a pre-cast ExpressPlus PAGE 4-20% gel
(Genscript, Piscataway, NJ) and gels electrophoresed for 85 min until the dye front was
near, but not at the foot of the gel. Proteins were transferred to PVDF membranes (BioRad) using the Bio-Rad wet-transfer apparatus in 1x Bio-Rad transfer buffer for 90 min.
The membrane was blocked in 5% dried milk in PBS supplemented with 0.1% Tween 20
(PBST) at RT for 60 min. Membranes were incubated with a primary antibody solution
containing mouse anti-mouse IDO antibody (Milipore) in blocking buffer overnight at 4°C.
Membranes were washed for 30 min in PBS changing the PBS every 5 min prior to
incubation in goat-anti-mouse HRP-conjugated secondary antibody solution for 30 min at
RT. Membranes were washed in PBST for 30 min as above. The membrane was
imaged with ECL femto solution (ThermoFisher) and images were taken with a
chemiluminescent camera (ThermoFisher). The ECL femto solution was washed off in
PBST for 30 min. The membrane was stripped using Restore Western blot stripping
buffer (ThermoFisher), washed in PBST, and blocked in 5% dried milk blocking buffer for
30 min. The membrane was incubated in rabbit anti-mouse β-actin (Santa Cruz, Dallas,
TX) overnight at 4°C, washed in PBST as above, incubated in donkey anti-rabbit HRPconjugated secondary antibody (Santa Cruz) for 30 min at RT, washed again in PBST
for 30 min prior to development with ECL Pico solution (ThermoFisher), and the imaged
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with a chemiluminescent camera. From the images, ImageJ was used to determine the
intensity of the IDO and β-actin and the IDO/ β-actin ratio was determined.
Kynurenine detection and quantification
The release of kynurenine was determined from BMDCs cultured for 2 days in
R10 media alone or R10 media supplemented with 20 ng/ml GM-CSF prior to no
stimulation or stimulation with 30 μg/ml N-α-Syn for 1 hr. Cell culture supernatant was
clarified at 10,000 xg for 5 min, the resulting supernatant was transferred to a 1.5 ml
snap-cap tube, and stored at -80°C until analysis. For analysis, to each of the 100 μl of
supernatants, 10 μl of 10 μg/ml tryptophan HCl (Sigma Aldrich) was added to each
sample as an internal standard. A kynurenine standard curve was made by 2-fold
serially dilutions 50 μg/ml kynurenine (Sigma Aldrich) in acetonitrile (Fisher) down to
acetonitrile alone. Each standard also had 10 μl of 10 μg/ml tryptophan HCl added as
an internal standard. Ice-cold acetonitrile was added to each sample and standard and
mixed by vortexing for 3 min. Samples and standards were clarified by centrifugation at
14,000 RPM for 10 min, and 1 ml of supernatant was pipetted into a new 2 ml snap-cap
tube, and samples and standards were concentrated by speed vacuum for 3 hr, and
pellets were stored at -20°C overnight. All samples and standards were resuspended in
100 μl 0.1% formic acid in HPLC-grade water (Fisher), vortexed briefly, concentrated by
centrifugation at 14,000 RPM for 15 min, and 30 μl of each supernatant from each
standard/sample was pipetted into a 96-well plate for mass spectrometry analysis on a
C8 Luna PFP column attached to a Waters TQS Micro mass spectrometer.
CD4+ and CD11c+ cell isolation and BMDC co-culture
The CD4+ T cells used in co-culture were isolated from the spleens of male
C57BL/6J mice (Jackson Laboratories) as follows.

Mice were sacrificed by CO2
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asphyxiation and cervical dislocation and spleens removed, and pressed through a 70
μM cell strainer into 10 ml 1x HBSS. This cell suspension was drawn up through a 20
Ga. needle into a 50 ml conical tube. Cells were concentrated by centrifugation at 200
xg for 10 min, the supernatant was discarded, and the pellet was resuspended in 1 ml
ACK lysis buffer (Gibco) per spleen. Red blood cells were lysed by incubation at 37°C
for 2 min. Cells and ACK were diluted by adding 1x HBSS and cells concentrated by
centrifugation at 200 xg for 10 min. The supernatant was discarded, the cell pellet was
resuspended in Miltenyi CD4+ isolation buffer (0.5% BSA and 2 mM EDTA in 1x DPBS),
and an aliquot was diluted for cell counting. CD4+ T cells were negatively selected
using the Miltenyi CD4+ isolation kit according to the manufacture’s protocol. Briefly,
splenocytes were brought to 1x107 splenocytes per 90 μl CD4+ isolation buffer, 10 μl of
CD4+ selection antibodies were added, and incubated at 4°C for 15 min.

After

incubation, 30 μl CD4+ isolation buffer and 20 μl microbeads were added for every
1x107 splenocytes and the mixture was incubated at 4°C for 10 min.

The labeled

splenocytes were pipetted into a Miltenyi LS column, which was placed on a magnetic
rack. The antibody-bound, non-CD4+ cells adhered to the column and the CD4+ cells
flowed through the column into a collection tube. The column was washed 3 times in
Miltenyi CD4+ isolation buffer and cells were also collected into the same tube. The
CD4+ cells that flowed through the column were concentrated by centrifugation at 200
xg for 10 min. The pellet was resuspended in complete media (RPMI 1640 media + Lglutamine (Gibco), 10% FBS (Sigma), 1 mM sodium pyruvate (Cellgro, Pittsburgh, PA),
1x MEM non-essential amino acids (Hyclone, Logan, UT), 100 U penicillin, 100 g/ml
Streptomycin (Gibco), 10 mM HEPES (Gibco), 2 mM L-glutamine (Gibco), and 55 nM 2mercaptoethanol (Gibco)) and an aliquot was diluted 1:10 in trypan blue for cell counting.
Cell concentration was adjusted to 2x106 cells per ml of complete media. and an aliquot
of CD4+-enriched cells was stained for Tregs to determine purity.
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BMDCs were pretreated in R10 media alone or R10 media supplemented with 20
ng/ml GM-CSF for 2 days and either left unstimulated or stimulated with 30 μg/ml N-αSyn for 1 day.

BMDCs were scraped from the dish, washed 2 times in 1x DPBS,

resuspended in complete media, and an aliquot was diluted in trypan blue for cell
counting. The concentration was adjusted to 1x106 BMDCs per ml of complete media.
Co-cultures were initiated so that 1 ml of BMDCs and 1 ml of CD4+ T cell-enriched
splenocytes were pipetted into each well of a 24-well plate, then incubated at 37°C, 5%
CO2 for 5 days.
For transwell experiments, BMDCs and CD4+ cells were differentiated and
isolated as above, however, CD4+ T cells were brought to 10x106 cells/ml. To a 24-well
pate, 1 ml BMDCs (~1x106 BMDCs) was added to each well. The 3 μm transwell inset
(Corning, Corning, NY) was placed in the well and 100 μl CD4+ cells and 100 μl
complete media was added into the insert. The 24-well plate was incubated at 37°C, 5%
CO2 for 5 days.
CD11c+ cells were isolated from the spleen using the Miltenyi CD11c isolation kit
according to the manufacturer’s protocol. Single cell splenocytes were prepared and
adjusted to 1x108 cells/400 μl Miltenyi CD4+ isolation buffer.

For every 400 µl of

splenocytes, 100 μl CD11c microbeads was added and incubated for 15 min at 4°C.
Cells were washed in Miltenyi CD4+ isolation buffer, concentrated by centrifugation at
200 xg for 10 min and added onto a Miltenyi LS column placed within a magnetic field
and the column washed in Miltenyi CD4+ isolation buffer.

The LS columns were

removed from the magnet and CD11c+ cells were flushed from the column into a new
collection tube and cells were concentrated by centrifugation at 200 xg for 10 min. After
cell counting in trypan blue, CD11c+ cells were adjusted to ~1x106 CD11c+ cells/ml in
complete media and 1 ml of CD11c+ cells were co-cultured with 1 ml of enriched 2x106
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CD4+ T cells/ml into wells of a 24-well plate which was incubated at 37°C in 5% CO2
incubator for 5 days.
To determine the percentage of Tregs after co-culture, non-adherent cells were
removed from the culture, washed twice in 1x DPBS (Gibco), and concentrated by
centrifugation at 200 xg for 10 min. The cell pellet was resuspended in FSB, an aliquot
was counted in trypan blue, and 2.5-5x105 cells were stained for Treg purity.
Treg functional assay
Treg function was tested for its ability to suppress the proliferation of the
responder T cells (CD4+ CD25-) as described previously (Saunders et al., 2012; Olson
et al., 2015). Briefly, C57BL/6J mice were sacrificed by CO2 asphyxiation and cervical
dislocation. Splenocytes were isolated as described above and non-adhered cells were
removed as described above from co-culture of CD4+ cells and BMDCs. The Miltenyi
CD4+ CD25+ isolation kit was used to enrich Tregs (CD4+ CD25+) and responder T
cells (CD4+ CD25-) according to the manufacturer’s protocol. Briefly, for every 1x107
cells of splenocytes or non-adherent cells was added to 40 μl CD4+ isolation buffer and
10 μl CD4+ biotinylated antibodies and the suspension was incubated at 4°C for 5 min.
Then to every 1x107 cells was added 30 μl CD4+ isolation buffer, 20 μl Miltenyi antibiotin magnetic beads, and 10 μl anti-CD25-PE antibody and were incubated at 4°C for
10 min.

The labelled cells were passed through Miltenyi LD columns attached to

magnetic racks and the filtrate (CD4+ T cells) collected. Cells were concentrated by
centrifugation at 200 xg for 10 min, the pellet resuspended in 90 μl CD4+ isolation buffer,
10 μl anti-PE microbeads per 1x107 cells added and cell suspensions incubated at 4°C
for 15 min. The cellular filtrates served as responder T cells. The MS columns were
flushed by adding 1 ml CD4+ isolation buffer and the volume forced through the column
using the plunger. These cells were enriched Tregs. Aliquots of both cells were counted
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by trypan blue. Flow cytometry was performed on ~5x105 cells to confirm purity. Treg
concentrations were adjusted to ~1x106 cells/ml by the addition of complete media and
responder T cells were adjusted to 2x106 cells/ml in CFSE buffer (0.1% BSA in 1x
DPBS).
The responder T cells were labelled with carboxyfluorescein succinimidyl ester
(CFSE, ThermoFisher) according to the manufacturer’s protocol. Briefly, each vial of
CFSE was reconstituted with 18 μl dimethyl sulfoxide (DMSO, Sigma). For every 1 ml of
responder T cells to be labelled, 3 μl of CFSE was added to 1 ml CFSE buffer, cells and
buffer combined, and incubated for 15 min at 37 °C. To quench the reaction, 30 ml icecold complete media was added and the cell suspension was incubated on ice for 5 min.
Cells were concentrated by centrifugation at 300 xg for 5 min, the supernatant
discarded, the cell pellet resuspended in complete media, and cells concentrated by
centrifugation at 300 xg for 5 min. An aliquot was diluted in trypan blue for cell counting
and responder T cells were adjusted to 5x105 responder T cells/ml in complete media.
To a U-bottom 96-well plate, 100 μl of Treg suspension and 100 μl complete
media was added to a well and this volume was diluted by 2-fold serial dilutions into 5
wells to yield ~50,000, 25,000, 12,500, 6,250 or 3,125 Tregs per well. To the first 4 wells
in the dilution was added to 50,000 CFSE-labelled responder T cells in 100 µl to yield
Treg:responder T cell ratios of 1, 0.5, 0.25, and 0.125:1. The fifth well is a Treg-only
control. CD3/CD28 Transactivator beads (ThermoFisher) were used to stimulate the
proliferation of responder T cells by washing 1.25 μl transactivator beads per well
(~50,000 beads) in CFSE buffer, adjusting the concentration of 10 µl per well in
complete media, and pipetting 10 µl of beads to each well of the plate. The plate was
incubated at 37°C in 5% CO2 for 3 days. The plate was concentrated by centrifugation
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at 300 xg for 5 min, fixed in 100 µl 1% paraformaldehyde in 1x DPBS, and assessed by
flow cytometric analysis.
Adoptive transfer, MPTP intoxication, mouse perfusion, and immunochemistry for mac-1
or tyrosine hydroxylase
To determine if BMDCs, CD4+ CD25+, and non-adherent cells from the coculture of BMDCs and CD4+ T cells were neuroprotective after MPTP intoxication, the
following protocol was used. BMDCs, CD4+ CD25+, and non-adherent cells from coculture were isolated, and adoptively transferred via intravenous (i.v.) tail injection ~8-10
hr post MPTP intoxication.

MPTP was handled and administered according to

established protocols (Jackson-Lewis and Przedborski, 2007) and animal protocols
approved by National institutes of Health and the University of Nebraska Medical Center
Institutional Animal Care and Use Committee.

Briefly, mice were injected 4 times

intraperitoneally at 2 hour intervals with 10 ml DPBS/kg as a control or 12 or 16 mg free
base MPTP (Sigma)/kg. Seven days after MPTP intoxication, mice were sacrificed to
assess surviving tyrosine hydroxylase (TH) immunohistochemistry as described below.
To determine whether BMDCs are neuroprotective if administered prior to MPTP
intoxication, BMDCs were differentiated in R10 media supplemented with 20 ng/ml GMCSF for 8 days and then in R10 media alone for 3 days. At this time, BMDCs were
removed from the dish by cell scraper and adjusted to ~1.5x106 BMDCs/250 μl 1x
DPBS. This volume was administered by tail vein to 8-9-week-old male C57BL/6J mice
at 1 and 2 weeks prior to MPTP intoxication with 16 mg/kg of MPTP. This adoptive
transfer protocol for BMDCs was described for the experimental autoimmune
encephalomyelitis (EAE) model of multiple sclerosis (Prado et al., 2012).
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Two (for Mac-1 immunohistochemistry) or 7 (for TH immunohistochemistry) days
after MPTP intoxication, mice were sacrificed, perfused, and brains removed and
processed for immunohistochemistry as previously described (Kosloski et al., 2013;
Olson et al., 2015).

Briefly, mice were terminally anesthetized with Fatal-Plus

(pentobarbital) (Vortech, Dearborn, MI) and mice were transcardially perfused with 1x
DPBS (Cellgro, Corning, NY) until all blood was flushed. At this time, the mouse was
fixed with 4% paraformaldehyde in DPBS. The brain was removed and post-fixed in 4%
paraformaldehyde for 24 hr. Brains were then incubated in 30% sucrose at 4°C to
remove the formaldehyde and cryopreserve tissues prior to snap-freezing brains for 15
sec in 2-methyl butane (ThemoFisher) which has been chilled on dry ice for 20 min.
Brains were embedded in OCT (Tissue Tek, Radnor, PA) and 30 μm sections of the
midbrain and striatum were cut and stored in 0.1% sodium azide (Sigma) in PBS at 4°C
until immunohistochemistry was performed (Kosloski et al., 2013; Olson et al., 2015).
For Mac-1 staining, 6 free floating sections of substantia nigra from each mouse
were washed in 1x PBS (Cellgro), endogenous peroxidases blocked by incubation in 3%
hydrogen peroxide (ThermoFisher) and 10% methanol (ThemoFisher, in PBS), and
nonspecific staining blocked in 5% normal rabbit serum in PBS (Vector labs, Burlingame,
CA).

Sections were incubated at 4°C with 1:500 dilution of rat anti-Mac-1 primary

antibody (Bio-Rad) in 2% normal rabbit serum (in PBS) overnight, washed, and
incubated in a 1:500 dilution of biotinylated rabbit anti-rat antibody in 2% normal rabbit
serum in PBS (Vector labs) followed by ABC biotin-avidin peroxidase solution (Vector
Labs) prior to color generation with 3,3'-diaminobenzidine (DAB).

The number of

reactive Mac-1+ microglia per total area was determined by stereological analysis using
Stereo Investigator software and the optical fractionator module (MBF Bioscience,
Williston, VT) (Kosloski et al., 2013; Olson et al., 2015).
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For TH staining, 6 free-floating sections of the striatum and 12 free-floating
sections of the substantia nigra from each mouse were washed in 0.1 M Tris-buffered
saline (TBS) and endogenous peroxidases were blocked with 3% hydrogen peroxide in
methanol and 0.1 M TBS. Sections were blocked in 5% normal goat serum (Vector
Laboratories, in 0.1 M TBS) in 0.1 M TBS prior to staining with 1:2,000 or 1:1,000
dilution of anti-tyrosine hydroxylase (TH) antibody (EMD/Milipore, Burlington, MA) in 2%
normal goat serum in 0.1 M TBS for 48 hr at 4°C. Sections were then washed in 0.1 M
TBS, stained with a goat anti-rabbit secondary antibody (Vector Laboratories) in 2%
normal goat serum in 0.1 M TBS, and washed again in 0.1 M TBS prior to incubation
with avidin-biotin complex kit (Vector Laboratories) and development with DAB in PBS.
Sections were washed in 0.1 M TBS and transferred to slides.

Midbrain sections

containing the substantia nigra were Nissl counter-stained prior to counting TH+ Nissl+
and TH- Nissl+ neurons by stereological analysis using Stereo Investigator software with
the optical fractionator module (MBF Bioscience, Williston, VT).

TH density of

dopaminergic termini in the striatum was determined using ImageJ (Kosloski et al., 2013;
Olson et al., 2015).
Adoptive transfer of BMDCs into mice with and without MPTP for Treg percentage and
function
To determine if BMDCs induce Tregs in vivo, BMDCs were differentiated in R10
media supplemented with 20 ng/ml GM-CSF for 8 days and then in R10 media alone for
3 days. At this time, BMDCs were removed from the dish by cell scraper and brought to
~1.5x106 BMDCs/250 μl 1x DPBS. This volume was administered via tail vein injection
to 8-9 week-old male C57BL/6J mice (Jackson Labs) 1 and 2 weeks prior to sacrifice to
test Treg induction in the absence of MPTP or 2 days after MPTP intoxication which was
done 1 week after the second BMDC adoptively transfer. As a control for Treg induction
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without MPTP, mice received 50 µg/kg mouse recombinant GM-CSF i.p. injected on
each of 5 days prior to sacrifice. For both experiments, mice were sacrificed by CO 2
asphyxiation and cervical dislocation.

Spleen and lymph nodes (cervical, brachial,

axillary, and inguinal) were removed, kept separate for each mouse, and single cell
suspensions prepared for each tissue.

Flow cytometry was performed to test the

percentage of Tregs in ~500,000 splenocytes or lymph node cells.

The remaining

splenocytes were pooled by treatment group, Tregs (CD4+ CD25+), and responder T
cells (CD4+ CD25-) were isolated, and Treg suppression assays performed.

Blood

samples were collected by submandibular bleed using 5 mm GoldenRod lancets
(ThermoFisher) and blood was collected in BD microtainer EDTA-coated tubes 1 day
prior to each adoptive transfer and sacrifice. At least 50 μl blood was collected per
mouse and Treg frequencies were determined by flow cytometry.
MES23.5 cell culture
MES23.5 cells were cultured in MES23.5 media (DMEM/F12 with L-glutamine
and 15mM HEPES supplemented (Gibco) and supplemented with 2% heat-inactivated
FBS (Sigma), 100 U penicillin, 100 g/ml Streptomycin (Gibco), 1x N-2 supplement
(Gibco)). The cells were grown on poly-D-lysine-coated T-75 flasks (BD Falcon). Flasks
or 96-well plates (BD Falcon) were coated with 10 ml or 100 µl/well in 5 µg poly-dlysine/ml at 37°C overnight followed by removing the volume of coating solution,
washing with sterile MQ water, and allowing the flask or plate to dry.

Cells were

removed from the flask by incubation in 1 mM EDTA (Gibco) and ~1x106 MES23.5 cells
were passed to a new flask with cells passed 2 times per week.
BV2 cell culture
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BV2 cells were cultured in BV2 media (1x DMEM with glucose, glutamine, and
phenol red (Gibco) supplemented with 5% FBS, 100 U penicillin, 100 g/ml streptomycin
(Gibco), 10 mM HEPES (Gibco), 2 mM L-glutamine (Gibco), and 55 nM 2mercaptoethanol (Gibco)). BV2 cells were passed 2 times per week by removing the
BV2 cells from T-75 flasks (BD Falcon) using 1 mM EDTA (Gibco) and ~1x106 BV2 cells
were passed to a new flask for passage into new T-75 flasks.
To stimulate BV2 cells, ~1x106 BV2 cells in 0.5 ml of volume was added to each
well of a 24-well plate. Each well was adjusted to 1 ml total volume by adding BV2
media, BMDC supernatant (supernatants of BMDC culture from which cells were
removed by centrifugation at 400 xg for 10 min), or R10 media. LPS stimulation was
achieved by adding 100 ng of LPS from E. coli O55:B5 (Sigma) to each well.
Supernatants from each well were combined by treatment group and cells concentrated
by centrifugation at 400 xg for 10 min.
Celltiter-Glo Cell Viability Assay
Cell viability was determined using the CellTiter-Glo assay (Promega) as follows.
Either ~20,000 or 10,000 MES23.5 cells (for MPP+ or BV2 supernatant respectively)
was added to a black-walled 96-well assay plate which was coated with poly-D-lysine.
An equal volume (50 µl) of MES23.5 media, R10 media, or BMDC supernatant was
added to all wells. As controls, equal volumes of media without cells were added to
other wells. After 24 hours of incubation, an equal volume (100 µl) of either MES23.5
media containing 0 – 1,000 µM MPP+ (Sigma), or BV2 media or supernatant was added.
MES23.5 cells were incubated for 24 hr. Afterwards, the media was removed from each
well and 100 µl CellTiter-Glo assay reagent (reconstituted as described in the kit) was
added and the 96-well plate was incubated at RT for 2 min with shaking followed by
equilibration at RT for 10 min prior to reading luminescence. The raw luminescence
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values from the no cell control wells were subtracted from all other wells.

The

background corrected values were divided by the control values obtained from treatment
with media or BV2 media to determine the percent viability.
Cytokine bead array
Concentrations of IL-2, IL-4, IL-6, IL-10, IL-17a, TNF, and IFNγ were determined
using the Th1/Th2/Th17 cytokine bead array (BD) as follows. Standards from the kit
were reconstituted according to the manufacturer’s protocol and 2-fold serially diluted
into 5 ml flow cytometry tubes in duplicate.

In triplicate 50 µl samples of BV2

supernatant were added to 5 ml flow cytometry tubes. Capture beads from all analytes
were combined and 50 µl assay detection reagent were added to 50 µl standards or
samples which were incubated at RT for 2 hr. All samples and standards were washed
in the assay wash buffer and beads were concentrated by centrifugation at 200 xg for 5
min. The supernatant was discarded and pellet resuspended in 300 µl wash buffer and
analyzed by flow cytometry. The mean fluorescent intensity was determined for each
cytokine in all samples and standards. The log 10-transformed mean fluorescent intensity
was plotted against log10-transformed concentration of the standards. The curve was
fitted by five parameter logistical regression to determine the standard curve. Based on
standard curve, the concentration of each cytokine was determined from all samples.
Testing splenic DC percentage after GM-CSF administration
Approximately 11-week-old C57BL/6J mice (Jackson Labs) were i.p. injected
with 50 µg/kg mouse recombinant GM-CSF or a commensurate volume of 1x DPBS
each of five days prior to sacrifice.

Mice were sacrificed by CO 2 asphyxiation and

cervical dislocation, spleens removed, and a single cell suspensions prepared. Cells
were immunostained for the surface expression of CD11c, CD11b, CD86, MHC II, Jag-1,
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OX40L, CD39, and CD73 and percentages within the lymphocyte population determined
by flow cytometric analysis using the previously-described antibodies.
Statistics
For comparisons of multiple groups with only one parameter, one-way ANOVA
was performed followed by Tukey’s post-hoc test was used. For comparisons of multiple
groups with 2 or more parameters a two-way ANOVA was performed followed by
Tukey’s or Newmann-Keuls post-hoc test. To determine if surface marker expression on
BMDCs correlates with Treg induction, Pearson’s correlation was calculated using Prism
GraphPad version 6.

For immunohistochemistry data of neuron counts and striatal

density, all values outside the 99% confidence interval were censored and significance
was determined by one-way ANOVA followed by Tukey’s post-hoc test. Statistics were
performed using Prism GraphPad version 6 (GraphPad Software Inc.). A value was
considered significant when the multiple comparison-adjusted P value was less than
0.05.

RESULTS
Activation of DC2.4 and DC3.2 cells with LPS and N-α-Syn is mitigated by GM-CSF
One of the functional definitions of tolerogenic DCs is the lack of an inflammatory
response to maturation stimulation (Mahnke et al., 2002). To test if GM-CSF is inducing
a tolerogenic state, we first needed to determine culture conditions where DCs are
activated by LPS (a strong, general proinflammatory stimulus), N-α-Syn (a posttranslational form of α-Syn which is only found in synucleopathy patients (Duda et al.,
2000; Giasson, 2000)), or Poly I:C (a mimic of double stranded RNA). One of DCs
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responses to proinflammatory stimulus is increasing nitric oxide (NO) production. The
DC lines DC2.4 and DC3.2 were stimulated for 24 hr with increasing (0-100 µg/ml) LPS,
N-α-Syn, or Poly I:C concentrations and the Griess assay was used to test the
concentration of released nitrite (the product of the oxidation of nitric oxide after release
from BMDCs). LPS, and to a lesser extent N-α-Syn, significantly increase the release of
nitrite in the media of both DC lines compared to media alone (0 µg/ml) (Figure 3.2A).
Poly I:C did not increase the concentration of nitrite compared to media at any
concentration. For LPS, maximal nitrite concentration was found at 10 µg/ml and for Nα-Syn the maximal nitrite concentration was found at 30 µg/ml. These concentrations
were used for all future experiments with these cell lines.
To determine if GM-CSF can diminish the concentration of released nitrite,
DC2.4 and DC3.2 cells were cultured in cells with 10 µg/ml LPS and increasing
concentrations (0-200 ng/ml) of GM-CSF, and the concentration of nitrite was tested with
the Griess assay. None of the tested concentrations of GM-CSF significantly decreased
the LPS-induced increase in nitrite concentration in either cell line (Figure 3.2B). This
was done with GM-CSF administered at the same time as LPS. If GM-CSF is inducing
tolerogenic DCs, it may need to be administered before the stimulation with LPS to see
an effect. DC2.4 cells were treated for 2 days with increasing concentrations of GMCSF (0-200 ng/ml) prior to stimulation with LPS and N-α-Syn for 24 hr.

GM-CSF

induces a dose-dependent decrease in nitrite after LPS and N-α-Syn stimulation (Figure
3.2C). It appears that even though 200 ng/ml GM-CSF leads to the most suppression of
nitrite release, this is significant, but not dramatically different than 20 ng/ml.
determine if this decrease in nitrite concentration is due to a loss of DC viability, the

To
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Figure 3.2 GM-CSF pre-treatment, but not co-treatment, decrease the LPS- and N-αSyn-induced increase in nitrite release in DC2.4 and DC3.2 cells with no decrease in cell
viability

104
Figure 3.2 GM-CSF pre-treatment, but not co-treatment, decrease the LPS- and Nα-Syn-induced increase in nitrite release in DC2.4 and DC3.2 cells with no
decrease in cell viability
A) DC lines DC2.4 and DC3.2 were stimulated with increasing concentrations of LPS, Nα-Syn, or Poly I:C for 24 hours and the Griess assay was used to test nitrite
concentration in the supernatant. B) DC2.4 and DC3.2 cells were treated for 24 hours
with 10 µg/ml LPS, increasing concentrations of GM-CSF or the combination of GM-CSF
and LPS and nitrite concentration in the supernatant was determined by the Griess
assay. C) DC2.4 cells were pre-treated with increasing concentrations of GM-CSF for 2
days prior to 24 hours of stimulation with 10 µg/ml LPS or 30 10 µg/ml N-α-Syn and the
NO concentration in the supernatant was determined by the Griess assay. D) Cell
viability was determined after 2 days of 20 ng/ml GM-CSF pre-treatment, then 24 hours
of stimulation with 10 µg/ml LPS or the combination, and the AlamarBlue cell viability
assay was used to determine the percentage of the dye reduced. Significance was
determined by One-way ANOVA followed by Tukey’s post-hoc test where a result is
significant if p<0.05. For A and B, a-significant from media alone, b-significant from LPS
control and n=4 in A and n=5 in B. For C, a-significantly different from media, bsignificantly different from 10 µg/ml LPS, 1-significantly different from 0 ng/ml GM-CSF,
2-significantly different from 2 ng/ml GM-CSF, 3-significantly different from 20 ng/ml GMCSF and n=3. For D, a-significant from media alone, b-significant from GM-CSF control,
c-LPS control and n=6.
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alamarBlue cell viability assay was used. DC2.4 and DC3.2 cells were cultured in media
or 20 ng/ml GM-CSF for two days, prior to simulation with LPS for 24 hr. For both DC
lines, the neither treatment with GM-CSF or LPS stimulation separately or in
combination decreased cell viability compared to media alone, unstimulated control
(Figure 3.2D).
To test the activation of DC2.4 cells by another method, we tested the surface
expression of activation markers and co-stimulatory molecules. DC2.4 cells were pretreated for 2 days with GM-CSF prior to 24 hr stimulation with LPS and N-α-Syn and flow
cytometry was performed.

Few DC2.4 cells (5% or less) expressed CD11c (Figure

3.3A), an integrin receptor which is a marker for myeloid lineage DCs (Ziegler-Heitbrock
et al., 2010). CD86 is an activation marker for DCs which binds to CD28 on T cells,
leading to T cell proliferation and activation (Lu et al., 1997). Even when cultured in
media alone, about 90% of DC2.4 cells express CD86 (Figure 3.3B). Pre-treatment with
GM-CSF, LPS or N-α-Syn stimulation, or a combination can do decrease the high, basal
surface expression of CD86.

Less than 5% of DC2.4 cells express OX40L, a co-

stimulatory molecule which preferentially promotes Th2 CD4+ cells proliferation
(Ohshima et al., 1998) and Treg survival (Griseri et al., 2010) (Figure 3.3C). Jagged-1
(Jag-1) is a Notch-1 ligand which also promotes the differentiation of Tregs (Hoyne et al.,
2000). GM-CSF, LPS and N-α- Syn, alone or in combination increases Jag-1 surface
expression on DC2.4 cells (Figure 3.3D). In all conditions, GM-CSF does not promote
the surface expression of co-stimulatory molecules OX40L and Jag-1.

In addition,

DC2.4 cells constitutively express high CD86 in all conditions, meaning there is no
upregulation following stimulation with LPS and N-α-Syn. As a result, the activation of
DC2.4 could not be determined by flow cytometry. Because CD86 surface expression is
not changed on DC2.4 cells and the expression of Jag-1 and especially OX40L was low
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Figure 3.3 Flow cytometric analysis of DC2.4 cells after GM-CSF pre-treatment and LPS
and N-α-Syn stimulation
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Figure 3.3 Flow cytometric analysis of DC2.4 cells after GM-CSF pre-treatment and
LPS and N-α-Syn stimulation
DC2.4 cells were pre-treated in 20 ng/ml GM-CSF for 2 days prior to 24 stimulation with
10 µg/ml LPS or 30 µg/ml N-α-Syn prior to staining cells for CD11c (A), CD86 (B),
OX40L (C), and Jag-1 (D). Data presented are from 1 replicate so no statistical
analyses were performed.
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and relatively unchanged, DC2.4 cells are not the best model for determining if GM-CSF
is inducing a tolerogenic DCs.
BMDC activation by LPS and N-α-Syn is mitigated by GM-CSF
Due to GM-CSF being unable to induce a tolerogenic state in DC lines, we next
sought to determine if GM-CSF can induce a tolerogenic state in BMDCs. First, we
needed to determine optimal differentiation conditions for BMDCs by culturing BMDCs
with 10 or 20 ng/ml GM-CSF with and without 10 ng/ml IL-4. After 8 days, BMDCs were
cultured in media alone for 3 days, 20 ng/ml GM-CSF for 3 days or 20 ng/ml GM-CSF for
2 days prior to 1 day of stimulation with 10 μg/ml LPS and surface markers were
determined by flow cytometry. In all conditions, 50% or more of the BMDCs expressed
CD11c with a generally higher percentage of CD11c+ cells found on BMDCs
differentiated without IL-4 (Figure 3.4A).

Unlike the DC2.4 cells, LPS stimulation

increase the surface expression of CD86 in all BMDC differentiation conditions (Figure
3.4B). BMDC differentiation with IL-4 increased the percentage of unstimulated BMDCs
expressing CD86. All conditions displayed fewer CD86-expressing BMDCs than DC2.4.
OX40L expression was higher when BMDCs were differentiated with IL-4 (Figure 3.4C).
When BMDCs were differentiated without IL-4, LPS-stimulation of BMDCs decreased
the number of OX40L+ cells, however, BMDCs differentiated with IL-4 prior to LPS
stimulation appeared to increase the number of BMDCs expressing OX40L.
Differentiating BMDCs in the presence of IL-4 appears to diminish the number of BMDCs
expressing Jag-1 (Figure 3.4D). For BMDCs differentiated without IL-4, the number of
Jag-1+ BMDCs increases with GM-CSF treatment and increases further with LPS
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Figure 3.4 Flow cytometric analysis of BMDCs after differentiation in GM-CSF or GMCSF and IL-4 prior to stimulation with LPS
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Figure 3.4 Flow cytometric analysis of BMDCs after differentiation in GM-CSF or
GM-CSF and IL-4 prior to stimulation with LPS
BMDCs were differentiated from the bone marrow for 8 days with 10 or 20 ng/ml GMCSF with 0 or 10 ng/ml IL-4. After differentiation, BMDCs were cultured in media alone,
media supplemented with 20 ng/ml GM-CSF or media supplemented with 20 ng/ml GMCSF for two days prior to 24 hours of stimulation with 10 µg/ml LPS. Surface expression
of CD11c (A), CD86 (B), OX40L (C), and Jag-1 (D) was determined by flow cytometry.
There are 2 replicates of CD11c and 1 replicate of CD86, OX40L, and Jag-1. No
statistics could be performed.
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stimulation. The conclusion from this experiment is that differentiating BMDCs in 20
ng/ml GM-CSF without IL-4 appears to be the optimal condition for expressing all 4 of
the markers tested. BMDC differentiated with this condition showed a high percentage
positive for CD11c, a noticeable increase in CD86+ cells after stimulation and a
noticeable increase in the percentage of Jag-1+ BMDCs with GM-CSF treatment or LPS
stimulation.

Because BMDCs exhibit lower basal activation state compared to the

DC2.4 cells, BMDCs are a better model for testing the tolerogenic state of DCs.
Since there were surface expression differences on BMDCs with GM-CSF
culture followed by LPS and N-α-Syn stimulation compared to DC2.4 cells, we next
tested if BMDCs increase the release of nitrite after stimulation with LPS and N-α-Syn
stimulation. Stimulation with LPS and N-α-Syn increase the release of nitrite compared
to BMDCs continued in culture with GM-CSF. The continued culture of BMDCs with
GM-CSF prior to LPS and N-α-Syn stimulation mitigates the increase in nitrite
concentration (Figure 3.5A). These data show that BMDCs can release nitrite after
stimulation, just as DC2.4 cells. However, it should be noted that the increase in nitrite
after stimulating BMDCs with LPS and N-α-Syn stimulation is less than the increase after
stimulating DC2.4 cells.
To ensure that the changes in nitrite production were not due to the loss of
BMDCs by GM-CSF culture without or with LPS or N-α-Syn stimulation, the alamarBlue
cell viability assay was performed. The continued culture of BMDCs in GM-CSF prior to
LPS stimulation significantly lowered cell viability compared to media and GM-CSF
controls, however the cell viability was still over 90% (Figure 3.5B). LPS stimulation
alone, and N-α-Syn stimulation with or with continued GM-CSF culture, did not affect cell
viability. These data demonstrate that the decrease in nitrite production is not due to a
dramatic loss of BMDCs.
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Figure 3.5 BMDC culture with GM-CSF mitigates the LPS- or N-α-Syn-induced increase
in the nitrite concentration in the supernatant, without effecting cell viability
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Figure 3.5 BMDC culture with GM-CSF mitigates the LPS- or N-α-Syn-induced
increase in the nitrite concentration in the supernatant, without effecting cell
viability
BMDCs were matured for 8 days with 20 ng/ml GM-CSF. BMDCs were either cultured
in media alone or 20 ng/ml GM-CSF for 2 days prior to being stimulated for 24 hours
with 100 ng/ml LPS or 30 µg/ml N-α-Syn. A) The Griess assay was used to measure the
nitrite concentration in the supernatant. Significance was determined by One-way
ANOVA followed by Tukey’s post-hoc test, n=9. a-significantly different from media
alone, b-significantly different from GM-CSF control, c-significantly different from LPS or
N-α-Syn control. B) Cell viability was also tested using the alamarBlue assay where cell
viability was determined by measuring the percentage of the alamarBlue dye reduced.
Significance was determined by One-way ANOVA followed by Tukey’s post-hoc test and
p<0.05. a-significantly different from media alone, b-significantly different from GM-CSF
control, n=9.
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After determining the conditions to differentiate the BMDCs, the next experiments
performed were designed to test if GM-CSF promotes a tolerogenic state in BMDCs.
Tolerogenic DCs display low expression of co-stimulatory molecules, even with a
maturation stimulus.

To test this hypothesis, flow cytometric analysis was used to

determine if GM-CSF, N-α-Syn or the combination significantly increases the surface
expression of different co-stimulatory molecules. The percentage of CD11c+ cells in the
single cell suspension was determined by flow cytometry. More than 75% of cells in all
treatment groups are positive for the DC marker CD11c, even though there was a
significant reduction of CD11c+ cells in BMDCs continued in GM-CSF culture prior to Nα-Syn (Figure 3.6A). Flow cytometry was also used to determine the surface expression
of the myeloid-origin cell marker CD11b. As with CD11c, BMDCs continued in GM-CSF
culture prior to N-α-Syn stimulation display significantly reduced surface CD11b,
however more than 95% of single cells are CD11b+ (Figure 3.6B). When DCs mature,
they upregulate their surface expression of co-stimulatory molecules, such as MHC II
and CD86. The mean fluorescent intensity (MFI) of the activation state of MHC II and
CD86 on CD11c+ BMDCs was significantly increased after N-α-Syn stimulation of
media-cultured BMDCS, but this was significantly diminished by pretreatment with GMCSF (Figure 3.6C, D). The MFI of OX40L was not altered by the pretreatment with GMCSF, N-α-Syn stimulation, or a combination (Figure 3.6E). The surface expression of
Jag-1 is significantly increased with GM-CSF pretreatment which is further increased by
N-α-Syn stimulation (Figure 3.6F). The surface expression of CD11c, OX40L, and Jag-1
are similar to the results in Figure 3.4. We also tested the expression of the surface
ATPases CD39 and CD73. CD39 is the enzyme that converts extracellular ATP to AMP
and CD73 converts AMP to adenosine (Deaglio et al., 2007). Neither the continuation of
GM-CSF culture, nor the stimulation with N-α-Syn increased the surface expression of
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Figure 3.6 Surface expression of co-stimulatory molecules on CD11c+ BMDCs
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Figure 3.6 Surface expression of co-stimulatory molecules on CD11c+ BMDCs
BMDCs were cultured in media alone or with 20 ng/ml GM-CSF for 2 days prior to
stimulation with 30 µg/ml N-α-Syn for 1 day. On the X-axis, treatment groups are
designated as (1) media-cultured, unstimulated BMDCs; (2) GM-CSF-cultured,
unstimulated BMDCs; (3) media-cultured, N-α-Syn-stimulated BMDCs; and (4) GM-CSFcultured, N-α-Syn-stimulated BMDCs. BMDCs were stained for CD11c, CD11b, MHC II,
CD86, OX40L. Jag-1, CD39 and CD73 for flow cytometric analysis. Panels A and B are
the percentage of single cells positive for CD11c and CD11b respectively. The numbers
are the mean percentage of single cells positive for each marker. The mean fluorescent
intensity (MFI) was determined on CD11c+ cells for MHC II (C), CD86 (D), OX40L (E),
Jag-1 (F), CD39 (G) and CD73 (H). There are 7 replicates for each treatment group.
Significance was determined by one-way ANOVA and Tukey’s post-hoc test. asignificantly different from media BMDCs, b-significantly different from GM-CSF-treated
BMDCs c-significantly different from N-α-Syn-treated BMDCs.
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CD39 and CD73 (Figure 3.6G, H). These data demonstrate that continued culture with
GM-CSF diminishes the N-α-Syn-induced increase of CD86 and MHC II surface
expression and increases Jag-1 surface expression. In total, these data indicate that the
BMDCs tested are in a tolerogenic state due to their decreased expression of the costimulatory molecules (MHC II and CD86) and increased expression of anti-inflammatory
Jag-1.
Next, we wanted to test the expression of proinflammatory cytokines and other
proinflammatory mediators. From all 4 BMDC treatment groups, RNA was isolated,
cDNA was generated, and PCR arrays were run to test the expression of
proinflammatory genes relative to the media-cultured, unstimulated BMDCs. GM-CSF
culture without stimulation did cause 2-fold upregulation of IL6, CXCL9, CXCL3, CCL17,
SELE, CCL24, CCR1, CXCR2, and TNFSF14 and the downregulation of CXCL10,
CD40, TNF, TLR1, and BCL6 (Figure 3.7).

N-α-Syn stimulation of media-cultured

BMDCS increased expression of several genes including CXCL10, IL6, IL23A, PTGS2,
CD40, among others. Several genes are downregulated including CCR2, FOS, CXCR4,
IL6RA among others. The continued culture in GM-CSF prior to N-α-Syn stimulation
diminished the expression of several genes such as IL6, PTGS2, CD40, and LTA among
others. Conversely, several genes were increased with the continued culture in GMCSF prior to N-α-Syn stimulation, for example, IL23A, NOS2, and IL1A. Three genes
that were downregulated by N-α-Syn stimulation in media-cultured BMDCs were further
downregulated with GM-CSF pretreatment; these genes are CXCR2, CXCR4 and FOS.
However, other genes downregulated by N-α-Syn stimulation of media-cultured BMDCs
were not as downregulated in GM-CSF-cultured BMDCs such as TNFSF14, IL6RA, and
CCR2.
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Figure 3.7 Gene expression of GM-CSF, N-α-Syn, or GM-CSF+N-α-Syn-treated BMDCs
compared to media-cultured, unstimulated BMDCs
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Figure 3.7 Gene expression of GM-CSF, N-α-Syn, or GM-CSF+N-α-Syn-treated
BMDCs compared to media-cultured, unstimulated BMDCs
BMDCs were differentiated for 8 days with 20 ng/ml GM-CSF and half of the BMDCs
were cultured for 2 days with media alone 20 ng/ml GM-CSF. Some BMDCs from each
culture condition were stimulated with 30 µg/ml N-α-Syn for 6 hr. RNA was isolated,
converted to cDNA and PCR arrays of pro-inflammatory genes were performed. Gene
expression was determined relative to the media-cultured, unstimulated BMDCs. n=6.
The fold change is indicated, and red shading indicates upregulation of gene expression
and green shading indicates downregulation.
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This gene expression data highlights several key points. N-α-Syn stimulation
increases the expression of proinflammatory cytokines like IL6, IL23A, TNF, IL1A, IL1B,
IL18, and IFNG which may be increased or decreased by continued culture with GMCSF. The expression of the anti-inflammatory gene IL10 was increased with N-α-Syn
stimulation of media-cultured BMDCs, and further increased with continued culture in
GM-CSF prior to N-α-Syn stimulation. The increase in anti-inflammatory and decrease
in proinflammatory cytokines are in line with GM-CSF-cultured BMDCS being
tolerogenic. However, some proinflammatory genes are increased, which is counter to
our hypothesis. Next, we tested the expression of other markers of maturation in our
BMDCs.

Several genes associated with Toll-like receptor signaling, such as TLR1,

TLR3, TLR2, CD14, MYD88, and NFKB1 are increased by N-α-Syn stimulation of
media-cultured BMDCs, and continued culture in GM-CSF decreased the expression of
TLR1 and TLR3 but increased the expression of TLR2. This suggests that GM-CSF
pretreatment may alter the expression of the TLRs, including TLR1, TLR2, and TLR4,
which can be receptors for α-Syn (Su et al., 2008; Stefanova et al., 2011; Fellner et al.,
2013; Daniele et al., 2015).

However, the expression of MYD88 and NFKB1, the

downstream signaling cascade of the Toll-like receptors, and CD14, the co-receptor for
TLR4, was not affected by the continued culture of BMDCs in GM-CSF. This suggests
that it is not that GM-CSF is able to diminish the ability of the BMDCs to respond to N-αSyn, but rather GM-CSF alters the response of the BMDCs. The continued culture of
GM-CSF diminished the N-α-Syn-induced expression of CD40. The gene expression of
CD40, a T cell co-stimulatory molecule, is similar to the surface expression of CD86, a
co-stimulatory molecule with similar function. CCR7 is marker of DC maturation (Worbs
and Forster, 2007), which was decreased -1.42-fold in the continued culture in GM-CSF
without stimulation. However, N-α-Syn stimulation increases CCR7 expression, which is
further increased by continued culture of BMDCs with GM-CSF.

Lastly CEBPB, a
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transcription factor involved in TNFα expression (Pope et al., 1994) was increased by
stimulation with N-α-Syn and expression was further increased by culture with GM-CSF
prior to N-α-Syn stimulation. In total, these gene expression changes demonstrate that
GM-CSF does not prevent the maturation of BMDCs or diminish the ability of BMDCs to
respond to the N-α-Syn stimulation. However, GM-CSF does alter how BMDCs respond
to N-α-Syn stimulation, which increases the expression of some proinflammatory and
anti-inflammatory genes.
We also tested the release of nitrite from these BMDCs. Overall, there was no
significant change in nitrite concentration between the BMDC treatment groups (Figure
3.8).

However, there was a trend to more nitrite release with N-α-Syn stimulation

compared to all other groups, but the concentration of nitrite was decreased compared
to previous experiments (Figure 3.5). Interestingly, in the PCR array from Figure 3.7,
NOS2, the gene for the major producer of NO in activated BMDCs, inducible nitric oxide
(iNOS), was significantly increased with N-α-Syn stimulation and NOS2 was more highly
expressed in BMDCs continued in culture with GM-CSF prior to N-α-Syn stimulation.
The expression of NOS2 does not correlate with the nitrite concentration determined by
the Griess assay.
In addition to testing the expression of proinflammatory genes, release of
proinflammatory cytokines and chemokines from different treatment groups of BMDCs
was tested by a Luminex magnetic bead assay. N-α-Syn stimulation of media-cultured
BMDCs significantly increased the release of IL-1β, IL-10, Lix, MIG, IL-6, IL-12p70, IL13, IL-15, IFNγ, RANTES and TNFα compared to the media-cultured, unstimulated
controls (Figure 3.9).

Continued culture in GM-CSF prior to N-α-Syn stimulation

increased the release of IL-1α, IL-1β, IL-2, IL-5, IL-7, IL-9, IL-10, IL-12p40, IL-17, and IP10. The continued culture in GM-CSF prior to N-α-Syn stimulation decreased the
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Figure 3.8 Nitrite concentration in supernatant from BMDCs
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Figure 3.8 Nitrite concentration in supernatant from BMDCs
BMDCs were matured for 8 days with 20 ng/ml GM-CSF. BMDCs were then cultured in
media alone or 20 ng/ml GM-CSF for 2 days prior to being stimulated for 24 hours with
30 µg/ml N-α-Syn or being left unstimulated. The Griess assay was used to measure
nitrite concentration in the supernatant. Significance was determined by One-way
ANOVA followed by Tukey’s post-hoc test and p<0.05. n=28 (4 technical replicates from
each of 7 wells of BMDCs from each treatment group).
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release of Lix and MIG. The continued culture in GM-CSF decreased MIP2 release
without N-α-Syn stimulation; however, N-α-Syn stimulation after the continued culture of
BMDCs in GM-CSF prevented this decrease. Continued culture of BMDCs in GM-CSF
prior to N-α-Syn stimulation increased the release of IL-10, an anti-inflammatory
cytokine.

The continued culture in GM-CSF did not significantly alter the N-α-Syn-

induced release of proinflammatory cytokines IL-6, IL-12p70, IL-13, IL-15, IFNγ, MIP2,
RANTES, and TNFα.

In total, these data show that the continued culture in GM-CSF

pretreatment does not mitigate the release of proinflammatory cytokines or chemokines,
but does increase the release of IL-10. While there are changes in the expression on
the RNA level, but this does occur on the level of protein release. These data suggest
that GM-CSF is more an immune modulator altering the response of BMDCs as
opposed to broadly suppressing the immune response.
Lastly, we tested if the continued culture of BMDCs in GM-CSF with or without Nα-Syn stimulation increases the expression of IDO in lysate as well as kynurenine
release in the supernatant. IDO is the enzyme that converts tryptophan to kynurenine
(King and Thomas, 2007). The increase in IDO expression, kynurenine concentration,
and concentration of kynurenine’s metabolites are inducers of Tregs (Munn and Mellor,
2013) and may be part of the mechanism of Treg induction. BMDCs were cultured in
media alone or with GM-CSF and left unstimulated or stimulated with N-α-Syn as above.
BMDCs were lysed and Western blot was used to determine the expression of IDO
relative to β-actin.

Media-cultured, unstimulated BMDCs displayed the highest

expression of IDO, which was significantly decreased by continued culture in GM-CSF,
with or without N-α-Syn stimulation (Figure 3.10A). Mass spectrometry was used to
quantify the kynurenine concentration in the media. There was no significant difference
in the concentration of released kynurenine between
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Figure 3.9 Cytokines and chemokines released from BMDCs
BMDCs were differentiated for 8 days in 20 ng/ml GM-CSF prior to culture with media
alone or 20 ng/ml GM-CSF for 2 days, then stimulation with 30 µg/ml N-α-Syn for 1 day.
On the X axis, treatment groups are designated as (1) media-cultured, unstimulated
BMDCs; (2) GM-CSF-cultured, unstimulated BMDCs; (3) media-cultured, N-α-Synstimulated BMDCs; (4) GM-CSF-cultured, N-α-Syn-stimulated BMDCs. The supernatant
was removed and the Luminex XMAP pro-inflammatory cytokine and chemokine array.
There are three 2-3 technical replicates for each of 7 wells of BMDCs (n=19 for each
group). Significance was determined by One-Way ANOVA and Tukey’s post-hoc test.
a-significantly different from media BMDCs, b-significantly different from GM-CSF-tested
BMDCs c-significantly different from N-α-Syn-treated BMDCs (p>0.05).
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treatment groups, but the media-cultured, unstimulated BMDCs appear to exhibit the
highest concentration of released kynurenine (Figure 3.10B). This finding is contrary to
our hypothesis that the continued culture in GM-CSF would increase expression of IDO
or release of kynurenine, which are markers of tolerogenic DCs.
In conclusion, from the flow cytometric data, it appears that GM-CSF decreases
the surface expression of co-stimulatory molecules, and increases the surface
expression of Jag-1, which is in line with our hypothesis of GM-CSF inducing a
tolerogenic state. However, GM-CSF does not mitigate the expression or release of
proinflammatory cytokines, or increase the expression of IDO or kynurenine. These data
do not support the hypothesis. Overall, it appears that GM-CSF is altering how BMDCs
respond to stimulation with N-α-Syn, but does not maintain the tolerogenic state.
BMDCs increase Treg frequencies
In the above section, we characterized the surface markers, genes expressed,
and products released by BMDCs cultured in media alone or GM-CSF prior to N-α-Syn
stimulation. One of the properties of tolerogenic DCs is the ability to induce Tregs
(Maldonado and von Andrian, 2010) and the next experiment was to determine if
BMDCs cultured in media or GM-CSF with and without N-α-Syn stimulation were able to
induce Tregs in culture. BMDCs were differentiated and cultured as described above
and were co-cultured with CD4+ cells isolated from spleens of C57BL/6J mice. After 5
days, the percentage of Tregs (CD4+ CD25+ Foxp3+) in the non-adhered cells was
determine by flow cytometric analysis. In CD4+ cells prior to co-culture, ~2% of the
CD4+ cells are Tregs (Figure 3.11A). All BMDC treatment groups significantly increased
the percentage of Tregs (CD4+ CD25+ Foxp3+) compared to CD4+ cells alone. Mediacultured, unstimulated and N-α-Syn-stimulated BMDCs induced significantly more Tregs
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Figure 3.10 Expression of IDO and kynurenine release in the supernatant
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Figure 3.10 Expression of IDO and kynurenine release in the supernatant
BMDCs were differentiated for 8 days with 20 ng/ml GM-CSF. At this time, the BMDCs
were cultured in media alone or in 20 ng/ml GM-CSF for 2 days. BMDCs were left
unstimulated or stimulated with 30 µg/ml N-α-Syn for 24 hour. A) Western blot was
performed on lysate and the ratio of intensity for IDO and β-actin from each of the
treatment groups (n=2 media, n=6 GM-CSF, n=7 N-α-Syn, and n=7 GM-CSF + N-α-Syn)
was graphed. Significance was determined by one-way ANOVA followed by Tukey’s
post-hoc test and was significance was determined by p<0.05. B) HPLC and Mass
spectroscopy was used to determine the concentration of kynurenine in the supernatant
of BMDCs treated as above. n=7 for all groups. Significance was determined by Oneway ANOVA followed by Tukey’s post-hoc test.
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than the GM-CSF-cultured BMDCs.

GM-CSF-cultured, N-α-Syn-stimulated BMDCs

induced significantly fewer Tregs than all other BMDC treatment groups. CD4+ T cells
cultured with CD3/CD28 transactivator beads also increased the percentage of Tregs
relative to CD4+ cells prior to culture, but to a significantly decreased degree than all
BMDC treatment groups except for the GM-CSF-cultured, N-α-Syn-stimulated BMDCs
(Figure 3.11A). In a separate experiment, CD4+ cells were stained before culture (CD4+
alone), with media-cultured, unstimulated BMDCs directly or in transwell, or with CD11c+
cells positively enriched from the spleen of naïve C57BL/6J mice. Non-adhered cells
were removed and the percentage of Tregs was determined by flow cytometry. While
there were fewer Tregs in this experiment compared to the experiment in Figure 3.11A,
media-cultured, unstimulated BMDCs still increased the percentage of Tregs ~20 fold
compared to the starting CD4+ T population (Figure 3.11B). When CD4+ T cells were
cultured in a transwell assay with media-cultured BMDCs, the percentage of Tregs was
reduced compared to direct culture, (Figure 3.11B). Culture of CD4+ cells in a transwell
assay increased Tregs ~3-fold, which was not significant compared to the starting CD4+
population, which is similar to the ~5-fold increase with CD3/CD28 transactivator beads.
When splenic CD11c+ DCs were cultured with CD4+ cells, there was not a significant
increase in the percentage of Tregs compared to the starting CD4+ population (Figure
3.11B). However, the splenic CD11c+ cells increased Tregs ~3-fold, compared to the
starting CD4+ population, similar to the CD3/CD28 transactivator beads and transwell
culture. Combined, these data show that direct contact is needed for BMDCs to induce
Tregs, and that Tregs induction is more than activation of T cells in general since neither
CD3/CD28 activator beads nor CD11c+ DCs induce Tregs to the same percentage.
However, contrary to our hypothesis, continuing GM-CSF culture significantly decreases
the ability of BMDCs to induce Tregs, both with and without N-α-Syn stimulation.

131

Figure 3.11 BMDCs induce functional Tregs in vitro
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Figure 3.11 BMDCs induce functional Tregs in vitro
BMDCs were cultured with media or 20 ng/ml GM-CSF for 2 days prior to stimulation
with 30 µg/ml N-α-Syn for 1 day. These BMDCs or CD3/CD28 transactivator beads
were then co-cultured with CD4+ T cells isolated from spleens for 5 days. Non-adhered
cells were removed from co-culture and the percentage of Tregs (CD25+ Foxp3+) was
determined within the CD4+ T population. (A) Representative, flow cytometric plots of
non-adhered cells from the starting CD4+ T cells or the co-culture of CD4+ cells with
BMDCs or CD3/CD28 beads are presented. Quantification of 3 co-cultures of BMDCs of
each treatment group with CD4+ T cells. Significance was determined by one-way
ANOVA followed by Newman-Keuls post-hoc test. a-significantly different from CD4+ T
cells alone, b-significantly different from media-cultured BMDCs, c-significantly different
from GM-CSF-cultured, unstimulated BMDCs, d-significantly different from mediacultured, N-α-Syn-stimulated BMDCs, e- significantly different from GM-CSF-cultured, Nα-Syn-stimulated BMDCs. (B) CD4+ T cells were cultured with media-cultured,
unstimulated BMDCs directly or in transwell and CD4+ T cells were cultured with
CD11c+ cells isolated from the spleen of naïve mice. Quantification of 3 co-cultures of
BMDCs of each treatment group with CD4+ T cells. Significance was determined by
one-way ANOVA followed by Tukey’s post-hoc test. a-significantly different from CD4+
T cells alone, b-significantly different from media-cultured BMDCs. (C) Non-adhered
cells from media-treated BMDCs were removed after 5 days of co-culture and Tregs
(CD4+ CD25+). Tregs (CD4 CD25+) and responder T cells (CD4+ CD25-) were isolated
from the spleens of naïve mice. Dilutions of Tregs were cultured with CFSE-labelled
CD4+ CD25- cells, which were stimulated with CD3/CD28 beads. Linear regression was
performed to compare the slopes of the lines. a-significantly different slope (p=0.006)
from spleen-derived Tregs.
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To determine if CD4+ CD25+ Foxp3+ cells induced by BMDCs possess the
proliferation suppression function, CD4+ CD25+ cells were isolated from co-culture with
BMDCs and CD4+ T cells from naïve mouse spleen to test the ability of Tregs to
suppress the proliferation of CFSE-labelled CD4+ CD25- responder T cells (Figure
3.11C).

The BMDC-induced Tregs suppress CD4+ CD25- proliferation to a greater

extent than splenic Tregs.

These results demonstrate that BMDCs can induce the

formation of Tregs in the contact-dependent manner and these Tregs possess
suppressive function.
Next, to determine if the surface expression of markers on BMDCs correlates
with the induction of Tregs, 3 replicates of BMDCs were cultured with CD4+ cells
isolated from mouse spleens. The surface expression of each of the 8 surface markers
was determined by mean fluorescent intensity (MFI). Treg percentage was determined
in the non-adhered cells. Interestingly, there was a positive correlation between MFI of
CD39, MHC II, and CD11c expression (Pearson’s correlation of 0.8357. 0.7573 and
0.6266 respectively, Figure 3.12). There were weaker positive correlations with Jag-1,
CD73, and CD11b (Pearson’s correlation of 0.5535. 0.5396 and 0.5310 respectively,
Figure 3.12). There were moderate negative correlations between OX40L and CD86
and Treg induction (Pearson’s correlation of -0.5504 and -0.4373 respectively, Figure
3.12). These data may suggest that the surface expression of proteins like CD39 may
play a role in the development of Tregs. Interestingly, Jag-1 expression did not seem to
strongly correlate with Tregs and OX40L expression negatively correlates with Treg
induction. This is of note since both markers are reported to be important for Tregs
induction (Gopisetty et al., 2013).
The increased percentage of the Tregs induced by BMDCs could be due to
proliferation of the existing Treg population or inducing non-Tregs to become Tregs. To
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test this, splenocytes were enriched for CD4+ CD25- (non-Tregs, non-effector T cells)
and CD4+ CD25+ (Tregs) and both were separately labelled with CFSE and cultured
with media-cultured, unstimulated BMDCs or alone for 5 days. Non-adhered cells were
stained for CD4, CD25, and Foxp3 and flow cytometry was performed to determine the
percentage of Tregs and the percentage of proliferating cells within the Treg population.
For the CD4+ CD25- cells alone, less than 1% of the CD4+ cells were Tregs, but when
cultured with media-cultured, unstimulated BMDCs, the percentage of Tregs in the
population increased to ~11% of the population (Figure 3.13A). Based on the CFSE
labelling, ~40% of the induced Tregs are proliferating. Because the majority of Tregs did
not proliferate and the Tregs that did proliferate, this demonstrates that BMDCs are
inducing non-Tregs to become Tregs. The 10-fold increase in Treg percentage cannot
be accounted for by the proliferation of a minority of Tregs. In the culture of CD4+
CD25+ cells alone, ~22% of the CD4+ T cells are Tregs, but when cultured with BMDCs
the percentage of Tregs increased to ~50%. Of these Tregs, ~41% are proliferating
(Figure 3.13B); however, ~52% of the Tregs alone are proliferating.

Since the

percentage of proliferating Tregs is similar with or without culture with BMDCS, the
increase in the percentage of Tregs is likely due to the induction of non-Tregs in the
culture to become Tregs. Combined, these data suggest that BMDCs can induce the
proliferation of Tregs, but it appears that more of the increase in the percentage of Tregs
is induced from the non-Treg population.
BMDCs are neuroprotective in the MPTP model
After characterizing the effects of GM-CSF on BMDCs, we next wanted to test
the ability of these cells to be protective in the MPTP model. Adoptive transfer of Tregs
into MPTP-intoxicated mice leads to protection of dopaminergic neurons in the
substantia nigra and the termini of those neurons in the striatum (Reynolds et al., 2007).
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Figure 3.12 Correlation of BMDC surface markers with Treg induction
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Figure 3.12 Correlation of BMDC surface markers with Treg induction
The mean fluorescent intensities (MFI) of CD11c, CD11b, MHC II, CD86, Jag-1, OX40L,
CD39, and CD73 on CD11c+ BMDCs were graphed with the frequency of Tregs (CD4+
CD25+ Foxp3+) after 5 days of co-culture. The black dots are co-culture of mediatreated, unstimulated BMDCs with CD4+ cells, the red dots are co-culture of GM-CSFculture, unstimulated BMDCs with CD4+ cells, the blue dots are co-culture of mediatreated, 30 µg/ml N-α-Syn-stimulated BMDCs with CD4+ cells, the green dots are coculture of GM-CSF-cultured, 30 µg/ml N-α-Syn-stimulated BMDCs with CD4+ cells.
Pearson correlation of the MFI of each marker with Treg frequency is indicated on each
graph. The dotted lines represent the 95% confidence interval for the linear regression
best-fit line.
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Because Tregs are induced by DCs, we hypothesized that the adoptive transfer of
tolerogenic DCs will increase the percentage of Tregs and protect dopaminergic neuron
loss after MPTP. The media-cultured, unstimulated BMDCs were the most tolerogenic
given the low co-stimulatory molecule expression, low cytokine production, and highest
induction of Tregs, so these BMDCs were used in all in vivo experiments. Initially, the
adoptive transfer of BMDCs 8 hr after intoxication with 12 or 16 mg/kg was tested for the
protection of dopaminergic (tyrosine hydroxylase positive, TH+ Nissl+) neurons. We
found no significant protection of TH+ Nissl+ neurons in the substantia nigra in mice
receiving BMDCs compared to MPTP control mice (Figure 3.14). This result suggested
that there was insufficient time for BMDCs to migrate from the site of injection into the
tail vein to the secondary lymph organs to induce Tregs and protect dopaminergic
neurons.

However, in the 16 mg/kg MPTP mice, there was a trend toward

neuroprotection with the adoptive transfer of BMDCs. This may suggest that BMDCs
induce a greater effect when inflammation is greater.
In order to give BMDCs more time to induce Tregs and be neuroprotective in
vivo, BMDCs were adoptively transferred 1 and 2 weeks prior to MPTP. This transfer
scheme was used because it was protective in the EAE model (Prado et al., 2012).
Seven days after MPTP intoxication, at the peak of dopaminergic neuron loss
(Kohutnicka et al., 1998), mice were sacrificed and immunohistochemistry was
performed for dopaminergic (TH+ Nissl+) neurons and the dopaminergic (TH+) termini in
the striatum. MPTP intoxication decreased the counts of TH+ neuron counts in the
substantia nigra, but this loss was mitigated by the adoptive transfer of BMDCs (Figure
3.15). There was no significant change in the number of non-dopaminergic (TH- Nissl+)
neurons, suggesting that the decrease in dopaminergic neurons was not due to the
downregulation of TH. MPTP also significantly decreased the density of TH staining in
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Figure 3.13 BMDCs cause both induction and proliferation of Tregs
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Figure 3.13 BMDCs cause both induction and proliferation of Tregs
BMDCs were generated by culturing bone marrow with 20 ng/ml GM-CSF for 8 days.
BMDCs were then cultured in media alone for 3 days. At this time, BMDCs were
cultured with A) CFSE-labelled CD4+ CD25- cells or B) CFSE-labelled CD4+ CD25+
cells enriched from the spleens of naïve mice. As a control, the CD4+ CD25- and CD4+
CD25+ cells were cultured alone. After 5 days, flow cytometric analysis was performed.
The percentage of Treg (CD25+ Foxp3+ T cells) within the CD4+ T cell population is
indicated in the top line. The percentage of proliferating Tregs are indicated in the
bottom line. Each is a single replicate so no statistics could be performed.
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Figure 3.14 Adoptive transfer of BMDCs before MPTP does not protect dopaminergic
neurons
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Figure 3.14 Adoptive transfer of BMDCs before MPTP does not protect
dopaminergic neurons
BMDCs were differentiated for 8 days in 20 ng/ml GM-CSF prior to 3 days of
pretreatment in media alone. Approximately, 1.5x106 BMDCs were transferred i.v. in
250 µl 8 hours after intoxication with 4 doses of 12 or 16 mg/kg MPTP. Seven days after
MPTP intoxication, mice were sacrificed and immunohistochemistry for tyrosine
hydroxylase (TH) was performed on 30 µM sections containing the substantia nigra.
Substantia nigra sections were Nissl counter stained. Stereology was used to count
dopaminergic neurons (TH+ Nissl+) in the substantia nigra. The scale bar is 200 µm.
n=2 for PBS, n=4 for 12 mg/kg MPTP, n=2 12 mg/kg MPTP + BMDCs, n=5 for 16 mg/kg
MPTP and n=5 for the MPTP + BMDCs. Significance was determined by one-way
ANOVA followed by Tukey’s post hoc test. No values were determined to be statistically
significant.
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the striatum. The adoptive transfer of BMDCs did protect the TH termini in the striatum.
Combined, these data show that the adoptive transfer of BMDCs prior to MPTP
administration protects dopaminergic neuron cell bodies and termini from degeneration.
To determine if BMDCs decrease neuroinflammation, reactive microglia in the substantia
nigra were counted.

BMDCs were adoptively transferred as before, mice were

intoxicated with 16 mg/kg MPTP, and 2 days after intoxication, at the peak of
neuroinflammation (Jackson-Lewis et al., 1995; Kohutnicka et al., 1998), mice were
sacrificed,

brains

perfused

and

fixed

in

4%

paraformaldehyde

and

immunohistochemistry was performed on sections of the substantia nigra for Mac-1.
Based on the sterologic counting of the reactive microglia per area, MPTP significantly
increased the number of reactive microglia relative to PBS (Figure 3.16). However, the
adoptive transfer of BMDCs significantly decreased the number of reactive microglia
compared to the MPTP control, but this decrease was not to the level of the PBS control.
To determine if the adoptive transfer of BMDCs decreases the expression of
proinflammatory mediators induced by MPTP, mice were sacrificed 2 days after MPTP
treatment, and RNA was isolated from hemisected midbrains to test expression using a
PCR array for the inflammatory response and autoimmunity. With gene expression
normalized to the PBS control mice, MPTP intoxication increased the expression more
than 2-fold of CCL3, CXCL10, CCL4, IL1R1, IL1RN, CEBPB, TLR2, and CSF1 (Figure
3.17). The expression of these genes, especially CXCL10 (the gene for IP-10), IL1R1
(IL-1 receptor 1), and CEBPB, a transcription factor upregulated in activated microglia
(Straccia et al., 2011), are indicative of the MPTP-induced neuroinflammation.

MPTP

more than 2-fold downregulated C3AR1, MYD88, TLR1, CCL2, CCR3. CCR1, TLR9,
CCL11, CXCR4, CCL25, CCL12, RIPK2, and TLR3. The adoptive transfer of BMDCs
did not greatly decrease the expression of any genes upregulated by MPTP. However,
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Figure 3.15 BMDCs are neuroprotective in the MPTP mouse model
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Figure 3.15 BMDCs are neuroprotective in the MPTP mouse model
BMDCs were differentiated for 8 days in 20 ng/ml GM-CSF prior to 3 days of culture in
media alone. Approximately 1.5x106 BMDCs were transferred i.v. in 250 µl 1 and 2
weeks prior to intoxication with four doses of 16 mg/kg MPTP. Seven days after MPTP
intoxication, mice were sacrificed and immunohistochemistry for tyrosine hydroxylase
(TH) was performed on 30 µM sections containing the substantia nigra and striatum.
Substantia nigra sections were Nissl counter-stained. Stereology was used to count
neurons (both TH+ Nissl+ and TH- Nissl+) in the substantia nigra. The scale bar is 200
µm. n=6 for PBS, n=8 for MPTP and n=7 for MPTP + BMDC group. Numbers in the
TH+ Nissl+ bars are the percentage of neurons remaining compared to PBS controls.
Significance was determined by one-way ANOVA followed by Tukey’s post hoc test. asignificantly different from PBS, b-significantly different from MPTP. From the striatum,
the scale bar is 1 mm. TH density was determined for 1.4 mm2 area for each striatum
which was normalized to density for the PBS striatum. n=7 for PBS, n=7 for MPTP and
n=6 for the MPTP + BMDC group. Significance was determined by one-way ANOVA
followed by Tukey’s post hoc test. a-significantly different from PBS, b-significantly
different from MPTP.
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Figure 3.16 BMDCs decrease the number of reactive microglia in the MPTP model
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Figure 3.16 BMDCs decrease the number of reactive microglia in the MPTP model
BMDCs were differentiated for 8 days in 20 ng/ml GM-CSF prior to 3 days of
pretreatment in media alone. Approximately, 1.5x106 BMDCs were transferred i.v. in
250 µl one and two weeks prior to intoxication with four doses of 16 mg/kg MPTP. Two
days after MPTP intoxication, mice were sacrificed and immunohistochemistry for Mac1+ microglia was performed on 30 µM sections containing the substantia nigra.
Stereology was used to count the number of reactive microglia per area the substantia
nigra. The scale bar is 200 µm for the larger image and the inset scale bar is 20 µm.
n=5 for PBS, MPTP, and MPTP + BMDC group. Significance was determined by OneWay ANOVA followed by Tukey’s post hoc test. a-significantly different from PBS, bsignificantly different from MPTP.
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there was an almost 2-fold increase in the expression of IL1RN, the antagonist for IL-1
receptor (Gabay et al., 2010), which would diminish IL-1 signaling.

Of the genes

downregulated by MPTP, there was an increase the expression of CCL2, CCL12,
RIPK2, and TLR3, suggesting BMDCs are compensating for the downregulation of these
genes by MPTP. In addition, the adoptive transfer of BMDCs more than 2-fold increased
proinflammatory genes IL6RA, IL17A, TNF, and IL6 and the anti-inflammatory IL10.
BMDCs also increased the expression of chemokine-related genes: CXCL2, CXCR2,
CCL1, CXCL1, CXCR1, CXCL3, CXCL9, CCR4, CCR2, CCL20, CCL24, CXCL5, and
CCL8. Combined, these data demonstrate that BMDCs do not suppress the expression
of all pro-inflammatory genes, but does increase the expression of anti-inflammatory
genes such as IL10 and IL1RN, which is contributing to the decreased microgliosis in
Figure 3.16. In addition to these anti-inflammatory genes, BMDCs are also increase the
expression of chemokines which may be altering the balance of infiltrating immune cells
may which also be contributing to the decreased neuroinflammation.
To better identify which genes are changed in the midbrain by the adoptive
transfer of BMDCs prior to MPTP intoxication compared to MPTP control, Ingenuity
Pathway Analysis was employed. There were 24 genes which were 2-fold or more
changed which are associated with the inflammatory response. While the pattern of
expression is indicative of inflammation as indicated by the increase in TNF, CCL11,
CXCL10, CXCL6, CXCR4, CCR1, CCR3, and genes related to pathogen recognition
such as TLR1, TLR2, TLR3, TLR9, MYD88, and RIPK2. However, some gene changes
are indicative of a decreased inflammation.

These include downregulation of IL-1

receptor 1, which is the receptor of IL-1α and IL-1β that transduces signals intracellularly
(Sims et al., 1993), CEBPB, a transcription factor which induces TNF expression
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Figure 3.17 Gene expression of MPTP and BMDCs + MPTP midbrain compared to PBS
control midbrain
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Figure 3.17 Gene expression of MPTP and BMDCs + MPTP midbrain compared to
PBS control midbrain
BMDCs were differentiated for 8 days in 20 ng/ml GM-CSF prior to 3 days of
pretreatment in media alone. These BMDCs were transferred i.v. 1 and 2 weeks prior to
intoxication with 4 doses of 16 mg/kg MPTP. Two days after intoxication, PBS, MPTP
and BMDC + MPTP mice were sacrificed and the brain was removed and hemisected,
and the midbrain was incubated in RNAlater for 24hr prior to freezing at -80°C. RNA
was isolated from the midbrain, copied to cDNA, and PCR arrays of pro-inflammatory
genes were run. (A) Gene expression was determined relative to the PBS control
midbrains. n=3 for PBS and n=4 for MPTP and MPTP+BMDC. Fold change was
determined using SA Bioscience software. (B) Ingenuity Pathway Analysis was used to
determine the expression of genes associated with the inflammatory response in
BMDCs + MPTP midbrain compared to MPTP control mice. Red indicates an
upregulation of genes and green represents a downregulation of gene expression with
the darker color indicating the larger change in gene expression. The orange lines
indicate an effect in line with increased inflammation. The yellow lines are gene
changes inconsistent with inflammation.

150
(Pope et al., 1994), and chemokines CCL3L3 and CCL4, which promote inflammation
(Yang and Wang, 2015) and leukocyte recruitment into the brain (Ubogu et al., 2006).
CCL24 is a chemokine released from M2 macrophages which can recruit T cells,
especially Tregs (Watanabe et al., 2002; Zamarron and Chen, 2011). In glioblastoma
multiforme, CCL2 is important for Treg recruitment into the brain and may perform a
similar function after MPTP intoxication (Jordan et al., 2008; Chang et al., 2016). IL1RN
prevents the recruitment of IL-1 receptor associated protein to IL-1 receptor which is
required for transduction of signals within the cell (Dinarello, 2009), therefore its
increased expression, when combined with the downregulation of IL1R1 would diminish
IL-1α and IL-1β signaling. Combined, these data show that the adoptive transfer of
BMDCs diminish, the MPTP-induced inflammation, in line with the data from Figure 6.
BMDCs induce Tregs in vivo
To determine if the neuroprotective effects of BMDCs are due to their ability to
increase Treg percentage and/or function in vivo, BMDCs were adoptively transferred
into mice as described and sacrifice was performed 1 week after the second transfer of
BMDCs. As a control, 50 μg/kg GM-CSF was i.p. administered to a group of mice every
day for 5 days prior sacrifice.

The percentages of CD4+ T cells and Tregs were

determined by flow cytometry. To test the percentages of CD4+ T cells and Tregs in the
blood were determined in blood from cheek bleeds performed 1 day before each transfer
or sacrifice. There was no change in the percentage of CD4+ T cells in the blood over
time nor was there a change in the percentage of CD4+ cells in the spleen or in the
lymph nodes at time of sacrifice in unmanipulated controls, GM-CSF-treated controls or
BMDC-transferred mice (Figure 3.18A). There was also no increase in Tregs over time
in the blood, nor in the lymph nodes at time of sacrifice (Figure 3.18B). In the spleen,
GM-CSF did trend to increase the percentage of Tregs, however, the increase was not
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significant and was not an increase to the degree previously reported (Kosloski et al.,
2013).

The adoptive transfer of BMDCs decreased the percentage of Tregs in the

spleen significantly compared to the GM-CSF-treated control, but the decrease was not
significantly different from the unmanipulated control. Since there was a significantly
decreased percentage of Tregs in the spleen, next the suppressive function of Tregs
was determined. There was no significant change in the function of Tregs from control
or GM-CSF-treated mice (Figure 3.18C). However, the adoptive transfer of BMDCs
significantly decreased the function of Tregs relative to both the control and GM-CSFtreated Tregs. These data demonstrate that, without any inflammation, the adoptive
transfer of BMDCs decreased the percentage and function of Tregs.
In models where the adoptive transfer of BMDCs ameliorate disease and
increase Tregs, there was an ongoing to autoimmune response (Li et al., 2008; Mari et
al., 2016).

To test if BMDCs increase the percentage and/or function after MPTP

intoxication, BMDCs were adoptively transferred 1 week apart and mice were MPTP
intoxicated one week after the second transfer. Two days after MPTP intoxication, at the
peak of neuroinflammation, mice were sacrificed and CD4+ T cell and Treg percentages
and Treg function from the spleen was determined. There was no significant change in
the percentage of CD4+ cells in any treatment group, but mice receiving BMDCs prior to
MPTP displayed significantly more splenic Tregs than either PBS or MPTP controls
(Figure 3.19A). By multiplying the percentage of CD4+ T cells and Tregs by the count of
total splenocytes, we determined the number of CD4+ T cells and Tregs.

MPTP

intoxication decreased the number of CD4+ cells in the spleen compared to the PBS
control. This was increased by the adoptive transfer of BMDCs. The number of Tregs in
the spleen was decreased in the MPTP control mice, but was increased by the adoptive
transfer of
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Figure 3.18 Treg frequency and function after the transfer of BMDCs
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Figure 3.18 Treg frequency and function after the transfer of BMDCs
BMDCs were differentiated for 8 days in 20 ng/ml GM-CSF followed by culture in media
alone for 3 days. These BMDCs were i.v. transferred into the tail vein of C57BL/6J mice
two weeks and one week prior to sacrifice. One day prior to each transfer and sacrifice,
mice were cheek bleed. As a positive control, mice were i.p. administered with 50 µg/kg
GM-CSF once per day for 5 days. (A) The frequency of CD4+ T cells in the single cell
population and (B) Tregs (CD4+ CD25+ Foxp3+) in the CD4+ T cell populations were
determined by flow cytometry. Significance was determined by one-way ANOVA
followed by Tukey’s post hoc test a-significantly different from control and b-significantly
different from GM-CSF mice. Control n=11, GM-CSF n=10, and i.v. BMDC n=12.
Pooled spleens from all three groups had Tregs (CD4+ CD25+) enriched and dilutions
were cultured with CFSE-labelled CD4+ CD25- cells that were stimulated with
CD3/CD28 beads and proliferation suppression assay was used to test Treg function.
Linear regression was used to compare the slope and elevation. a-significantly different
slope rom control Tregs, b -significantly different elevation compared to GM-CSF Tregs.
N=6 for all three treatment groups.
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Figure 3.19 Treg frequency and function after adoptive transfer of BMDCs prior to MPTP
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Figure 3.19 Treg frequency and function after adoptive transfer of BMDCs prior to
MPTP
BMDCs were differentiated for 8 days in 20 ng/ml GM-CSF prior to 3 days of
pretreatment in media alone. These BMDCs were transferred i.v. 1 and 2 weeks prior to
intoxication with 4 doses of 16 mg/kg MPTP. Two days after MPTP intoxication, mice
were sacrificed and spleens were removed. (A) Flow cytometry was used to determine
the frequency of CD4+ cells in the total splenocyte population and the frequency of
Tregs (CD25+ Foxp3+) in the CD4+ population. Based on this frequency and the
splenocyte counts, the counts of CD4+ and Tregs were determined. n=5 for all 3
groups. Significance was determined by One-way ANOVA followed by Tukey’s post hoc
test. a-significantly different from PBS and b-significantly different from MPTP. (B)
CD4+ CD25+ cells were enriched from the pooled splenocytes for each treatment group
and dilutions of Tregs were cultured with CFSE-labelled CD4+ CD25- cells and
CD3/CD28 transactivator beads for 3 days. Linear regression was used to compare the
slope and elevation. a-significantly different elevation from PBS Tregs, b-significantly
different elevation compared to MPTP Tregs. N=3 for all 3 treatment groups except for
0.125:1 dilution which only had 1 replicate for each treatment group and 1:1 MPTP
Tregs with 2 replicates.
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Tregs. These data highlight that BMDCs increase the percentage and the number of
Tregs in the spleen following MPTP intoxication. To test if BMDCs increase the function
of Tregs, we isolated CD4+ CD25+ Tregs from spleens and assessed isolates for the
capacity to suppress CD3/CD28 stimulated responder T cells. Interestingly, it appears
that MPTP treatment increases the suppressive function of Tregs relative to the Tregs
from PBS control mice (Figure 3.19B).

Transfer of BMDCs diminishes the MPTP-

induced increase in Treg suppressive function. More work will need to be done to verify
the result of this experiment, but the data in Figure 3.19 show that BMDCs increase the
percentage of Tregs in the spleen after MPTP, demonstrating the necessity of
inflammation to increase the percentage of Tregs.

However, these BMDC-induced

Tregs possess the same suppressive function compared to the PBS control.
BMDC-induced Treg neuroprotection
To determine if the Tregs that are generated from the co-culture of BMDCs and
CD4+ cells are neuroprotective, BMDCs differentiated for 8 days in 20 ng/ml GM-CSF
followed by 3 days in media alone were co-cultured with CD4+ cells for 5 days. Either
the total non-adhered population or the CD4+ CD25+ cells enriched from the nonadhered population using the Miltenyi CD4+ CD25+ isolation kit as described above
were transferred into MPTP-intoxicated mice. The resulting ~400,000 CD4+ CD25+
cells or ~4,000,000 non-adherent cells were adoptively transferred into the tail vein of
mice ~10 hours after intoxication with 16 mg/kg MPTP. Based on the purity of the CD4+
CD25+ cells, the ~400,000 cells correspond to ~200,000 Tregs (CD4+ CD25+ Foxp3+)
and the ~4,000,000 non-adhered cells correspond to ~400,000 Tregs. The adoptive
transfer of BMDCs increases the number of Tregs in the spleen by ~200,000. The
adoptive transfer of CD4+ CD25+ cells or non-adhered cells did not protect TH+ Nissl+
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Figure 3.20 BMDC-induced Tregs are not neuroprotective
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Figure 3.20 BMDC-induced Tregs are not neuroprotective
BMDCs were differentiated for 8 days in 20 ng/ml GM-CSF prior to 3 days of
pretreatment in media alone. BMDCs were co-cultured with CD4+ cells from
splenocytes. After 5 days, the non-adhered cells were removed and either the whole
population or enriched the CD4+ CD25+ cells were transferred i.v. in 250 µl 10 hours
after intoxication with 16 mg/kg MPTP. The flow cytometry was performed to determine
purity of Tregs. For the CD4+ CD25+ enriched cells, 60.6% of the CD4+ were CD25+
Foxp3+ cells which corresponds to ~200,000 Tregs transferred. For the non-adhered
population, 12% of the CD4+ population were CD25+ Foxp3+ cells which corresponds to
~400,000 Tregs transferred. Seven days after MPTP intoxication, mice were sacrificed
and immunohistochemistry for tyrosine hydroxylase (TH) was performed on 30 µM
sections containing the substantia nigra and striatum. Substantia nigra sections were
Nissl counter stained. Stereology was used to count neurons (both TH+ Nissl+ and THNissl+) in the substantia nigra. The scale bar is 200 µm. n=12 for PBS, n=9 for MPTP,
n=7 for the MPTP + BMDC Treg groups, and n=5 for the MPTP+BMDC non-adhered
cells. Numbers in the TH+ Nissl+ bars are the percentage of neurons remaining
compared to PBS controls. Significance was determined by one-way ANOVA followed
by Tukey’s post hoc test. a-significantly different from PBS, b-significantly different from
MPTP. From the striatum, the scale bar is 1 mm. TH density was determined for 1.4
mm2 area for each striatum which was normalized to density for the PBS striatum. n=7
for PBS, n=7 for MPTP and n=6 for the MPTP + BMDC group. Significance was
determined by one-way ANOVA followed by Tukey’s post hoc test. a-significantly
different from PBS.
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neurons in the substantia nigra or TH+ termini in the striatum (Figure 3.20). These data
suggest that this number of Tregs from BMDC co-culture is insufficient to protect
dopaminergic neurons. Previously, the lowest number of transferred Tregs which lead to
neuroprotection was 500,000 (Reynolds et al., 2007), so more Tregs may need to be
transferred to promote neuroprotection. It is also possible that the Tregs from BMDC coculture may be less neuroprotective, even if they possess increased proliferation
suppression function (Figure 3.11).
BMDC supernatant does not protect MES23.5 cells, but does decrease BV2 release of
nitrite, TNF and IL-6
We next wanted to determine if BMDCs are having direct effects on microglia
and dopaminergic neurons apart from inducing Tregs. In our experiments, we have not
determined if the BMDCs can migrate to the brain, however, DCs can migrate to the
brain after EAE (Clarkson et al., 2014; Clarkson et al., 2015) and stroke (Felger et al.,
2010; Manley et al., 2013) in order to promote the T cell response. It is unclear to what
degree the neuroprotective effects are due to the co-stimulatory surface expression or
the released products of BMDCs. To test the role of released products from BMDCs in
decreased neuroinflammation and neurodegeneration, the BMDC supernatant was
tested for the ability to protect the MES23.5 dopaminergic neuron line from toxic insult.
MES23.5 cells were cultured for 24 hours with clarified conditioned media from the
culture of media-cultured, unstimulated BMDCs after 11 days in culture. As controls,
MES23.5 cells were also cultured in MES23.5 media or R10 (BMDC) media. After this
pre-treatment, MES23.5 cells were treated with increasing concentrations of MPP+ (01,000μM) for 24 hours. At this time, the CellTiter-Glo cell assay was used to determine
the production of ATP in MES23.5 cells, which is a surrogate marker for cell viability.
MPP+ was toxic starting at 10 µM in the R10 media-cultured MES23.5 cells, 100 µM for
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Figure 3.21 BMDC supernatant does not protect MES23.5 cells viability after culture
MPP+ and BV2 supernatant
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Figure 3.21 BMDC supernatant does not protect MES23.5 cells viability after
culture MPP+ and BV2 supernatant
MES23.5 neurons were cultured for 24 hours in and equal volume of MES23.5 media,
supernatant from BMDCs cultured for 8 days in 20 ng/ml GM-CSF and 3 days in R10
media, or R10 media. (A) MES23.5 neurons were treated for 24 hr in an equal volume
of MES23.5 media containing 0 - 1,000 µM MPP+. Cell viability was determined by
celltiter-glo assay. Significance was determined by one-way ANOVA followed by
Tukey’s post-hoc test. The following markers correspond to significance from the
following treatment groups a-0, b-0.1, c-1, d-10 e-100 µM or 1-MES23.5 media. n=4.
(B) MES23.5 neurons were treated with BV2 media or supernatants from BV2 cells
cultured with and without 100 ng/ml LPS in BV2 media, BMDC supernatant, or R10
media. After 24 hr of treatment, cell viability was determined by the CellTiter-Glo assay.
Significance was determined by one-way ANOVA followed by Tukey’s post-hoc test.
The following markers correspond to significance from the following treatment groups aBV2 media, b-BV2 supernatant, c-BV2 + BMDC supernatant, d-BV2 + R10 media, eBV2 media + LPS, f-BV2 + BMDC supernatant + LPS. n=10 for BV2 media and BV2
supernatant unstimulated, n=7 BV2 + BMDC supernatant, BV2 + R10 media, BV2
supernatant, BV2 + BMDC supernatant, and BV2 + R10 media stimulated with LPS.
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the BMDC-cultured MES23.5 cells, and 1,000 μM for MES23.5 media-cultured MES23.5
cells (Figure 3.21A). BMDC supernatant was unable to protect MES23.5 cells relative to
the two media controls. In fact, there was a trend toward decreased cell viability, though
this was not significant. It is interesting that the MES23.5 cells cultured with R10 media
or BMDC supernatant decreased cell viability at lower concentration of MPP+ than
MES23.5 cells.

This suggests that something in the R10 media, independent of

products released from BMDCs, facilities MPP+ toxicity. Possibly, this is due to the
increased concentration of FBS or decreased concentration of N2 supplement that does
not directly decrease cell viability, but fails to maintain MES23.5 cell viability with
increased MPP+ toxicity.
Because only a small amount of the neurodegeneration is caused by MPP+ in
the MPTP model (Benner et al., 2008; Brochard et al., 2009), BMDC supernatant was
tested for the ability to protect MES23.5 cells from the supernatant from BV2 microglia
cell line. BV2 cells were cultured for 1 day with BV2 media, BV2 media and BMDC
supernatant, and BV2 media and R10 media with and without 100 ng/ml LPS. The
conditioned media from these different treatment groups or BV2 media alone was then
added to MES23.5 cells cultured with MES23.5 media, BMDC supernatant, or R10
media as above and cell viability was determined with the celltiter-glo assay. MES23.5
cells cultured with different BV2 supernatants tended to exhibit decreased cell viability
(Figure 3.21B).

BV2 cells stimulated with LPS were not significantly more toxic to

MES23.5 cells than the unstimulated BV2 cells. Regardless if BMDC supernatant was
cultured with BV2 cells or MES23.5 cells, there was not significant protection of
MES23.5 cells. Interestingly, the group that trended to display decreased cell viability
was the supernatant from BV2 cells cultured with BMDC supernatant and LPS
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stimulation. As with MPP+-treated MES23.5 cells, BMDC supernatant did not increase
the cell viability of MES23.5 cells.
Because BMDC supernatant was unable to protect MES23.5 cells, next the
ability of BMDC supernatant to decrease the release of proinflammatory mediators was
tested.

First, we used the Griess assay to test the concentration of nitrite in the

supernatant of LPS-stimulated or unstimulated BV2 cells cultured with BV2 media,
BMDC supernatant, or R10 media. There was limited nitrite in the any unstimulated BV2
supernatant (Figure 3.22).

However, there was a significant increase in nitrite

concentration in all LPS-stimulated BV2 cell supernatants.

This increase in nitrite

concentration was significantly mitigated by culture of BV2 cells with BMDC supernatant
compared to either of the media-cultured BV2 cells. Cytokine bead array (CBA) was
used to test the release of IL-2, IL-4, IL-6, IL-10, IL-17, TNF, and IFNγ from the same
treatment groups of BV2 cells as above. Only IL-6 and TNF were significantly elevated
in LPS-stimulated BV2 cells (Figure 3.22). As with nitrite, BMDC supernatant decreased
the release of both IL-6 and TNF compared to either media. These data suggest that
BMDCs release some factor that decreases the reaction of BV2 cells to activation with
LPS. However, the reduced release of IL-6, TNF, and nitrite does not protect MES23.5
cells from MPP+ or BV2 supernatant (Figure 3.21).
GM-CSF does not increase the percentage of CD11c+ dendritic cells in the spleen
To determine if administration of GM-CSF increases the percentage of splenic
myeloid DCs (CD11c+ CD11b+ cells), 50 μg/kg GM-CSF was i.p. administered each day
for 5 days prior to sacrifice. The spleen was removed and flow cytometry was used to
determine the percentage and the mean fluorescent intensity of DC markers. There was
no significant change in the percentage of CD11c+ CD11b+ myeloid DCs in the spleen
(Figure 3.23A). There was not change in the percentage of CD11c+ CD11b+ cells
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Figure 3.22 Release of cytokines and nitrite from BV2 cells treated with BMDC
supernatant and LPS
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Figure 3.22 Release of cytokines and nitrite from BV2 cells treated with BMDC
supernatant and LPS
BV2 cells were cultured in BV2 media, BMDC supernatant from BMDCs cultured for 8
days in 20 ng/ml GM-CSF and 3 days in R10 media, or R10 media with or without 100
ng/ml LPS. After 24 hr of culture the supernatant was removed and nitrite was
determined by the Griess assay and the concentration of IL-6 and TNF was determined
by CBA. Significance was determined by one-way ANOVA followed by Tukey’s post hoc
test. The following markers correspond to significance from the following treatment
groups a-BV2 media, b-BMDC supernatant, c-R10 media, d-BV2 media + LPS, e-BMDC
supernatant + LPS. n=6 for all nitrite samples, n=3 for CBA.
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Figure 3.23 Frequency of DCs in the spleen after GM-CSF administration
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Figure 3.23 Frequency of DCs in the spleen after GM-CSF administration
Mice were either not injected (control) or were given i.p. 50 µg/kg GM-CSF daily for 5
days. Spleens were removed and flow cytometry was performed to determine the
frequency of CD11c+ CD11b+ dendritic cells in the single cells of the spleen (A). We
also determined the frequency of CD11c+ CD11b+ cells expressing surface MHC II+,
CD86+, Jag-1+, OX40L+, CD39+, and CD73+. Significance was determined by
unpaired t test and no surface markers were determined to change significantly. (B) We
also determined the MFI of CD11c, CD11b, MHC II, Jag-1, CD39, and CD73 on the
surface of CD11c+ CD11b+ cells. Significance was determined for by unpaired t test
significance was determined if the p <0.05. a-significantly different from control. n=5 for
all groups.
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expressing MHC II, CD86, OX40L, Jag-1, CD39, and CD73.

There was also no

significant change in the MFI of CD11c, CD11b, MHC II, Jag-1, and CD39 on CD11c+
CD11b+ cells ((Figure 3.23B).

GM-CSF did significantly decrease the surface

expression of CD73 on CD11c+ CD11b+ cells. Combined, these data demonstrate that
GM-CSF does not increase the percentage and expression of these markers. This is
notable, given that culturing BMDCs with GM-CSF increasing the surface expression of
Jag-1 and trends to increase surface CD73 (Figure 3.6). While it is possible that GMCSF may be decreasing the expression of other markers not tested, these data suggest
that GM-CSF alone is insufficient to alter splenic DCs to increase the percentage of
Tregs as reported previously (Kosloski et al., 2013). It possible that if these mice were
intoxicated with MPTP it would increase the percentage of CD11c+ CD11b+ cells
expressing Jag-1 or other surface markers which would promote Tregs in the spleen.

DISCUSSION
Our first hypothesis was that GM-CSF induces and maintains a tolerogenic state
in DC lines. DC2.4 and DC3.2 both release more nitrite when stimulated with LPS or Nα-Syn which is mitigated by pre-culture with GM-CSF (Figure 3.2). However, the DC2.4
cell line expresses high surface levels of the co-stimulatory molecule CD86 without
stimulation which is not decreased by GM-CSF culture (Figure 3.3). This suggests that
the cells lines are not in a tolerogenic state and GM-CSF cannot induce a tolerogenic
state given the conditions tested. It is possible that a tolerogenic state could be induced
with another inducer such as vitamin D, IL-10, or TGFβ, but GM-CSF unto itself cannot
induce this state. Since the DC2.4 and DC3.2 cell lines are derived from BMDCs (Shen
et al., 1997), but are more mature than the other BMDCs used in these experiments, it is
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unclear if these results are due to the immortalization of these cells, or because of their
more mature state.
BMDCs display a trend to release lower concentrations of nitrite after continuing
GM-CSF culture prior to LPS or N-α-Syn stimulation (Figures 3.5 and 3.8), similar to
pretreating DC2.4 and DC3.2 cells with GM-CSF.

However, BMDCs exhibit lower

surface expression of CD86 (Figure 3.4 and 3.6) compared to DC2.4 cells making them
a better model of tolerogenic DCs than DC2.4 cell lines. Interestingly, adding IL-4 during
maturation increases the surface expression of CD86 and OX40L and decreases Jag-1
surface expression (Figure 3.4).

As a result, IL-4 was omitted from all future

experiments because it promotes differentiation of DCs to a more mature state
compared to the BMDCs matured without IL-4, in line with prior research (Sallusto and
Lanzavecchia, 1994; Lutz et al., 2000).
In the absence of LPS or N-α-Syn stimulation, BMDCs are in a tolerogenic
state as determined by low costimulatory molecules (Figure 3.6), low expression and
release of proinflammatory cytokines (Figure 3.7, 3.9), increased expression of IDO, a
trend to increased kynurenine (Figure 3.10), and induction of Tregs in culture (Figure
3.11). However, when cultured in media alone prior to stimulation with N-α-Syn, surface
expression of co-stimulatory molecules is increased (Figure 3.6), expression and release
of proinflammatory cytokines is increased (Figure 3.7, 3.9), and IDO expression and
kynurenine is decreased (Figure 3.10), indicating these BMDCs are in a semi-mature
state. GM-CSF culture prior to N-α-Syn stimulation does mitigate the surface expression
of CD86 and MHC II (Figure 3.6) and increases Jag-1 surface expression. There was a
mitigation of the expression and release of some proinflammatory cytokines and
chemokines, but most were not affected or were increased by GM-CSF culture (Figure
3.7 and 3.9). IDO expression and kynurenine was not effected by GM-CSF culture prior
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to N-α-Syn stimulation (Figure 3.10). Additionally, GM-CSF decreases the expression of
CD40 (Figure 3.9), after N-α-Syn stimulation, in line with the decrease in the CD86
surface expression (Figure 3.6). However, GM-CSF does not decrease the expression
of maturation markers such as CEBPB and CCR7 or TLR signaling genes such as
CD14, MYD88, and NFKB1 (Figure 3.9).

Combined, these data suggest GM-CSF-

differentiation of bone marrow to BMDCs induces a tolerogenic state which is maintained
with the culture in media and GM-CSF. However, upon stimulation, N-α-Syn stimulation
induces a semi-mature state. GM-CSF cannot maintain the tolerogenic state, given that
BMDCs increase the expression and release of proinflammatory cytokines, increased
expression of maturation markers, and decreased IDO expression and kynurenine
concentration. However, GM-CSF is changing how the BMDCs respond to stimulation
with altered expression and release of cytokines, including increased IL-10 expression
and release as well as increased Jag-1 surface expression (Figure 3.7, 3.9).
Another characteristic of tolerogenic DCs is their ability to induce Tregs
(Maldonado and von Andrian, 2010). Culture of media-alone BMDCs with or without Nα-Syn stimulation with CD4+ cells, leads to an increase in the percentage of Tregs
(Figure 3.11). However, this was significantly mitigated by continuing the culture with
GM-CSF, even without N-α-Syn stimulation (Figure 3.11). The resulting CD4+ CD25+
cells do possess Treg suppressive function indicating these are bonafide Tregs. The
Tregs were being induced by a mechanism other than proliferation of CD4+ cells, since
CD3/CD28 beads do not increase the percentage of Tregs to the same degree as
BMDCs. This was borne out by CFSE-labelled CD4+ CD25- and CD4+ CD25+ cells
cultured with BMDCs. There is minimal proliferation of Tregs in both populations (Figure
3.13). Since a minority proportion of the Tregs proliferated, the majority of Tregs from
the co-culture were induced from the non-Treg CD4+ population.

In addition, the
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induction of Tregs is DCs. This demonstrates that some molecules on the surface of
BMDCs promote Treg induction. Based on correlation analysis, several surface markers
that bind to receptors on CD4+ cells do positively correlate with Treg induction, including
MHC II and Jag-1 (Figure 3.12).

It is unclear to what degree these, or other co-

stimulatory molecules, are responsible for inducing Tregs. While the increase in Jag-1
expression is line with other research demonstrating a role for Jag-1 inducing Tregs
(Gopisetty et al., 2013), the negative correlation with OX40L does not correspond with
prior work showing OX40L is involved in Treg induction (Haddad et al., 2016). This may
indicate that surface expression of OX40L is sufficient to promote Tregs, or other costimulatory molecules, which have not been identified, may be playing a role.

It is

interesting that the increase in IDO expression, kynurenine release and surface
expression of CD39 and CD73 appear to increase in the BMDCs which are strong
inducers of Tregs, yet do so through soluble mediators. Since Tregs are still induced in
the transwells, there may be a role for these mediators, in addition to the co-stimulatory
molecules.
The

ability

of

Tregs

generated

from

BMDC-CD4+

co-culture

to

be

neuroprotective in the MPTP model was also tested. As of now, the mechanism by
which Tregs are neuroprotective has not been determined. In Figure 3.11, the ability of
Tregs to suppress proliferation of CFSE-labelled CD4+ CD25- responder T cells is
shown.

To see if this increase in Treg function correlates with increased

neuroprotection, both non-adhered cells and enriched CD4+ CD25+ were transferred
into MPTP-intoxicated mice. In both cases, there was no significant neuroprotection
(Figure 3.20). The most probable explanation is that insufficient cell numbers were
transferred to detect protection, given that previously the fewest number of Tregs
transferred which demonstrated an effect was ~500,000 Tregs (Reynolds et al., 2007).
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The transfer of a greater number of Tregs into each mouse could test this. Another
possibility is that the BMDC-induced Tregs posses less neuroprotective function and
even more Tregs will need to be transferred to detect a significant effect.
Our second aim was to determine if the transfer of tolerogenic DCs leads to the
same effects as GM-CSF in the MPTP model. Adoptive transfer of BMDCs after MPTP
did not lead to protection of dopaminergic (TH+ Nissl+) neurons in the substantia nigra
(Figure 3.14). This is thought to be due to the BMDCs having insufficient time to migrate
to the secondary lymph organs and induce Tregs that release mediators and/or migrate
to the substantia nigra to protect neurons.

To test this, we adoptively transferred

BMDCs prior to MPTP intoxication. In this case, BMDCs protect both the (TH+ Nissl+)
neurons in the substantia nigra and the TH+ termini in the striatum (Figure 3.15). Given
this BMDC transfer paradigm, the number of reactive microglia is decreased in the
substantia nigra (Figure 3.16), indicative of decreased neuroinflammation. Interestingly,
of the genes 2-fold increased in MPTP control mice relative to PBS control mice, none
were noticeably decreased by the adoptive transfer of BMDCs, suggesting BMDCs were
not decreasing the expression of genes upregulated by MPTP (Figure 3.17A). There
was an almost 2-fold increase in the expression of Il1RN, which may be part of the
mechanism of the decreasing neuroinflammation by suppressing IL-1 receptor signaling.
However, there was an increase in the expression of several genes for which expression
was decreased in the MPTP control mice relative to PBS control, including CCL2,
CCL12, RIPK2, and TLR3. Of the genes altered between the MPTP midbrain and the
BMDC + MPTP midbrain, 24 genes were associated with inflammatory response (Figure
3.17B).

The adoptive transfer of BMDCs increases the expression of several

chemokine-related genes including: CCR1, CCR3, CXCL10, CXCL6, CXCR4, CCL11,
CCL24, CCL25, and CCL2, the gene upregulated in the pathway. It is possible that at
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least part of the protective mechanism of BMDCs is altering the chemokine balance
changing the immune cell infiltration. This is an interesting possibility since GM-CSF
treatment also increases the expression of several chemokines, like CCL2 increased
here (Kosloski et al., 2013). CCL2 is an interesting chemokine since it is a ligand for
CCR4 (Yoshie and Matsushima, 2015), and CCR4 is the major chemokine receptor on
Tregs (Yi and Zhao, 2007; Chakraborty et al., 2012). It is possible that the increase in
CCL2 is increasing the migration of Tregs into the midbrain, which facilitates
neuroprotection.

More work will be needed to test this possibility.

These data

demonstrate that, like GM-CSF, BMDC transfer decreases neuroinflammation and
neurodegeneration following MPTP.
GM-CSF increases the percentage of Tregs in mouse spleen without MPTP
(Kosloski et al., 2013). BMDCs were not able to increase Treg percentage or Treg
function in vivo in the absence of MPTP (Figure 3.18). However, GM-CSF, used here as
a positive control, was unable to increase Tregs to the same degree as published
previously (Kosloski et al., 2013). Treg function was also not increased by either GMCSF, which was not previously reported, or by BMDC transfer. This result suggests that
GM-CSF may work on another cell type in vivo without inflammation to induce Tregs. It
is possible that Tregs express the receptor for GM-CSF (Kared et al., 2008) and
therefore GM-CSF may directly promote the proliferation of Tregs. Another possibility is
that GM-CSF induces the proliferation of other immune cells such as myeloid-derived
suppressor cells (MDSCs) which protect against and promote recovery after
neurodegeneration (Saiwai et al., 2013) and induce Tregs (Huang et al., 2006; Serafini
et al., 2008). When BMDCs were transferred prior to MPTP intoxication, this increased
the percentage of Tregs in the spleen (Figure 3.19). This also increased the number of
Tregs in the spleen. This is in line with prior data, which showed GM-CSF promotes
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Tregs in vivo during ongoing inflammation in various models of autoimmunity (Sheng et
al., 2008; Cheatem et al., 2009; Ganesh et al., 2009). Interestingly, MPTP intoxication,
but not the adoptive transfer of BMDCs, increases Treg function. This experiment was
performed once and there was overall less inhibition compared to prior functional assays
(Figures 3.11, 3.18). More work would need to be done to verify these results. While
most research has not focused on the suppressive function of Tregs, the results here
suggest that BMDCs and GM-CSF increase Treg number, but not function. This is
contrary to administering sargramostim in Parkinson’s disease does increase Treg
function as well as number (Gendelman et al., 2017).
Our next experiment was to determine if BMDCs may be neuroprotective by
mechanisms other than inducing Tregs.

It is unclear if the mechanism of

neuroprotection is mediated though cell-to-cell contact or through the release of antiinflammatory factors by BMDCs. To test that latter possibility, we cultured the MES23.5
dopaminergic neuron cell line with supernatant from BMDCs, prior to treating cells with
MPP+ or supernatant from BV2 microglia (Figure 3.21).

In both cases, BMDC

supernatant did not protect the cultured MES23.5 cells from either the neurotoxin MPP+
or the neuroinflammatory mediators from BV2 microglia cell lines. Interestingly, culturing
BV2 microglia in BMDC supernatant did decrease the release of nitrite, IL-6, and TNF
(Figure 3.22). This would indicate that the factors released from BV2 cells that are toxic
to MES23.5 cells are not these proinflammatory mediators.

However, BMDC

supernatant decreased the release of these mediators that reduce neuroinflammation in
vivo, thus not leading to neuroprotection. These results suggest that BMDC supernatant
may not directly protect dopaminergic neurons in vivo, but may decrease microglia
activation, perhaps due to the release of kynurenine (Figure 3.10) or another factor
which was not measured.
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Lastly, I tested if GM-CSF increases the number of myeloid DCs or the
tolerogenic state of DCs in the spleen. This would be consistent with myeloid DCs
inducing Tregs and provide further evidence that DCs are the cells inducing Tregs.
Here, we found no increase in the percentage of CD11c+ CD11b+ cells in the spleen,
nor changes in the expression of surface molecules such as Jag-1, OX40L, MHC II,
CD86, CD39, and CD73 (Figure 3.23). Based on this, GM-CSF alone does not appear
to increase the percentage or tolerogenic state of splenic myeloid DCs. It is possible
that other surface molecules are increased on splenic DCs that induce Tregs but were
not tested here, such as PD-L1. It is also possible that other DC subsets are affected by
GM-CSF and induce Tregs. GM-CSF may act on other immune cell types, like MDSCs,
to induce Tregs, or GM-CSF may act on Tregs directly. All are possibilities to be tested
further.
In conclusion, GM-CSF promotes a tolerogenic state as part of the differentiation
of bone marrow progenitors to immature DCs. However, GM-CSF cannot maintain the
tolerogenic state after stimulation with N-α-Syn, but GM-CSF does alter how BMDCs
respond to the stimulus. GM-CSF culture with BMDCs diminishes the induction of Tregs
in culture. Tolerogenic BMDCs are neuroprotective, decrease neuroinflammation and
increase Tregs in the spleen after MPTP intoxication.

The neuroprotection may be

related to inducing Tregs as wells as decreasing microglia activation, but BMDC
supernatant is not directly neuroprotective, at least in cultured MES23.5 cells. GM-CSF
is not increasing percentage of myeloid DCs or the expression of surface markers in
vivo. This suggests that GM-CSF may act on DCs in vivo to promote Tregs during the
MPTP-induced inflammation. However, GM-CSF may be promoting Tregs via another
mechanism other than through DCs. In addition, neuroprotection may be mediated by a
mechanism other than Treg induction.
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CHAPTER FOUR
CYTOKINE ENVIRONMENT IN THE VENTRAL MIDBRAIN AND
CERVICAL LYMPH NODE TWO DAYS AFTER MPTP
INTOXICATION

ABSTRACT
CD4+ T cells are required for neurodegeneration following MPTP intoxication.
The adoptive transfer of Th1 and Th17 T CD4+ cells exacerbates MPTP intoxication, but
it is unknown if MPTP intoxication differentiates naive CD4+ cells to these subtypes. To
test this, the expression and release of proinflammatory cytokines in the cervical lymph
node and ventral midbrain was determined at peak neuroinflammation two days post
MPTP intoxication. Flow cytometry was also used to test the percentage of B cells, T
cells and activated APCs in different lymph node populations after MPTP intoxication.
Based on these data, MPTP increases the MFI of MHC II on APCs in the cervical lymph
nodes and increases B cells in the brachial and axillary lymph nodes. No changes in the
CD3+ T cell percentage were detected. In the cervical lymph nodes, expression of IFNγ
and IL-4 was increased with increased expression of IP-10 in the ventral midbrain.
Gene expression of many proinflammatory and anti-inflammatory genes were increased
in the cervical lymph node and CXCL10 in the ventral midbrain. These data found few
changes in the expression of proinflammatory cytokines, which may be due to the timing
or location of samples tissues. The changes seen may suggest an environment that
promotes Th1 or Th2 T CD4+ cells.
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INTRODUCTION
No rodent PD models exist that fully recapitulates all the features of PD. The
MPTP model which is commonly used to mimic neuroinflammation and dopaminergic
neurodegeneration in PD. MPTP readily crosses the blood-brain barrier (BBB), taken
into astrocytes, and is converted into the neurotoxic metabolite MPP+ by monoamine
oxidase B (MAO-B) (Cohen et al., 1984; Heikkila et al., 1984). MPP+ is then released
and specifically taken up through dopamine transporters due to the structural similarity to
dopamine (Klein et al., 1985).

Once in the dopaminergic neurons, MPP+ can be

transported through vesicular monoamine transporter 2 (VMAT2) into intracellular
vesicles for storage (Staal and Sonsalla, 2000), resulting in little dopaminergic neuron
injury. As a result, VMAT2 expression is thought to play a major role in the susceptibility
to MPTP (Lohr et al., 2016). MPP+ can also be transported to mitochondria and block
complex I of the electron transport chain (Singer et al., 1988). In doing so, metabolic
disruption and loss of ATP synthesis in dopaminergic neurons leading to neuronal death.
Why dopaminergic neurons in the substantia nigra pars compacta are specifically lost
while dopaminergic neurons in neighboring brain regions are not is not clear.

The

difference in MPTP sensitivity may be related to VMAT2 expression, dopamine
transporter expression of downstream signaling molecules like JNK and Jun both of
which are downregulated in MPTP-resistant mouse strains (Boyd et al., 2007).
As dopaminergic neurons are lost in the substantia nigra, inflammation mediated
by activated microglia increases (Członkowska et al., 1996; Kohutnicka et al., 1998).
After MPTP intoxication, microglia exhibit an activated M1 phenotype and release
proinflammatory cytokines such as IL-1β as well as reactive oxygen and nitrogen
species (Wu et al., 2002).

Activated microglia are required for neurodegeneration

because MyD88 knockout mice are resistant to MPTP-induced degeneration (Cote et al.,
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2011).

MPP+ kills or injures a fraction of the dopaminergic neurons lost; most

dopaminergic neurons are lost due to resulting neuroinflammation (Reynolds et al.,
2010; Cote et al., 2011). In addition to the activation of resident microglia, infiltrating
macrophages and neutrophils play a role (Cote et al., 2011), showing that the innate
immune system is important for neuroinflammation following MPTP intoxication.
In addition to the innate immune response to the MPP+, the adaptive immune
response plays a role as well.

SCID mice, which lack lymphocytes, are relatively

resistant to MPTP-induced neurodegeneration (Benner et al., 2008). More specifically,
mice that lack CD4+ T cells do not lose nigral dopaminergic neurons following MPTP
intoxication, but mice lacking CD8+ cells are sensitive to MPTP intoxication (Brochard et
al., 2009). Interestingly, more CD8+ T cells infiltrate into the substantia nigra than CD4+
T cells in the MPTP model and in PD patients (Kurkowska-Jastrzebska et al., 1999;
Depboylu et al., 2012) and the percentage of CD8+ cells increase and CD4+ T cells
decreases after MPTP intoxication (Zhou et al., 2015). Adoptive transfer of effector
CD4+ T cells exacerbates nigal dopaminergic neuron loss after MPTP intoxication
(Reynolds et al., 2007).

Exacerbation of MPTP-induced neurodegeneration was

greatest by adaptive transfer of N-α-Syn-specific Th17 cells, and to a lesser extent, with
Th1 CD4+ cells, but not Th2 cells (Reynolds et al., 2010; Liu et al., 2017). On the other
hand, the adoptive transfer of Tregs were neuroprotective (Reynolds et al., 2007) in the
MPTP model.
MPTP not only alters the number and distribution of innate and adaptive immune
cells, release of proinflammatory cytokines and chemokines are increased. In the serum
and midbrain after MPTP, there is an increase in TNF-α, IL-6, and IL-1β levels are
increased (Kaku et al., 1999; Barcia et al., 2005; Shen et al., 2005; Zhao et al., 2007).
Not only do these cytokines play a role in neurodegeneration, they polarize CD4+ T cells
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to Th1 or Th17 cells which also play a degenerative role in the MPTP model as indicated
above. In addition, antigens from brain, including nitrated α-synuclein, are detected in
cervical lymph nodes, the regional draining lymph nodes from the brain (Benner et al.,
2008). Given that the cervical lymph nodes also contain activated APCs, the possibility
of an induced adaptive immune response toward this neoantigen exists.

To better

characterize the early stage of the inflammatory response to MPTP, lymph node
populations and the ventral midbrain were isolated to test immune cell numbers by flow
cytometric analysis and cytokine expression by PCR array and Luminex arrays. It is
hypothesized that MPTP intoxication will increase proinflammatory gene expression in
the lymph nodes and the midbrain. The resulting increase in proinflammatory cytokines
in these regions would promote differentiation of antigen-specific CD4+ T cells toward
Th1 and Th17 subtypes and neurodegeneration and neuroinflammation.
While CD4+ T cells play a role in MPTP pathology that worsens by Th1 and Th17
cells, whether and to what extent, MPTP activates CD4+ cells in the periphery is unclear.
MPTP increases the concentration of several cytokines in the plasma, including IL-6
(Luo et al., 2004; Shen et al., 2005), TNF-α (Barcia et al., 2005), and to a lesser extent
IL-1β (Barcia et al., 2005; Shen et al., 2005).

However, the concentration and

expression of cytokines in the cervical lymph nodes has not been determined.

In

addition, the expression of IL-1β, TNF-α, CCL3, CXCL10 and CCL2 is increased
(Kalkonde et al., 2007; Zhao et al., 2007) in the ventral midbrain and striatum. However,
the expression of these cytokines and chemokines is dependent on the time post MPTP
intoxication and the brain region. This experiment was undertaken to test the gene
expression and cytokine release in the cervical lymph nodes and ventral midbrain.
Because of the importance of the peripheral immune system, we well also tested the
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percentage of B cells, T cells, and activated antigen presenting cells by flow cytometry in
different lymph node populations.

MATERIALS and METHODS
Mice, MPTP intoxication and Isolating lymph nodes and ventral midbrain
Male, approximately 6-week-old C57Bl/6J mice were obtained from Jackson
Laboratories.

All studies were conducted in accordance with National Institutes of

Health (NIH) and the Institutional Animal Care and Use Committee (IACUC) of the
University of Nebraska Medical Center (UNMC). All animals had ad libitum access to
food and water and were maintained in a 12-hour light/12-hour dark cycle.
Mice were randomized into one of two groups. One was given 4 subcutaneous
(s.c) injections at two hour intervals of 18 mg (free base)/kg MPTP (Sigma-Aldrich). The
other group was a control group with s.c. injection of DPBS (Gibco). MPTP was handled
and administered in accordance with the published guidelines from the NIH and UNMC
IACUC (Jackson-Lewis and Przedborski, 2007).
After 2 days, 3 mice from MPTP- and DPBS-treated groups were sacrificed by
CO2 asphyxiation and cervical dislocation for flow cytometric analysis. The cervical and
deep cervical lymph nodes (cLN), brachial and axillary lymph nodes (b/aLN) and inguinal
lymph nodes (iLN) were removed and kept separate for each mouse and were placed in
a 70 µM filter. The remaining 3 mice from each treatment group were sacrificed by CO 2
asphyxiation and cervical dislocation for RNA and protein extraction. The cLN were
removed and placed in a 1.5ml snap-cap tube containing RNAlater (ThermoFisher). The
brain was removed, the frontal cortex and cerebellum was dissected and the remaining
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ventral midbrain (VMB) was placed in a 1.5ml snap-cap tube containing RNAlater.
These samples were kept separate and were kept on ice until tissue homogenization.
The PARIS kit (Ambion, Waltham, MA) was used to homogenize cLN and VMB
tissue and isolate protein and RNA. Tissue was removed from RNAlater, blotted on a
Kimwipe, placed in a 1.5 ml tube containing 600 µl cold disruption buffer. Each tissue
from each mouse was homogenized separately. Approximately 300 µl of homogenized
tissue was pipetted into two 1.5ml tubes, one for protein isolation and the other for RNA
isolation as described below.
Flow cytometry
The different lymph node populations were pressed through a 70 µM filter and
the cells were concentrated by centrifugation at 300 xg for 10 min. The pellet was
resuspended in 1 ml 1x Hanks Buffered saline solution (HBSS) (Gibco) for cell counting.
A volume containing ~500,000 cells was pipetted into 5 ml flow cytometry tubes and
cells were concentrated by centrifugation at 300 xg for 10 min. Cells were blocked for
20 min on ice in 10 µg/ml rat gamma globulin in FSB (0.5% bovine serum albumin
(BSA), 0.1% sodium azide in 1x DPBS (Gibco)) to block Fc receptors.

Cells were

stained with anti-CD11b-PECy7, anti-MHC II-AlexaFluor 700, anti-CD3-PE and antiCD19-FITC (eBioscience) for 20 min at 4°C. Cells were washed in FSB and cells were
concentrated by centrifugation at 400 xg for 5 min 2 times. Cells were fixed in FACS Fix
(1% formaldehyde in 1x DPBS (Gibco)) at RT for 15 min. Cells were concentrated by
centrifugation at 400 xg for 5 min. Cells were resuspended in FSB for analysis using a
LSR II (BD) in the Flow Cytometry Research Facility at UNMC.
Gates were drawn so that ~2% of the isotype control sample were positive for
each of the markers. The percentage of the total population positive for CD3 (T cells),
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CD19 (B cells), and CD11b+MHC II+ (activated APCs) were determined. The MFI was
also determined for each marker.
Protein isolation and luminex array
Proteins were isolated from the tissue homogenates as follows.

The

homogenate was clarified by centrifugation at 10,621 xg in a Beckman (Brea, CA)
1470R centrifuge for 10 min. The supernatant was transferred to a 1.5 ml tube and was
stored at -20°C until future analysis.
Total protein concentration was determined in each sample using the
bicinchoninic acid assay(BCA) total protein assay (Pierce, Waltham, MA) performed by
adding 200 µl of the BCA working solution (50:1 solution A:solution B) to 25 µl of an
undiluted or 1:10 dilutions of VMB homogenate or 1:2 dilution of cLN homogenate. The
plate was incubated at 37°C for 30 min, allowed to equilibrate to RT for 10 min prior to
reading at 562 nm. Based on the normalized absorbance readings and a BSA standard
curve, the protein concentration was determined.
The Milipore (Billerica, MA) Milliplex xMAP mouse cytokine and chemokine
magnetic bead kit was used to determine the concentration of cytokines and cytokines
from each sample as follows. The 96-well plate was washed in wash buffer prior to
adding 25 µl of standards, quality control samples and triplicates of each tissue (~250 µg
cLN, ~650 µg VMB total protein). To wells with standards and quality controls, 25 µl of
PARIS disruption buffer was added.

The samples had 25 µl assay buffer added.

Antibody solution containing antibodies against IFNγ, IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-6,
IL-7, IL-9, IL-10, IL-12p40, IL-12p70, IL-13, Lix, IL-15, IL-17, IP-10, MIP-2, MIG,
RANTES, and TNF-α was added to all wells and the plate was incubated at 4°C with
shaking overnight. The beads were concentrated on a magnet and washed in wash
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buffer 2 times. To each well was added 25 µl of detection antibodies and incubated at
RT for 1 hr. To each well was added 25 µl streptavidin-PE was added to each well and
the plate was incubated at RT for 30 min. The beads were then concentrated on a
magnet and washed in wash buffer twice before being for resuspended in 150 µl sheath
fluid and data was collected using a Millipore Magpix system with Luminex Xponent 4.2
software (Luminex corporation Austin, TX). The software calculated the concentration of
each of the cytokines and chemokines in each sample.

The mean cytokine and

chemokine concentrations were determined for 3 replicates from the 3 mice for each
tissue for the DPBS mice.

Mean concentrations from MPTP-treated mice were

normalized to those of DPBS-treated mice.
RNA isolation, cDNA conversion, PCR arrays and gene expression analysis
RNA was isolated from the cLN and VMB homogenate using the PARIS kit. An
equal volume of 2x PARIS lysis/binding buffer (ThermoFisher) (~300 µl) was added to
~300 µl of homogenate and 300 µl 200 proof ethanol and the solution was mixed. This
volume was pipetted into a spin column and was passed through at 20,817 xg
(Eppendorf 5417R, Hamburg, Germany) for 1 min. The eluate was discarded and 700 µl
PARIS wash solution 1, was passed through the filter at 20,817 xg for 1 min and the
eluate was discarded. For each RNA sample, 500 µl PARIS wash solution 2/3 was
passed through the filter at 20,817 xg for 1 min and the eluate was discarded. After
drying the filter by centrifugation at 20,817 xg for 1 min, 40 µl of PARIS elution buffer
heated to 95°C was added to each column and eluted from the column at 20,817 xg for
1 min. This was repeated with an additional 10 µl PARIS elution buffer passed through
at 20,817 xg for 1 min. RNA concentration and A260/A280 was determined by UV
specteophotometry (ND-1000, NanoDrop Technologies Inc. Wilmington, DE). Samples
were stored at -20°C until cDNA conversion could be performed.
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To generate cDNA from the RNA template, the RevertAid first strand cDNA
synthesis kit (ThermoFisher) was used as follows. A volume of the RNA to yield 80 ng
from each of the samples was added to each of five 0.2 ml tubes with enough water to
bring the volume to 11 µl, and 1 µl oligo dT primers was added to each sample and
incubated at 65°C for 5 min. Eight microliters of master mix (containing 5x reaction
buffer, Ribolock Rnase inhibitor, 10 mM dNTPs, and revertAID RT) was added and
incubated at 42°C for 60 min for single strand synthesis. The reaction was terminated
by incubation at 70°C for 5 min and aliquots were combined and frozen at -20°C until the
PCR arrays were run.
To run the array, the whole volume of 2x RT2 SYBR green master mix (Qiagen)
(1,350 µl), 1,248 µl Rnase-free water, and ~400 ng cDNA from a single sample was
mixed with 25 µl was added to each well of a Mouse Inflammatory Cytokines and
Receptors array (Qiagen).

The array was performed on an Eppendorf Realplex2

mastercycler gradient S using a PCR program with a 10 min hot start at 95°C, 40 cycles
of 15 sec at 95°C, and 60°C for 1 min using a 26% ramp rate. A melting curve was run
at the end. Ct values were determined for each well from each sample. Fold change
was calculated using the ΔΔCt method.

Housekeeping genes were averaged for

normalization included for cLN samples are ACTB, GAPDH, GUSB, and HSP90AB1 and
for VMB samples ACTB, B2M, GAPDH, GUSB, and HSP90AB1 were averaged for
normalization. Fold regulation was -1/fold change.
Statistics
Significance of fold changes for cell percentages or MFIs in MPTP-intoxicated
mice compared to DPBS control mice were determined by one-way ANOVA followed by
Sidak’s post hoc test. The fold change between the cytokine in the cLN and VMB was
assessed by two-way ANOVA followed by Sidak’s post hoc test comparing the DPBS
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and MPTP for each tissue for each cytokine. All statistics and graphs were generated by
using GraphPad Prism version 6.

RESULTS
Flow cytometry
The purpose of this experiment was to determine the effect of MPTP on the
distribution of T cells (CD3+), B cells (CD19+), and activated APCs (APC, CD11b+ MHC
II+) at peak neuroinflammation, once mice were administered 18 mg/kg MPTP or DPBS
in 4 s.c. injections, each administered every 2 hours. After 2 days, mice were sacrificed
and the cervical lymph nodes (cLN), brachial/axillary (b/aLN), and inguinal lymph nodes
(iLN) were isolated and flow cytometry was performed to determine the percentages of
cell types and then normalized to the DPBS controls. In all 3 lymph node populations,
there was a trend toward increased activated APCs after MPTP intoxication, but this did
not reach statistical significance (Figure 4.1A). As CD11b+ cells upregulate MHC II
surface expression when they become activated (Ponomarev et al., 2005), we assessed
MFI on the surface of MHC II on CD11b+ cells. MHC II MFI for MPTP-intoxicated mice
was increased compared to DPBS controls, but only reached statistical significance in
the cLN (Figure 4.1B). This result is congruent with previous research showing antigens
from the brain drain into the cLN population after MPTP intoxication (Benner et al.,
2008). We also found that percentages of CD19+ B cells were significantly greater in
b/aLN in the MPTP-intoxicated mice (Figure 4.1C). B cells appeared to be elevated in
the iLN of MPTP mice as well, but did not reach significance.

Interestingly, MPTP

intoxication did not seem to affect CD19+ cell percentages in cLN. Lastly, no significant
changes in the percentages of CD3+ T cells, though a trend toward decreased
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Figure 4.1 Flow cytometric profile in lymph nodes after MPTP intoxication
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Figure 4.1 Flow cytometric profile in lymph nodes after MPTP intoxication
Cervial (cLN), brachial and axillary (b/aLN) and inguinal lymph nodes (iLN) from DPBS
control or MPTP-intoxicated mice were pressed through a cell strainer and the resulting
single cells were stained with anti-CD11b, anti-MHC II, anti-CD19 and anti-CD3
antibodies for flow cytometric analysis. The frequency of cell type was divided by the
average of the DPBS for each lymph node population to normalize. Black bars are the
DPBS controls and the red bars are from MPTP mice. (A) Fold change in activated
antigen presenting cells (CD11b+ MHC II+) in MPTP-intoxicated mice compared to
control for all lymph nodes. (B) Fold change in the MHC II mean fluorescent intensity on
CD11b+ cells was compared for MPTP-intoxicated LN compared to DPBS LN. (C) Fold
change in B cells (CD19+) in MPTP-intoxicated mice compared to control for all lymph
nodes. (D) Fold change in T cells (CD3+) in MPTP-intoxicated mice compared to control
for all lymph nodes. Mean ±SEM for n=3 mice per group and compared by one-way
ANOVA and Sidak’s post-hoc test whereby a-p ≤ 0.05 compared to DPBS-treated
controls. n.s. = not significant.
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percentages were found in all lymph nodes (Figure 4.1D) which may be due to MPTPinduced cell death (Chi et al., 1992; Zhou et al., 2015). These data demonstrate that
MPTP-intoxication induces changes to the peripheral immune compartment including
increased activated APCs and B cells.
Cytokine and chemokine expression in the cLN and VMB after MPTP
To determine the cytokine environment at the peak of neuroinflammation post
MPTP, ventral midbrain (VMB) and cLN were homogenized and proteins extracted 2
days after MPTP intoxication.

The extracted proteins were tested using a Millipore

xMAP magnetic bead array for inflammatory cytokines and chemokines.

MPTP-

intoxicated mice show slight, though not significant, elevated levels of IFNγ, IL1-β, IL-4,
IL-5, IL-7, IL-9, IL-10, IL-12p40, IL-12p70, IL-13, Lix, IL-15, IL-17, IP-10, MIP-2,
RANTES, and TNF-α, but only IFNγ and IL-4 reached statistical significance in cLN
(Figure 4.2A).

In the ventral midbrain (VMB), only IP-10 was significantly elevated

following MPTP (Figure 4.2B). These were unexpected results since MPTP is known to
induce proinflammatory cytokines such as IL-6 and TNF-α (Luo et al., 2004; Barcia et al.,
2005; Shen et al., 2005; Kalkonde et al., 2007; Zhao et al., 2007).
To test if MPTP increases the expression of proinflammatory cytokine and
chemokine genes, RNA was extracted from VMB and cLN homogenate, RNA was
converted to cDNA, and real time PCR was performed using an array for
proinflammatory cytokines and chemokines and their receptors. Genes increased or
decreased by more than 2-fold in the cLN (Figure 4.3A) or VMB (Figure 4.3B) are listed.
The only 2 genes with more than 10-fold increase in expression in the cLN were IL2RG
and BMP2. Expression of proinflammatory cytokines such as IL17A, TNF, IL1A, and
IL17B were increased, as were the anti-inflammatory gene expression is increased
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Figure 4.2 Changes in cytokines and chemokines in the cervical lymph nodes (cLN) and
ventral midbrain (VMB) after MPTP intoxication
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Figure 4.2 Changes in cytokines and chemokines in the cervical lymph nodes
(cLN) and ventral midbrain (VMB) after MPTP intoxication
Homogenates of cLN and VMB were made and proteins extracted using the PARIS kit
for Milliplex xMAP analysis for inflammatory cytokines and chemokines. (A) The
average from each cLN sample was divided by the average of the DPBS control to
determine the fold increase for each cytokine or chemokine. (B) The average from each
VMB sample was divided by the average of the DPBS control to determine the fold
increase for each cytokine or chemokine. Means ± SEM for n=3 per treatment group
were determined by two-way ANOVA and Sidak’s post hoc test whereby a- p ≤ 0.05
compared to DPBS-treated controls.
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including IL33, IL5 and IL4, and the chemokines CCL1, CCL12, CCL3, CCL24, CXCL9,
CCL17, CCL11, and CCL5. Interestingly, despite significant increase of IFNγ protein in
the cLN, there is a more than 2-fold downregulation of IFNG expression.

Several

cytokine and chemokine receptors were downregulated, including CCR4, IL5RA, IL6RA,
CXCR5, IL10RB, IL1R1, IL10RA, CXCR3, CCR6, IL2RB, CCR3, CCR5, CCR1, CCR10,
and CCR2. Cytokine genes such as IL21, IL16, IL11, IL27, CSF1, CSF3, IL13, and IL15
were also downregulated. To visualize the connections between changed genes in cLN
after MPTP intoxication, Ingenuity Pathway Analysis was performed. Figure 4.4 is a
pathway of the cytokines and chemokines altered in this experiment. As noted above,
there is an increase and decrease in the expression of pro- and anti-inflammatory
cytokines. For example, Th2 helper T cell-related cytokines IL5, IL4 were increased, but
IL13 was decreased. Th17 helper T cell-related IL17A was increased, while IL21 is
decreased. The surface marker FASLG was increased, but the co-stimulatory molecule
CD40LG was decreased. These data show that MPTP induces many gene expression
changes that potentially could affect many different aspects of the interplay of innate and
the adaptive immunity toward the induction of responses to nitrated and misfolded
proteins such as N-α-Syn.
The only gene with more than 2-fold changed expression in the VMB after MPTP
intoxication was CXCL10, which is the gene for IP-10 (Figure 4.3B), also significantly
upregulated in Figure 4.2B. The data also point to a paucity of genes in the midbrain
that were not affected by 2 days after MPTP intoxication, the time of peak inflammation
in this model.
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Figure 4.3 Changes in gene expression following MPTP intoxication in the cLN and VMB
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Figure 4.3 Changes in gene expression following MPTP intoxication in the cLN
and VMB
Homogenates from cLN and VMN had RNA extracted using the PARIS kit prior to cDNA
conversion, and PCR using an array for pro-inflammatory cytokines, chemokines and
receptors. All changes reported are greater than 2-fold in the cLN (A) or in the VMB (B)
sampled 2 days following MPTP intoxication and relative to DPBS controls. Red cells
are more than 2-fold upregulated expression, while green cells are more than 2-fold
decreases in gene expression. There are 3 samples for each group of mice treated with
MPTP or DPBS.
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Figure 4.4 Map of dysregulated genes in the cLN following MPTP intoxication
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Figure 4.4 Map of dysregulated genes in the cLN following MPTP intoxication
Ingenuity Pathway Analysis was used to map the connections of all genes that were upor downregulated by at least 2-fold in the cLN assessed 2 days after MPTP intoxication.
Cells are labelled in black with a thicker boarder. Cytokines in the pathway that were not
disregulated are outlined in gray. Genes upregulated have a red outline and the darker
fill color signifies higher upregulation. Downregulated genes are depicted with green
outlines and the darker the fill color, the greater the downregulation.
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DISCUSSION
Data from this chapter have determined if there were changes to the distribution
of T cells, B cells, and activated APCs in different lymph node populations. Our findings
showed that there was no significant change in the percentage of activated APCs in the
MPTP lymph node compared to control. There was an increase in the MFI of MHC II on
APCs, but only in the cervical lymph nodes. This suggests an increase in activated
APCs in the draining lymph nodes from the brain, which is in line with previous data
(Benner et al., 2008). Little work has been published on the percentage of myeloid cells
in the periphery after MPTP intoxication, especially at this early time point. These data
would suggest that MPTP does not induce the proliferation or migration of APCs into
lymph nodes, but activates the existing APCs. This chapter also showed an increase in
B cells post MPTP. This is in contrast with other studies which indicated that MPTP
does not increase the percentage of B cells (Chi et al., 1992). However, this prior report
was testing B cell percentage in the spleen one week after intoxication. It is possible
that B cell percentage returns to basal levels by this time point and/or there is no change
in the percentage of B cells in the spleen.

Lastly, there was no change in the

percentage of CD3+ T cells in the MPTP-intoxicated mouse lymph nodes, which is also
in contrast to previous data (Chi et al., 1992). Prior research demonstrated that MPTP
decreased CD4+ CD3+ cells, but increased CD8+ CD3+ cells (Zhou et al., 2015). In
light of this result, it is possible this experiment may not detect an overall change in
CD3+ cells, even though the ratio of CD4+ to CD8+ cells may be altered. Future work
could resolve this issue by more specifically testing the percentage of different T cell
types. The trend toward decreased CD3+ T cells in lymph nodes due may also be
explained by increased mobilization of these cells into the periphery, and possibly the
brain.

197
Some care is needed in the interpretation of these results. Each group contains
only 3 mice. While this is sufficient for performing statistical analysis, there is insufficient
power to find statistically significant differences. This experiment also examined only
single time point. While day 2 is the peak of neuroinflammation, the initiation of the
adaptive immune response may begin prior to this time point. As a result, future work
should look at a time course before or after day 2 to see the rise, peak and diminution of
the adaptive immune response. It should also be noted we only examined in the lymph
nodes, and not the spleen, the circulating blood, or the brain. In conclusion, we do not
yet possess a full picture of how many of these immune cells are present and where
they are located at each time point during the course of MPTP intoxication.
We next examined the cytokine and the gene expression of cytokines in the
draining lymph nodes and the ventral midbrain. In the cervical lymph node, only IFNγ
and IL-4 were significantly increased on the protein level. This is of interest because the
increase in IFNγ has been reported previously in the serum and spleen (Huang et al.,
2014; Zhou et al., 2015). However, IL-4 was not increased in previous studies (Huang et
al., 2014).

While we did not test the release of cytokines in other lymph node

populations, it is possible that the increase in IL-4 may be responsible for the increase in
B cells because IL-4 is produced by Th2 CD4+ T cells which support the proliferation of
B cells. In the VMB, only the chemokine IP-10 was significantly increased. It is unclear
why this experiment did not find the increase of other proinflammatory cytokines found in
other studies. One possibility is the low number of mice. Another possibility is that the
wrong brain region was tested at the wrong time. TNF-α and IL-1β were found to be
elevated in the striatum, but not the substantia nigra at 1 day post MPTP, but this
increase was resolved by day 3 post MPTP (Kalkonde et al., 2007). A prior experiment
tested changes in the genes encoding TNF-α, IL-1β, IL-1α, IL-6, MMP-2, MMP-9 at
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different time points post MPTP in the ventral midbrain and striatum (Hébert et al.,
2003). This experiment reported different time courses for each gene and for each
tissue. This suggests it is important to evaluate over time, and in different tissues,
because the peak expression is different for each gene in each tisuue.

Future

experiments should examine both the ventral midbrain and the striatum at earlier and
later time points. If this is done, the MPTP-induced increase in the expression of the
proinflammatory cytokines would be better characterized.
We also tested mRNA expression of proinflammatory cytokines and chemokines.
In the cervical lymph node, the expression of IL4 was also increased on the mRNA level
to coincide with the protein expression. It is interesting that IFNG gene expression was
decreased while the concentration of IFNγ was increased. It is unclear why this is the
case, but this could indicate the beginning of a phenotypic shift from the initial
proinflammatory response to a compensatory anti-inflammatory response. In the ventral
midbrain, there was also only a 2-fold increase in CXCL10, and expression of the gene
for IP-10 was increased. Again, it is unclear why there was not more dysregulation of
genes in the ventral midbrain, but as above, isolation of RNA in both the striatum and the
VMB at earlier time points would be expected to detect increases in gene expression.
In conclusion, this chapter contains data that demonstrates changes to the
peripheral immune system and to the RNA and protein expression of proinflammatory
cytokines and chemokines at the peak of neuroinflammation. Because of this single
time point, it is possible, that there would be more changes at an earlier time point post
MPTP intoxication.
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CHAPTER 5
DISCUSSION AND FUTURE DIRECTIONS

DISCUSSION
GM-CSF as a pro- and anti-inflammatory cytokine
Previously, GM-CSF has been thought of as a proinflammatory cytokine. This is
due to GM-CSF promoting differentiation, proliferation, and survival of myeloid origin
cells such as DCs, macrophages and granulocytes. The use of GM-CSF as an adjuvant
improves the immune response to vaccines (Jones et al., 1996; Ryan et al., 2000;
Cruciani et al., 2007; Parmiani et al., 2007; Spitler et al., 2009; Garcia et al., 2014) and
in the experimental autoimmune encephalitis (EAE) model of multiple sclerosis (MS),
GM-CSF-secreting cells are responsible for the progression of symptoms (Codarri et al.,
2011). Genetic knockout of GM-CSF prevented EAE in one model (King et al., 2009),
and collagen-induced arthritis (Campbell et al., 1998) further suggesting that GM-CSF is
required for disease in some models of autoimmunity. However, GM-CSF can also
promote a tolerogenic state in DCs (Xu et al., 2008; Ganesh et al., 2009; Bhattacharya
et al., 2011), where the immune response to antigens is decreased. The divergent
effects of GM-CSF are reported in the results of Chapter 2 where sargramostim
treatment increased the expression of both pro- and anti-inflammatory genes in the
CD4+ CD25- cells of PD patients. To date, no molecular mechanism has been identified
to determine when GM-CSF boosts the immune response and when GM-CSF
diminishes the immune response. However, there are several possible explanations.
One possibility is that the concentration, duration of treatment, or the route of
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administration of GM-CSF determines the effect. To reconstitute the immune system
post-chemotherapy, sargramostim is administered i.v. at a dose of 250 µg/m2 per day
for 2 weeks (Nemunaitis et al., 1991; Rowe et al., 1995; Waller, 2007).

When

sargramostim has been tested as an adjuvant, the dose used is variable but range from
20 to 500 µg, usually delivered s.c. (Cruciani et al., 2007; Parmiani et al., 2007). In
Crohn’s disease (Korzenik et al., 2005; Valentine et al., 2009) and in PD (Gendelman et
al., 2017) sargramostim was administered s.c. at 6 µg/kg.

Because the dose of

sargramostim used as an adjuvant may be lower than that used to reduce inflammation,
there may be different effects depending on the concentration.

If this possibility is

correct, it would suggest that a higher dose of sargramostim is needed to lead to
decreased inflammation and induce Tregs, which would also suggest a different,
potentially lower affinity pathway compared to the pathways which differentiate and
proliferate myeloid cells. Another possibility is the length of administration which tends
to be shorter when sargramostim is used to repopulate the immune system and to act as
an adjuvant than when sargramostim is used to reduce symptoms of Crohn’s disease or
PD.

This would suggest that the longer sargramostim is administered, the more it

reduces inflammation. Perhaps this is a compensatory mechanism to ensure that the
increase in immune cells does not lead to autoimmune response.

Lastly, post-

chemotherapy, sargramostim is administered i.v., but as an adjuvant or to reduce
inflammation, sargramostim is administered s.c.
sargramostim

is

administered

may

also

Perhaps the route by which
effect

the

pharmacokinetics,

pharmacodynamics, or cells affected. This may also change the action and effect of
sargramostim. Combined, the dose, duration of treatment, or route of administration
may be responsible for the divergent effects of sargramostim.
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GM-CSF may also have effects not related to dosing. For example, there may
be a single GM-CSF-induced signaling cascade in all immune cells, but there may be
distinct subpopulations or activation states of immune cells which favor either
immunogenic or tolerogenic responses.

Other factors may control the relative

abundance and distribution of these immunogenic or tolerogenic subpopulations. GMCSF will then expand all myeloid cells, with the resulting immune response either being
immunogenic or tolerogenic due to the relative ratio of the immune cell subtypes and/or
activation states. As technology improves, we are gaining more of an appreciation that
genetic subpopulations exist within cells with the same surface markers.

This was

highlighted by a recent single cell RNA-Seq study of blood myeloid cells (Villani et al.,
2017).
Another possibility is that GM-CSF binding its receptor leads to different
intracellular pathways that are activated under different circumstances. After binding its
receptor, tyrosine kinases, especially JAK2, phosphorylate intracellular tyrosines in the
alpha and beta chains of the GM-CSF receptor. STATs, especially STAT5, bind to the
phosphorylated tyrosines which can activate MAP kinases, such as ERK1/2, p38, and
JNK, and PI3K pathways (de Groot et al., 1998). Activation of the MAPK pathway is
more associated with proliferation and differentiation of cells while the PI3K pathway is
more associated with the pro-survival function of GM-CSF. There may be a similar
effect between immunogenic and tolerogenic functions where different signaling
cascades induce different effects. To date, this possibility has not been investigated. It
would also be interesting to determine if different tyrosine kinases, phosphorylation of
different tyrosines, and/or different STATs binding to different tyrosines promote different
cascades that promote the expression of different cytokines. This could be tested by

202
activating DCs and using inhibitors and/or overexpression of different signaling pathways
to test the resulting expression of cytokines.
A final possibility is that other environmental factors bias the state of DCs which
bias the effect of GM-CSF binding its receptor.

Other factors may be biasing the

distribution of different immune subpopulations or may be activating different pathways
within target cells. If transcription factors are already increased from other signaling
cascades, GM-CSF signals may be biased for those pathways that may promote
different immune responses. More work is needed to differentiate these possibilities and
the ultimate effect of GM-CSF treatment on the immune system. This is important work
if GM-CSF will be used for therapy to ensure that the proper immune response is
achieved for the desired outcome.
GM-CSF induces tolerogenic DCs that induce Tregs
The data presented in Chapters 2 and 3 support the model that GM-CSF
modulates the immune response in DCs. These GM-CSF-treated DCs in turn bias the
activation state of CD4+ cells toward anti-inflammatory Tregs which can then be
neuroprotective in PD and the MPTP model of PD. The induction of Tregs is mediated
by the surface expression of anti-inflammatory co-stimulatory molecules and not by
soluble mediators.
In Chapter 2, sargramostim treatment significantly altered the expression of a
wide variety of genes in CD4+ CD25- cells in PD patients. Because the alpha chain of
the GM-CSF receptor is not detected on CD3+ cells (Santoli et al., 1988; Rosas et al.,
2007), it is unclear how sargramostim (human recombinant GM-CSF) is inducing the
dysregulation of these genes. It has yet to be determined if CD4+ CD25- cells express
the beta chain of the GM-CSF receptor, but if they do then it is possible that the
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exogenous GM-CSF is at high enough concentration to bind to this receptor and directly
alter gene expression. Another possibility is that GM-CSF is binding to its receptor on
myeloid cells (i.e. macrophages, monocytes and dendritic cells, neutrophils, and
eosinophils), activating these cells to release cytokines, chemokines, and/or other
mediators which are acting on CD4+ CD25- cells. These possibilities are not mutually
exclusive. We also do not know whether the dysregulation of genes is occurring in the
same or different CD4+ CD25- populations. It is possible that sargramostim-treated
patients contain different CD4+ CD25- populations in which some display increased
proinflammatory genes, and another population with increased anti-inflammatory genes.
Conversely, sargramostim may be increasing the expression of pro- and antiinflammatory cytokines in all CD4+ CD25- cells. The first possibility would suggest that
the global administration of sargramostim is affecting diverse cell types in different ways.
The second possibility would suggest that while sargramostim has a uniform effect on
CD4+ CD25-, the dysregulation is due to broad activation of CD4+ CD25- cells.
In Chapter 3, in the absence of stimulation, BMDCs are in a tolerogenic state.
While GM-CSF did not maintain this state after stimulation as determined by the
increase in the surface co-stimulatory molecules, increase and proinflammatory
cytokines, and decrease in kynurenine, GM-CSF alters how BMDCs respond to N-α-Syn
stimulation.

Extending GM-CSF culture increased Jag-1 surface expression, the

expression and release of IL-10, and decreased the surface expression of MHC II and
CD86. However, GM-CSF generally did not decrease the expression and release of
proinflammatory cytokines and chemokines. It is unclear how GM-CSF culture leads to
these seemingly divergent effects of increasing anti-inflammatory and proinflammatory
co-stimulatory molecules and cytokines. The binding of GM-CSF to its receptor, JAK2
activates STAT5 which can activate several downstream signaling cascades including
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MAPK and PI3K (de Groot et al., 1998). Tolerogenic DCs display a unique pattern of
gene expression separate from mature, immunogenic DCs.

Expectedly, tolerogenic

DCs exhibit decreased expression of proinflammatory cytokines and increased
expression of anti-inflammatory cytokines (Torres-Aguilar et al., 2010; Lee et al., 2016).
In addition, tolerogenic DCs may increase expression of IDO, an enzyme involved in
tryptophan metabolism and associated with the induction of Tregs (Steinman et al.,
2003; Maldonado and von Andrian, 2010; Li and Shi, 2015; Raker et al., 2015).
Tolerogenic DCs also increase the surface expression of PD-1, CD95L, ILT3 and ILT4,
all of which are involved in the suppression of immune cell activation or induction of
Tregs, or apoptosis (Sim et al., 2016). Also, CLIP, the invariant MHC II chain, was
increased on the surface of tolerogenic DCs which suggest a decrease in the
presentation of antigens which could explain why tolerogenic DCs are weaker inducers
of helper T cell proliferation (Torres-Aguilar et al., 2010). Tolerogenic DCs also show
decreased glycolysis (also detected in activated mature DCs) and increased oxidative
phosphorylation (Sim et al., 2016). This switch in energy production may be mediated
by a suppression of AKT signaling in tolerogenic DCs.

Tolerogenic DCs increase

expression of genes involved in lipid metabolism, apoptosis, cell membrane
homeostasis, and the inflammatory response, including an increase in NFKB1 (Lee et
al., 2016). Despite the plethora of information about gene signatures of tolerogenic DCs,
how GM-CSF is inducing and maintaining a tolerogenic state remains unclear.
In these experiments, we identified two anti-inflammatory mediators that are
upregulated by continued culture in GM-CSF: Jag-1 and IL-10. We tested the surface
expression of Jag-1, and not the total gene and protein expression, so whether GM-CSF
increases gene expression and translation of Jag-1 or merely mobilizes the Jag-1 to the
surface is unknown in this model. Cultured monocytes do increase jagged1 expression
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after culture with GM-CSF (Nomaguchi et al., 2001), so the possibility remains in our
system that total Jag-1 is increased after GM-CSF culture. How binding of GM-CSF to
its receptor is upregulating the surface expression of Jag-1 remains to be determined.
TNFα treatment increases jagged1 expression (Okada et al., 2016). In this system, and
the only source of TNFα would be from the BMDCs, but the continued culture of BMDCs
in GM-CSF decreased the expression of Tnf (Figure 3.7) and did not change the release
of TNFα (Figure 3.9), suggesting increases in Jag-1 surface expression are not related
to TNFα. Macrophage colony stimulating factor (M-CSF) regulates Jag-1 expression
through NF-κB (Brach et al., 1991), but the expression of Nfkb1 was not altered by
continued GM-CSF (Figure 3.7).

These results suggest that GM-CSF has another

mechanism of increasing jagged1 through a yet undescribed pathway.
IL-10 is an anti-inflammatory cytokine important for the anti-inflammatory
functions of Tregs and Th2 helper T cells. More is known about the regulation of IL-10
expression, though the regulatory effects on IL-10 by GM-CSF is unclear.

Several

transcription factors have been identified that regulate IL-10 gene expression, including
Sp1, Sp3, STAT3, ERK1/2, JUNK, p38, NF-κB, c/EBPα, and AP-1/c-Jun (Tone et al.,
2000; Ziegler-Heitbrock et al., 2003; Wang et al., 2005; Saraiva and O'Garra, 2010).
Whether any are increased by the binding of GM-CSF to its receptor is unknown.
Combined, the lack of knowledge about the molecular events by which GM-CSF induces
and maintains a tolerogenic state provides potential future directions. If a tolerogenic
state can be induced more directly and maintained without the off-target effects of GMCSF, could provide a putative novel therapy for PD and autoimmunity. Turning off the
tolerogenic state of DCs could also serve as a novel therapy for anti-tumor immune
responses.
Impact of GM-CSF on other cell types
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GM-CSF has broad effects throughout the body.

As a result, peripheral

administration of GM-CSF may afford beneficial effects in PD and in models apart from
the increase in the percentage and function of Tregs. As stated in Chapter 1, GM-CSF
has broad effects throughout the immune system including macrophages, monocytes,
DCs, neutrophils and eosinophils. GM-CSF also induces the proliferation of myeloidderived suppressor cells (MDSCs).

These cells are either monocyte or granulocyte

lineage and induced by proinflammatory stimuli including infections (Gabrilovich and
Nagaraj, 2009; Parker et al., 2015).

Activated MDSCs increase the expression of

reactive oxygen and nitrogen species (ROS/RNS), TGFβ, and PD-L1 as well as induce
Treg differentiation all of which suppress T cell immune responses.

GM-CSF

administration expands MDSCs in vitro and in vivo (Filipazzi et al., 2007; Dolcetti et al.,
2010; Rosborough et al., 2012).

The adoptive transfer of MDSCs reduces the

expression of perforin and IFNγ in CD3+ cells in cancer (Filipazzi et al., 2007). MDSCs
are also protective in the EAE model of MS, and MDSCs from MS patients suppress
CD4+ T cell proliferation (Ioannou et al., 2012).
The role of MDSCs in PD and the MPTP model of PD has not been tested.
Possibly in PD, MDSCs could be decreased in percentage and/or function, like Tregs. If
this is the case, the decrease may contribute to increased neuroinflammation of PD
patients. During inflammation, MDSCs may act similar to tolerogenic DCs to induce
Tregs or directly suppress T cell or myeloid effector cells. This potential dual role for
MDSCs merits further investigation, in PD, PD models, and other autoimmune disorders.
Another potential immune cell that may be affected by GM-CSF are B cells.
These lymphocytes have unique roles for producing immunoglobulins and presenting
antigens. In PD, frequency of circulating B cells are deceased compared to controls
(Bas et al., 2001; Niwa et al., 2012; Stevens et al., 2012; Horvath and Ritz, 2015). To
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date, the percentage of different B cell subsets or plasma cells remain undefined.
However, since the production of antibodies reactive to α-Syn is elevated (Papachroni et
al., 2007), antigen-specific B cells may play a significant role in the pathology of PD is
unclear.
B cells express the receptor for GM-CSF, and GM-CSF promotes the survival of
B cells (Harris et al., 2000). While the effects of GM-CSF on B cells of PD patients have
not yet been determined, several potential beneficial effects exist. For example, GMCSF may promote the survival of B cells that produce immunoglobulins to clear
misfolded antigens and protect in PD. Another possibility is that GM-CSF may modulate
the presentation of antigens by MHC II to helper T cells and modulate the response to
be more protective in PD. Since naïve B cells can induce Tregs in vitro (Reichardt et al.,
2007), GM-CSF may possibly have similar effects on the B cells as on myeloid cells by
increasing the expression of anti-inflammatory mediators and/or decreasing the
expression of co-stimulatory molecules; the combination of which would promote the
induction of Tregs. A final possibility is that GM-CSF increases numbers and function of
regulatory B cells (Bregs), a B cell subset that can suppress immune cells through IL-10dependent and independent mechanisms (Ray and Dittel, 2017). While a role for Bregs
in PD has yet to be identified, these regulatory cells, like Tregs and MDSCs, could play a
role in suppressing the inflammation and may comprise a component of the mechanism
for protection provided by GM-CSF.
Apart from its effects on the immune system, GM-CSF can have direct effects on
the nervous system. GM-CSF receptor is detected on neurons (Kruger et al., 2007) and
neural progenitor stem cells (Kim et al., 2004; Kruger et al., 2007). For neural progenitor
stem cells, administration of GM-CSF decreases differentiation of these stem cells into
astrocytes or neurons and protects them against apoptosis (Kim et al., 2004). GM-CSF
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treatment promotes axon regeneration in culture by inducing production of brain-derived
neurotropic factor (BDNF) (Bouhy et al., 2006). In models of stroke, penumbral neurons
around the infarct increase the expression of the GM-CSF-receptor and administration of
GM-CSF induces the expression of the pro-survival factor Bcl (Schabitz et al., 2008). In
fact, GM-CSF treatment decreases post-stroke infarct size. GM-CSF also protects the
PC12 neuron cell line from MPP+-mediated toxicity by the restoration of the Bcl-1/Bax
ratios, which promotes survival (Kim et al., 2009). As a result, the protection of THpositive neurons in the substantia nigra by intraperitoneal administration of GM-CSF
(Kim et al., 2009; Kosloski et al., 2013) may not be completely mediated by Tregs, but
rather by direct effects on neurons. Given that GM-CSF crosses the blood-brain barrier
(Schabitz et al., 2008), it may indeed elicit direct effects in the CNS.
In addition to neurons, the glia including astrocytes, oligodendrocytes and
microglia also express GM-CSF receptors (Baldwin et al., 1993; Sawada et al., 1993;
Lee et al., 1994; Guillemin et al., 1996). The precise in vivo role that GM-CSF plays in
the brain remains unclear, but in culture, astrocytes, oligodendrocytes and microglia
proliferate in response to GM-CSF treatment (Baldwin et al., 1993; Lee et al., 1994;
Guillemin et al., 1996). GM-CSF is increased in the cerebrospinal fluid of stroke patients
(Tarkowski et al., 1997), and cultured astrocytes produce GM-CSF after stimulation with
viral infection, or stimulation with TNF-α or LPS (Wesselingh et al., 1990; Frei et al.,
1992); all of which suggests a role for GM-CSF in response to inflammatory stimuli in the
brain. Seemingly the expression of GM-CSF appears to be protective by promoting
survival.

In fact, GM-CSF plays a role in the normal development of the brain, as

evidenced by decreased locomotor activity and spatial memory of GM-CSF-knockout
mice, which may be related to the decreased length of dendrites (Krieger et al., 2012).
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In conclusion, GM-CSF has direct, positive effects on the brain, however, to what extent
that these effects are independent of Tregs remains unclear.
A final, related possibility is that GM-CSF is acts on cells in the periphery and
lead to release of more products that can enter the brain and affect PD. While BMDC
supernatant was unable to decrease the MPP+- or BV2-supernatatnt-mediated killing of
MES23.5 cells (Figure 2.21), BMDC supernatant did decrease the release of proinflammatory cytokines from stimulated BV2 cells (Figure 2.22). The possibility has not
been ruled out that supernatants from DCs could go to the brain and either decrease the
activation state of activated microglia or protect dopaminergic neurons.

FUTURE DIRECTIONS
While the work done in Chapter 2 was performed on a set of patient samples
gathered for a specific study, this research could be continued with several potential
studies. First, this project examined gene expression in non-Treg, non-effetcor helper T
cells (CD4+ CD25-). This cell type was chosen because the identity of the T cells
relevant to disease progression or protection in PD were unknown.

However, by

excluding activated (CD4+ CD127+ CD25+) effector T cells, it is possible that we
excluded terminally differentiated T cells and addressed the effects of sargramostim on
T cells that could differentiate into Tregs of effector T cells.

Future work could be

undertaken to examine the expression of proinflammatory cytokines in these cells. In
our current study, the expression of 84 genes were included in the array, thus
continuation of this work using RNA-Seq or other technologies could examine the total
transcriptome of the isolated population or in single cells. The advent of single cell gene
expression allows the grouping of T cells into subpopulations by gene expression, and
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would allow for measure of unique helper T cell subsets that comprise the repertoire in
PD patients and healthy controls, or allow tracking the distribution of these subsets over
time. Lastly, no work has identified a population of T cells that are reactive to posttranslationally modified α-Syn. For instance, if APCs (be they monocytes, monocytederived macrophages or DCs or B cells) were co-cultured in the presence of modified αSyn antigens and T cells from PD or control patients, a proliferating helper T cell
population in response to the modified antigens could be identified.

These further

studies could vastly improve our understanding of T cell gene expression and reactivity
to self-antigens such as α-Syn.
The focus of Chapter 2 is on T cells and their function in PD. However, other
immune cells (for example neutrophils, or CD8+ cells) may be facilitating the
neuroinflammation and neurodegeneration in PD. While some work in the clinical trial
evaluated numbers and percentages of these cells in the periphery, no functional
assessment of these cell types were performed.

Because eosinophil numbers and

percentages in the blood were increased after sargramostim treatment (data not shown),
whether the function of those eosinophils are affected would be of particular interest.
This may not play a role in the development of PD or the clinical benefit in sargramostim,
but these cells may be playing a role in the adverse effects of sargramostim treatment.
As a result, understanding the effects of sargramostim on these cells may lead to a
better understand of possible adverse effects and procedures to mitigate those effects if
sargramostim is to be included as a PD therapeutic.
This clinical trial did not measure numbers or the percentages of MDSCs. To
date, no work has measured the number or function of MDSCs in PD. However, like
Tregs, these cells may be found in decreased number and function and contribute to the
unharnessed inflammation in PD patients. Given that GM-CSF can expand MDSCs, the
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observed improvement in motor function may be related to decreased inflammation
related, at least in part, to these cells. These studies would highlight the function and to
what extent MDSCs play a role in PD and whether increasing their number and function
would improve PD symptoms
As described in Chapter 3, we tested the hypothesis that GM-CSF induces a
tolerogenic state in DCs, which induce Tregs and/or are neuroprotective in the MPTP
model. This research could be continued with several different research projects. First,
while I examined all the cells from BMDC cultures (both adherent and non-adherent
CD11c+ and CD11c- cells), other published experiments with BMDCs isolated CD11c+
cells from only the non-adherent population. Further experiments could further test the
tolerogenic markers and functions of the non-adherent CD11c+ cells compared to the
total population. Also, flow cytometric analysis could be used to further characterize
other DC markers and other markers for co-stimulatory molecules or functional markers
that better describe the function of these cells. Recently, DCs have been characterized,
not by surface markers, but by ontology. Within the bone marrow, 2 progenitors give
rise to CD11c+ cells, the common DC precursor and the common monocyte progenitor
(Helft et al., 2015). While resulting DCs are all CD11c+ MHC II+, but the ontology
determines whether the resulting cells are DCs and macrophages. Future experiments
could better determine to what extent the BMDCs used here are macrophages or DCs.
More work is needed to determine the mechanism(s) of BMDC-mediated
induction of Tregs.

First, we should examine the surface expression of other co-

stimulatory molecules that induce Tregs, such as PD-L1 should be examined after
continued culture with GM-CSF. Next, blockade of OX40L, Jag-1, PD-L1, and others
with antibodies or antagonists should be evaluated to determine whether induction of
Tregs during the co-culture of BMDCs with CD4+ T cells could be inhibited. We should
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also begin to test the expression of these molecules on BMDCs generated in culture with
inhibitors or agonists for different components of GM-CSF signaling cascade to
determine what is important pathways for the induction of surface markers. Tregs from
BMDC co-cultures should also be better characterized with other Treg markers like
CD39, CD73, Lag-3, ICOS, PD-1, CTLA-4, Helios, GITR, as well as gene expression for
cytokines such as IL-35, TGFβ and IL-10. Determining increased expression in this
population may indicate which Treg functions are needed for suppression. This could be
tested by knocking out or blocking some specific factors to determine whether Tregs are
still suppressive in the proliferation suppression assay. Lastly, Tregs derived from coculture should be further tested for their ability to protect dopaminergic neurons after
MPTP intoxication.

We could use the induced Tregs to test which suppressive

function(s) are important for neuroprotection, however, the efficiency of in vitro induction
would need to be improved to provide sufficient numbers of Tregs for these studies.
In vivo, more experiments are needed to determine to what extent GM-CSF
induces tolerogenic DCs or other regulatory cells, such as MDSCs.

This could be

achieved by determining the peripheral percentages of these cell types in peripheral
blood after injection of GM-CSF. In vivo blocking of co-stimulatory molecules identified
above can determine the role of Treg-inducing myeloid cell types. This is important to
determine whether injection of GM-CSF working only through the tolerogenic DCs or
other cell types. Lastly, to test the neuroprotective capability, MDSCs can be adoptively
transferred to MPTP intoxicated mice and surviving neurons assessed. MDSCs can be
isolated from the spleens of mice and transferred after MPTP, as was previously
described with Tregs. Evidence of decreased neuroinflammation and neuroprotection
would indicate that other suppressor cell types protect in the model, while no changes
may suggest a uniqueness about the suppressive function of Tregs. Both of which are

213
novel findings and would lead to a better understanding of the immune system in the
MPTP model and PD.
The research in Chapter 4 can be continued by several possible future
experiments. In this experiment, we tested the expression of proinflammatory cytokines
at the peak of neuroinflammation. However, more than likely these cytokine genes peak
in the expression before the peak of neuroinflammation as defined by reactive microglia.
This would make sense if proinflammatory cytokines are needed for the activation of
microglia. Also, we tested gene expression and cytokine release at the same time. In
the future, the temporal kinetics of gene and protein expression should be better
delineated, particularly at earlier time points. We also only tested gene expression in the
midbrain and the cervical lymph nodes. Future experiments could test gene expression
and cytokine release in other tissues as well as at different time points. While not
typically assessed, the kinetics of gene expression and cytokine release in the striatum
would be of particular interest as well as in other lymph node populations, the peripheral
blood, and the spleen. We could also further test the percentage of additional immune
cells such as B cells, CD4+ and CD8+, and macrophages, and DCs in the cervical,
brachial, axillary, and inguinal lymph nodes as well as in the spleen and peripheral
blood. This would better complete the cellular signature of immune cells that react over
time after MPTP intoxication. In addition, future experiments could test the percentage
and function of other regulatory immune cells post-MPTP. While Tregs would be the
obvious target population, MDSCs, B regulatory cells, and CD8+ regulatory T cells would
be interesting populations to assess over time.

The results of these studies would

provide us a complete understanding in the MPTP model of immune repertoire of cells
and cytokines that could be brought to bear as putative therapeutic modalities for PD.
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